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Abstract 
 
G-protein-coupled receptors are of great pharmaceutical interest, comprising the 
majority of targets for currently marketed drugs. The theme of my thesis is the 
development of the structure prediction method, MembStruk, for the superfamily of G-
protein-coupled receptors. The first part of this thesis focuses on the methods and their 
validation. There are several steps involved in MembStruk that are detailed and tested for 
membrane proteins with known structures in the first few chapters (Chapters 2-6). 
Specifically, the first principles methods for predicting the transmembrane helical ranges 
and the helix hydrophobic centers are tested. The program for predicting the 
transmembrane helical ranges, TM2ndS, ranks in the top two when comparing 
performance with other top prediction methods. And because it is based on general 
principles, it can be applied robustly for membrane protein families for which little 
structural information is available. The simulation of the EC-II closing is also tested on 
bovine rhodopsin. The use of the MembStruk method on bovine rhodopsin as a validation 
case is presented in detail (Chapter 2). The large majority (71%) of the residues involved 
in binding in rhodopsin are predicted and the protein structure itself is 2.84 Å coordinate 
root mean square error in the transmembrane main chain atoms from the crystal structure.  
The second part of the thesis discusses applications on various G-protein-coupled 
receptor systems. The application of the MembStruk method to other peptide chemokine 
G-protein-coupled receptors like CCR1 and CCR5 is discussed in Chapter 9. The 
fundamental scientific problems of G-protein-coupled receptor modulation of absorption 
and relaxation properties of a bound chromophore (retinal) are addressed and results are 
presented for the predictions of these properties. 
 v
 The prediction of structure and function of G-protein-coupled receptors would 
allow for structure-based drug design and a rational approach to reducing drug cross-
reactivity across receptor families. 
 vi
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 The theme of my thesis is the development of the structure prediction method, 
MembStruk, for the superfamily of G-protein-coupled receptors (GPCRs). There are 
several steps involved in MembStruk that are detailed and tested for membrane proteins 
with known structures in the first few chapters. In particular, the use of the MembStruk 
method on bovine rhodopsin as a validation case is presented. This is followed by the 
application of the MembStruk method to other peptide chemokine GPCRs like CCR1 and 
CCR5.   
Figure 1: Schematic of rhodopsin 
and its interaction with the G-
protein. (Figure: Christian 
Altenbach) 
Membrane proteins make up 20-30% of 
genomes (Wallin et al., 1998) in various 
organisms and are important in various 
processes from ion transportation to detection of 
electromagnetic radiation.  Within this class, the 
GPCR superfamily comprises about 3-4% 
(Schoneberg et al., 2002) of the human genome. 
They act by transducing an extracellular signal 
into an intracellular signal cascade involving G-
proteins. The extracellular signal is usually 
chemical (peptides, lipids, neurotransmitters) but 
in the case of the opsin family, it is light of a specific frequency range. This is shown in 
Figure 1 for rhodopsin, where the particular G-protein used to propagate the signal is a 
heterotrimeric protein called transducin.  
In the case of rhodopsin, the bound chromophore is 11cis-retinal, as shown in 
Figure 2. Retinal, which is derived from ingested Vitamin A, actually absorbs light in the 
 3
UV radiation range when it is free in solution. Upon absorbing this photon, the free 
retinal undergoes isomerization to all-trans-retinal.  
 
Figure 2: The 
photoisomerization of 
free retinal at the 11-cis 
bond. (Figure:  
http://wunmr.wustl.edu/EduD
ev/LabTutorials/Vision/Visio
n.html) 
But this chromophore also binds to the GPCR rhodopsin and forms a Schiff base 
linkage with the protein, as shown in Figure 3. This bound chromophore, as opposed to 
its free form, absorbs light in the visible range with a maximum frequency of absorption 
of ~500 nm.  
 
Figure 3: The Schiff 
base bond formation 
of retinal with the 
protein lysine. (Figure:  
http://wunmr.wustl.edu/Ed
uDev/LabTutorials/Vision/
Vision.html) 
 
When bound to the protein, this chromophore undergoes isomerization (required 
for receptor activation) with an efficiency that is more than three times of that in its free 
state. In addition, within the opsin family, there are three human opsin proteins which 
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absorb maximally in the green, blue, and red range of visible light when bound to the 
same chromophore, and make possible color distinction in human vision. Thus, the roles 
which the GPCR plays in modulating the frequency of light absorption and isomerization 
efficiency are of fundamental scientific interest. 
In addition to the basic scientific questions which emerge from them, GPCRs are 
of particular interest pharmacologically, making up more than 45% of all known drugs on 
the market (Horuk, 2003). For example, drugs used for the treatment of schizophrenia, 
high blood pressure, migraines, and ulcers target the dopamine, adrenergic, serotonin, and 
histamine receptors respectively. 
 One of the great challenges in the field of drug development for GPCRs is the 
reduction of cross-reactivity of drugs across GPCR families, which leads to side effects 
and effectively lowers the drug dosage which one may give to a patient. This is 
sometimes due to the similar drug libraries used to derive a lead compound for different 
receptor targets. It is also due to sequence similarities common to the GPCRs with which 
the drug is cross-reacting. An example of this is the case of BX471, which is a human 
CCR1 antagonist in development; it exhibits cross-reactivity with the dopamine and 
muscarinic receptors (Hesselgesser et al., 1998). 
 To aid in the drug development process, the 3D structures of the GPCRs in 
question would provide a rational basis for increasing the potency of a drug while 
reducing action on other receptors that are not of interest (known as anti-targets). For 
soluble proteins, the relatively large number of X-ray crystal structures available has 
made the use of homology modeling feasible in many cases. On the contrary, there is 
currently one GPCR crystal structure available for bovine rhodopsin. As such, since the 
 5
sequence identity to rhodopsin is low for most GPCRs of interest (17 % for dopamine, 14 
% for serotonin), the use of homology modeling is not a feasible avenue for obtaining 
reliable structures for making predictions (Archer et al., 2003). 
 The MembStruk method (Floriano et al., 2000; Vaidehi et al., 2002; Trabanino et 
al., 2004) was developed by myself, Spencer Hall and Vaidehi, to predict GPCR structure 
using an approach very different from that of homology modeling. The MembStruk 
protocol determines the 3D structure of a GPCR beginning from the sequence and using 
mostly first principles in predicting the structure in various steps. The step which uses 
some crude structural information is the template building step, where the tilts of the 7Å 
frog rhodopsin structure (Schertler, 1998) are used to form an initial TM helical bundle. 
Aside from this, the TM helical extent, the translations of the helices along their axes, 
their rotations within the bundle, and their bends are determined from first principles. 
Judging from the success in predicting function (by ligand binding site and affinity 
determination) and direct structure (compared to crystal structure or mutagenesis studies), 
the use of this initial template seems to be justified (Freddolino et al., 2004; Kalani et al., 
2004). Even so, currently the group is working on determining the tilts using Monte Carlo 
methods treating each helix as a rigid body with mesoscale forcefield interactions with 
adjacent helices. 
 This thesis is divided into two large sections, with the first section focused on the 
methods developed for structure prediction and bioinformatics while the second section 
presents applications of methods to GPCRs for the prediction of structure, function, and 
spectroscopic properties. 
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Chapter 2 of this thesis describes the MembStruk procedure in detail and provides 
direct structural validation for the only GPCR with a crystal structure available, bovine 
rhodopsin. The main chain atoms of the TM region differ by 2.87 Å CRMS (coordinate 
root mean square) from the crystal structure. Also, the ligand was predicted to bind in a 
conformation which was 2.92 Å CRMS from the crystal conformation (Figure 4). In 
addition, a majority (71%) of the residues interacting with the ligand in the crystal 
structure are predicted to interact with the ligand in the MembStruk structure. This paper 
was adapted from a published article (Trabanino et al., 2004). 
CRMS=2.92 Ǻ
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focus.Figure 4:  A comparison of the predicted (purple) and crystal (blue)
conformations of bound 11cis-retinal Chapter 3 specifically details the TM2ndS program that I developed, which 
ts the TM helical regions of a membrane protein. The program is compared to all 
er major prediction programs. TM2ndS emerges as one of the top two methods in 
mance of TM helix prediction accuracy, which is most pertinent to the GPCR 
 Of these two methods, TM2ndS is the only program which uses general principles 
 7
and does not systematically “train” its parameters for better performance on available 
crystal structures. Thus, it is the top hydrophobicity-based first principles methods 
available for high residue accuracy in predictions for membrane proteins. The details of 
the TM2ndS performance using redefined standards for TM helices from crystal 
structures are also presented.  
 In Chapter 4 I discuss the method for hydrophobic center prediction for 
membrane proteins and provides validation for its use in orienting membrane helices 
along their axes. The correspondence with the actual bilayer center is also presented. 
 Chapter 5 overviews the development of a database of TM helix and center 
predictions for all human GPCRs (excluding the olfactory GPCRs) in the SwissProt 
sequence database as well as the family relationships in order to provide an organized 
manner of ascertaining possible similarities between proteins which may lead to ligand 
cross-reactivity. In addition, the relationships between all of these GPCRs using tree 
diagrams of the 7 TM cores are presented. Results on the usage of TM2ndS for mining 
unknown GPCRs from the genome are also shown. 
 The extracellular loop II (EC-II) is closed over the TM barrel in the crystal 
structure of bovine rhodopsin. In out predicted structures, we build both the ECII loop 
open structure and the closed structure. Chapter 6 focuses on prediction algorithm for the 
closing of the ECII loop, EC_LOOP_SIM and its usage is validated in the case of bovine 
rhodopsin. In addition, the role of the EC-II loop in a “closed” conformation in 
modulating the binding of ligands is discussed in the context of a possible binding 
mechanism for 11cis-retinal in bovine rhodopsin. 
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 Chapter 7 begins the section on the application of MembStruk for various GPCRs. 
Prediction of the structure of the three, green, red and blue colored opsins in human, and 
the mechanism for color distinction in humans at the molecular level are detailed in 
Chapter 7. The structures of the three opsin proteins responsible for color distinction are 
built using the crystal structure of bovine rhodopsin and the absorption spectra of the 
bound chromophore within the three proteins is predicted using a QM-fitted molecular 
dynamics together with QM/MM (quantum mechanics/ molecular mechanics) methods. 
The absorption maxima of the predicted spectra correspond well with the experimental 
maxima for the three proteins. 
 Chapter 8 is an extension of the previous chapter. It overviews the isomerization 
pathway along the potential energy surface and interprets this in terms of possible 
relaxation pathways for retinal after Frank-Codon excitation. In addition, the role of the 
protein in increasing isomerization efficiency is discussed in the context of the results. 
 Chapter 9 describes in detail the prediction of the structures and functions of the 
chemokine receptors human CCR1 (Figure 5) and CCR5 using the MembStruk protocol. 
This provides additional validation of the method and also provides insight into the 
causes of interspecies differences in binding affinity as well as manners of reducing cross 
selectivity of drugs to both these receptors. Specifically, the mouse and human receptors 
exhibit an important difference in the simulated EC-II loop (a glutamic acid in human to 
lysine in the mouse). 
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Figure 5: The predicted binding of the BX471 
antagonist to human CCR1. 
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Abstract 
 
G protein-coupled receptors (GPCRs) are involved in cell communication 
processes and with mediating such senses as vision, smell, taste, and pain. They 
constitute a prominent superfamily of drug targets, but atomic level structure is available 
for only one GPCR, bovine rhodopsin making it difficult to use structure-based methods 
to design receptor specific drugs. We have developed the MembStruk computational 
method for predicting the 3D structure of GPCRs mostly from first principles.  In this 
paper we validate the MembStruk procedure by comparing its predictions with the high- 
resolution crystal structure of bovine rhodopsin. The crystal structure of bovine rhodopsin 
has the second extracellular (EC-II) loop closed over the transmembrane regions by 
making a disulfide linkage between Cys110 and Cys187, but we speculate that opening 
this loop may play a role in the activation process of the receptor through the cysteine 
linkage with helix 3. Consequently we predicted two structures for bovine rhodopsin 
from the primary sequence (with no input from the crystal structure), one with EC-II loop 
closed as in the crystal structure and the other with the EC-II loop open. The MembStruk 
predicted structure of bovine rhodopsin with the closed EC-II loop, deviates from the 
crystal by 2.84 Å CRMS (coordinate root mean square) in the transmembrane  region 
main chain atoms. 
 The predicted three-dimensional structures for other GPCRs can be validated 
only by predicting binding sites and energies for various ligands.  For such predictions 
we developed the HierDock first-principles computational method. We validate 
HierDock by predicting the binding site of 11cis-retinal in the crystal structure of bovine 
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rhodopsin. Scanning the whole protein without using any prior knowledge of the binding 
site, we find that the best scoring conformation in rhodopsin is 1.1 Å CRMS from the 
crystal structure for the ligand atoms. This predicted conformation has the carbonyl O 
just 2.82 Å from the N of Lys 296. Making this Schiff base bond and minimizing leads to 
a final conformation only 0.62 Å CRMS from the crystal structure.   
We also used HierDock to predict the binding site of 11cis-retinal in the 
MembStruk predicted structure of bovine rhodopsin (closed loop). Scanning the whole 
protein structure, leads to a structure in which the carbonyl O is just 2.85 Å from the N of 
Lys 296. Making this Schiff base bond and minimizing leads to a final conformation only 
2.92 Å CRMS from the crystal structure.   
The good agreement of the ab initio predicted protein structures and ligand 
binding site with experiment validates the use of the MembStruk and HierDock methods. 
Since these methods are generic and applicable to any GPCR, they should be useful in 
predicting the structures of other GPCRs and the binding site of ligands to these proteins.  
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Introduction 
 
Integral membrane proteins comprise 20-30% of genes (Wallin et al., 1998) in 
humans and other higher forms of life, playing an important role in processes as diverse 
as ion translocation, electron transfer, and transduction of extracellular signals.  One the 
most important classes of transmembrane (TM) proteins is the G-protein-coupled 
receptor (GPCR) superfamily which upon activation by extracellular signals initiate an 
intracellular chemical signal cascade to transduce, propagate, and amplify these signals.  
GPCRs are involved in cell communication processes and in mediating such senses as 
vision, smell, taste, and pain.  The extracellular signals inciting this transduction are 
usually chemical, but for the opsin family, it is “visible” light (electromagnetic radiation). 
Malfunctions in GPCRs play a role in such diseases as ulcers, allergies, migraine, 
anxiety, psychosis, nocturnal heartburn, hypertension, asthma, prostatic hypertrophy, 
congestive heart failure, Parkinson’s, schizophrenia, and glaucoma (Wilson et al., 2000). 
Indeed although they comprise about 3-4% (Schöneberg et al., 2002) of the human 
genome, the GPCR superfamily represents one of the most important families of drug 
targets.  
Within a class of GPCRs (for example, adrenergic receptors) there are often 
several subtypes (for example, 10 for adrenergic receptors) all responding to the same 
endogenous ligand (epinephrine and norepinephrine for adrenergic receptors), but having 
very different functions in various cells.  In addition, many different types of GPCRs are 
similar enough that they are affected by the antagonists or agonists for other types (e.g., 
among adrenergic, dopamine, serotonin, and histamine receptors), leading often to 
undesirable side effects. This makes it difficult to develop drugs to a particular subtype 
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without side effects resulting from cross reactivity to other subtypes.  To design such 
subtype specific drugs, it is essential to use structure-based methods but this has not 
possible because there is no atomic level structure available for any human GPCR. 
Consequently design of subtype specific drugs for GPCR targets is a very tedious 
empirical process, often leading to drugs with undesirable side effects. The difficulty in 
obtaining 3D structures for GPCRs is obtaining high quality crystals of these membrane-
bound proteins sufficient to obtain high-resolution x-ray diffraction data and the 
difficulty of using NMR to determine structure on such membrane bound systems. Hence 
we conclude that to aid the structure-based drug design for GPCR targets, it is essential to 
develop theoretical methods adequate to predict the 3D structures of GPCRs from mostly 
first principles. For globular proteins there have been significant advance in predicting 
the 3D structures by using sequence homologies to family of known structures (Marti-
Renom et al., 2000); however, this is not practical for GPCRs since a high-resolution 
crystal structure is available for one GPCR, bovine rhodopsin which has low homology 
(<35%) to most GPCR’s of pharma interest.   
Consequently we have been developing the MembStruk method for prediction of 
3D structures for GPCRs from primary sequence without using homology modeling.  
MembStruk is based on the organizing principle provided by knowing that a GPCR has a 
single chain with seven helical TM domains threading through the membrane, which we 
find to provide sufficient structural information when combined with atomistic 
simulations (molecular dynamics and Monte Carlo) to deduce 3D structures for GPCRs 
adequate to predict the binding site and relative binding energy of agonists and 
antagonist.  We have been applying MembStruk to several GPCRs, where the validation 
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has been based on the comparison of the predicting binding site to experimental binding 
and mutation data.  In this paper we describe the details of the MembStruk method and 
validate the accuracy of the predictions by comparing with the only high-resolution 
crystal structure available for a GPCR, bovine rhodopsin.   
Because the function of a GPCR is to signal to the interior of the cell in the 
presence of a particular ligand bound to the extracellular surface, it is most relevant to 
determine the 3D structure for the conformation of the protein involved in activating G-
protein.  It is widely thought that there are two distinct conformations of GPCRs, one 
active and one inactive, in equlibrium, even in the absence of ligands (Melia et al., 1997; 
Strange 1998; Schöneberg et al., 2002).  This equilibrium is shifted when a ligand binds 
to the GPCR. Thus it would be valuable  to know four structures of the protein:  
• the apo-protein in both the active and inactive forms and  
• the ligand-bound form in both the active and inactive forms.   
so that one could study the process of GPCR activation. Even for bovine rhodopsin, there 
is crystal structure data for only one of these four (the ligand-bound inactive form). We 
postulate in this paper a model of activation involving the EC-II loop and TM3 in which 
the structure is assumed  
• to be in the active form, when the EC-II loop is ”open” and  
• to be in the inactive form when the EC-II loop is “closed.” 
It is the closed conformation that is observed in the rhodopsin crystal structure 
(Palczewski et al., 2000; Okada, et al., 2001). In this paper we report the MembStruk 
predicted structures for all four structures, although comparison can be made directly to 
experiment only for the closed loop with ligand case.  
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Except for bovine rhodopsin the only experimental validation for the accuracy of 
predicted GPCR structures must rest on predicting the binding sites and energies for 
various ligands and how they are modified by various mutations.  To make such 
predictions from first principles, we developed the HierDock method, which we validate 
here by predicting the binding site of retinal in bovine rhodopsin both for the 
experimental 3D structure and for the predicted structures (open and closed loop). 
The first report on MembStruk and HierDock (Floriano et al., 2000; Vaidehi et 
al., 2002) focused on olfactory receptors (OR), where ligand-binding data was available 
for 24 simple organic molecules to 14 different ORs (Malnic et al., 1999).  More recently 
these methods have been applied to predict the structures and function for GPCRs of such 
diverse subfamilies as: β1- and β2-adrenergic receptor, dopamine D2 receptor, 
endothelial differentiation gene (EDG) 6, sweet gustatory, and olfactory receptors 
(Vaidehi et al., 2002; Freddolino et al., 2003 in review; Kalani et al., 2003 
communicated; Floriano et al., 2003 communicated). The HierDock technique has also 
been validated for globular proteins where the crystal structures are available (Wang et 
al., 2002; Datta et al., 2002; Datta et al., 2003; Kekenes-Huskey et al., 2003 accepted; 
Floriano et al., 2003 accepted). We find that the predicted structures of the adrenergic and 
dopamine receptors lead to binding sites for the endogenous ligands in excellent 
agreement with the plentiful mutation and binding experiments.  Similarly the predicted 
binding sites and affinities for EDG 6, mouse I7 and rat I7 olfactory receptors, and 
human sweet receptor are consistent with the available experimental binding data.   
However a quantitative assessment of the accuracy of these structure and function 
prediction methods can be made only for bovine rhodopsin, for which there is a high- 
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resolution experimental crystal structure available with ligand attached to the protein.  
Thus this paper provides a detailed study of rhodopsin to validate the various steps 
involved in our procedures for prediction of the 3D structures of GPCRs (MembStruk) 
and for the prediction of the binding site and the binding energy of the retinal ligand to 
bovine rhodopsin (HierDock).   
Section 2 gives the details of the MembStruk and HierDock protocols, while 
Section 3 describes the results of structure and function prediction for bovine rhodopsin.  
These results are discussed in Section 4 followed by conclusions in section 5.  
Computational methods 
 
Force fields (FF) 
 
All calculations for the protein used the DREIDING FF (Mayo et al., 1990) with 
charges from CHARMM22 (MacKerell et al., 1998) unless specified otherwise. The non-
bond interactions were calculated using Cell Multipole Method (Ding et al., 1992) in 
MPSim (Lim et al., 1997). 
The ligands were described with the DREIDING FF (Mayo et al., 1990) using 
charges from quantum mechanics (QM) calculations on the isolated ligand [ESP charges 
calculated using Jaguar (Jaguar,v4.0)].  For the lipids we used the DREIDING FF with 
QEq charges (Rappé et al., 1991). Some calculations were done in the vacuum (e.g., final 
optimization of receptor structure to approximate the low dielectric membrane 
environment). For structural optimization in the solvent (water) we used the Analytical 
Volume Generalized Born (AVGB) (Zamanakos, 2001 Caltech Chemistry Thesis) 
approximation to Poisson-Boltzmann (PB) continuum solvation (PB). 
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 We use the Dreiding FF due to its generic applicability to all molecules 
constructed from main group elements (particularly all organics) since we will use our 
methods to predict the binding site and energy for a diverse set of ligands of interest to 
pharma. Indeed we find below that the minimized structure for bovine rhodopsin deviates 
from the crystal structure by only 0.29 Å, CRMS. The Dreiding FF with CHARMM22 
charges has been validated for molecular dynamics simulations and binding energy 
calculations for many proteins (Brameld et al., 1999; Datta et al., 2003; Wintrode et al., 
2003; Datta et al., 2002; Wang et al., 2002; Kekenes-Huskey et al., 2003; Floriano et al., 
2003) with similar accuracy.  
Validation of the force fields: The crystal structure of bovine rhodopsin 
(resolution 2.80 Å) was downloaded from protein database (pdb entry 1F88). The Hg 
ions, sugars, and waters were deleted from this structure. This crystal structure is missing 
10 complete residues in loop regions and the side chain atoms for 15 additional residues. 
We added the missing residues and side chains using WhatIf (Vriend et al., 1990). We 
then fixed the TM helices and minimized (using conjugate gradients) the structure of the 
loop region to an RMS force of 0.1 kcal/mol/Å. Then we added hydrogens to all the 
residues using the PolyGraf software. The potential energy of the entire structure of 
rhodopsin was then minimized (using conjugate gradients) to an RMS force of 0.1 
kcal/mol/Å . This minimized structure deviates from the x-ray crystal structure by 0.29 Å 
coordinate root mean square (CRMS) error over all atoms in the crystal structure. This is 
within the resolution of the crystal structure, validating the accuracy of the FF and the 
charges.  This FF minimized crystal structure is denoted as ret(x)/closed(xray).  
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The MembStruk protocol for predicting structure of GPCRs 
MembStruk uses the hydrophobic profile of multisequence alignment of GPCRs 
to assign the helical TM regions. This is combined with a series of steps of Monte Carlo 
like systematic search algorithm to optimize the rotation and translational orientation of 
the TM helices. This search algorithm allows the structure to get over barriers and make 
the conformational search more comprehensive. This is followed by molecular dynamics 
(MD) calculations at a variety of coarse-grain to fine-grain levels in explicit lipid bilayer.   
 MembStruk was first described in Floriano et al. 2000. This method (now labeled 
as MembStruk 1.0) was improved to include energy optimization to determine the 
rotation of helices in the seven helical TM bundle in Vaidehi et al. 2002, now referred to 
as MembStruk2.0. In the current paper we have modified MembStruk (now denoted as 
MembStruk3.5) to also include optimization of the helix translations along their axes and 
rotational optimization using hydrophobic moment of the helices. The MembStruk3.5 
procedure for predicting structures of GPCRs consists of the following steps: 
1. Prediction of TM regions from analysis of the primary sequence 
2. Assembly and coarse-grain optimization of the seven helix TM bundle 
3. Optimization of individual helices 
4. Rigid body dynamics of the helical bundle in a lipid bilayer 
5.  Addition of inter-helical loops and optimization of the full structure. 
Henceforth in this paper any reference to MembStruk always refers to MembStruk3.5 
unless mentioned otherwise. We will next discuss some of the details of these steps in 
MembStruk.  We should emphasize here that these steps are all automated into a single 
MembStruk procedure.  Thus the sequence is fed to MembStruk and the result at the end 
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is a final 3D structure for the protein in the lipid bilayer. A screenshot of the graphical 
user interface for part of this program is shown in Figure S5. Of course we also examine 
the various intermediate results generated in this procedure to allow us to detect 
problems, to gain insight into the validity of the various criteria, and to provide hints on 
improvements to make in the methods.  
Step 1: Prediction of TM regions (TM2ndS): Prediction of the TM helical regions 
for GPCRs from the sequence rests on the assumption that the outer regions of the TM 
helices (in contact with the hydrophobic tails of the lipids) should be hydrophobic and 
that this character should be largest near the center of the membrane (Donnelly et al., 
1993; Eisenberg et al., 1984). The TM2ndS method uses this concept to generate a 
hydrophobic profile:  
Step1a: Sequence alignment. The first part of step 1 for TM2ndS uses the SeqHyd 
hydrophobic profile algorithm, which is based on peak signal analysis of the hydrophobic 
profile for each amino acid. We first tested the use of the Prift scale (Cornette et al., 
1987) but we found that the hydrophobicity index value for Arg was opposite that 
expected for a charged residue, leading to obviously incorrect assignments. We then 
switched to the use of the Eisenberg hydrophobicity scale (Eisenberg et al., 1982) which 
is based on sound thermodynamic arguments. This scale has a range from –1.76 to 0.73 
and works well for Arg and other residues to give consistent TM predictions for the many 
systems we have investigated. The Eisenberg scale has been used in all published 
MembStruk results (1.0 onward). SeqHyd requires a multiple sequence alignment using 
sequences related to bovine rhodopsin. This is constructed by:  
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• Using an NCBI Blast search (Altschul et al., 1990,1997) on bovine rhodopsin 
(primary accession number P02699) to obtain protein sequences with bit scores above 
200 but not identical (to avoid numerical bias in later calculations) to bovine 
rhodopsin (E value less than e-100).  We prefer an ensemble of sequences providing a 
uniform distribution of sequence identities from 35 to 100%.  For bovine rhodopsin, 
this leads to the 43 sequences in Table S1 of the supplemental material. 
• These 43 sequences plus Bovine rhodopsin were used in ClustalW (Thompson et al., 
1994) to generate a pair-wise multiple sequence alignment. This sequence alignment 
included sequences with identities to the bovine rhodopsin sequence as low as 40%. 
In general we might include sequences with higher non-zero E-values, but including 
too low a homology might lead to additional alignment problems. 
Step 1b: Average consensus hydrophobicity and initial TM assignment. The second 
part of step1 of TM2ndS is to calculate the consensus hydrophobicity for every residue 
position in the alignment. This consensus hydrophobicity is the average hydrophobicity 
[using the Eisenberg hydrophobicity scale] of all the amino acids in that position over all 
the sequences in the multiple sequence alignment. Then, we calculate the average 
hydrophobicity over a window size (WS) of residues about every residue position, using 
WS ranging from 12 to 20. This average value of hydrophobicity at each sequence 
position is plotted to yield the hydrophobic profile, as shown in Figure 1 for WS=14.  
The baseline for this profile serves as the threshold value for determining the TM regions 
and is calculated as follows:   
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1) First, we obtain the global average hydrophobicity value over all residues in the 
protein but excluding the amino terminus region (34 residues) and the carboxyl 
terminus region (42 residues). This global average is 0.041 for bovine rhodopsin.  
2) If the baseline in 1) does not resolve the expected seven peaks, then TM2ndS 
automatically changes the baselines over a range of 0.05 from the global average 
(thus -0.009 to 0.091 for bovine rhodopsin). The baseline closest to the average that 
yields the 7 peaks is used for TM region prediction. This modified baseline 
(base_mod) is shown as the pink line in Figure 1. It provides the basis for the accurate 
determination of the TM regions in the sequence. This final baseline may be 
interpreted physically as a ∆G=0 value above which residues are thermodynamically 
stable in the transmembrane and below which they are not. This baseline is unique to 
the particular protein to which it is being applied, with its individual environmental 
factors (water clusters, ions, hydrophobic or hydrophilic ligand or interhelical 
interactions, membrane composition) that may change the relative stability of any 
particular residue. 
Below WS = 12 the fluctuations in hydrophobicity (“noise”) are too large to be 
useful. The lowest WS that yields seven peaks (with peak length greater than 10 and less 
than 50, and peak area greater than 0.8) is denoted as WSmin. The peaks ranges for WSmin 
are used as input for the helix capping module discussed in the next section.  
Figure 1 shows that assigning the TM region to helix 7 is a problem because it has 
a shorter length and a lower intensity peak hydrophobicity compared with all the other 
helices. This has been observed for other GPCRs (Vaidehi et al., 2002). The low intensity 
of helix 7 arises because it has fewer highly hydrophobic residues (ile, phe, val, leu) and 
 25
because it has a consecutive stretch of hydrophilic residues (e.g., KTSAVYN). These 
short stretches of hydrophilic residues (including Lys296) are involved in the recognition 
of the aldehyde group of 11-cis-retinal in rhodopsin.  For such cases, we use as the 
baseline for assigning the TM predictions the local average of the hydrophobicity (from 
minimum to minimum about this peak).  TM2ndS automatically applies this additional 
criteria when the peak length is less than 23, the peak area is less than 0.8, and the local 
average more than 0.5 less than the base_mod. For bovine rhodopsin only TM7 satisfies 
this criterion and the local average (0.011) is shown by the red line in Figure1. Thus, this 
local average is automatically applied for proteins where the residues are relatively 
hydrophilic but in which the helix might still be stable because of local environmental 
factors (mentioned above) that stabilize these residues. 
Step 1c: Helix Capping in TM2ndS: It is possible that the actual length of the helix 
would extend past the membrane surface. Thus, we carry out a step aimed at capping 
each helix at the top and bottom of the TM domain.  This capping step is based on 
properties of known helix breaker residues, but we restrict the procedure to not extend the 
predicted TM helical region more than six residues. We consider the potential helix 
breakers (Donnelly et al., 1994) as  
• P, G,  
• positively charges residues (i.e., R, H, K), and  
• negatively charged residues (i.e, E, D).  
TM2ndS first searches up to four residues from the edge going inwards from the initial 
TM prediction obtained from the previous section for a helix breaker. If it finds one, then 
the TM helix edges are kept at the initial values. However, if no helix breaker is found, 
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then the TM helical region is extended until a breaker is found, but with the restriction 
that the helix not be extended more than 6 residues on either side. The shortest helical 
assignment allowed is 21, corresponding to the shortest known helical TM region. This 
lower size limit prevents incorporation of narrow “noise” peaks into TM helical 
predictions.  
 We have used this TM2ndS algorithm for predicting the structure for ~ 10 very 
different GPCR classes (Vaidehi et al., 2002). In each case the predicted binding site and 
binding energy agrees well with available experimental data, providing some validation 
of the TM helical region prediction.  However only for bovine rhodopsin can we make 
precise comparisons to an experimental structure.  Figure 2 compares the predictions of 
TM helical regions for bovine rhodopsin to the TM helical regions as assigned in the 
crystal structure (Palczewski et al., 2000). To determine which residues have an alpha 
helical conformation, we analyzed the phi-psi angles using PROCHECK (Laskowski et 
al., 1993) and considered the experimental structure to be in an α-helix if -37 < φ < -77 
and -27 < ψ< -67. This led to slightly shorter helices than quoted in the crystal structure 
paper. Thus the lowercase letters in Figure 2 indicate residues which are outside the 
above range but quoted as helices in the experimental paper. The results are:  
• For TM1 our prediction adds P at the start and H at the end.  In our final structure the 
(φ,ψ) for this P is (Not applicable [N-terminus],-43.6) and for this H is (-54.3,-32.4) 
whereas the values obtained in the crystal structure are (-44.3,-24.9) and (-72.5, 69.5) 
respectively.  Since P and possibly H might be expected to break the helix, we are 
considering modifying our procedure to not keep such terminal P or H in the helix.  
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• For TM2 our prediction adds HG at the end.  In our final structure the (φ,ψ) for this H 
and G are (-73.6,-80.9) and (-55.0,148.8) whereas the values obtained in the crystal 
structure are (-74.2,0.5) and (66.1,9.0), respectively.  The crystal structure paper 
considered the H as part of the helix. Since HG could be expected to break the helix, 
we are considering modifying our procedure to not keep the terminal HG in the helix. 
In fact, the HG angles in our final structure fall outside our criteria for alpha helicity 
as a result of the MembStruk optimization of the structure.  
• For TM3 our predictions miss the RYVVV assigned in the crystal structure to the 
helix. Since the first and second V do not have (φ,ψ) in the usual range for alpha 
helices, we consider that the VVV should be excluded.  However, the polar character 
of RY leads TM2ndS to miss assigning them as part of the helix. The crystallographic 
(φ,ψ) for R and Y residues are (-55.5,-63.8), (-44.6,-56.3) whereas the values 
obtained in our final structure are (76.7,-51.4), (-62.9,119.2). It should be pointed out 
that the B-factors on the cytoplasmic end of the rhodopsin crystal structure are high in 
this region of the helix (pdb entry 1F88). This indicates that the helix is probably 
fluxional even when the receptor is not activated. Consequently caution should be 
used when comparing our predictions with the crystal structure at this end. Also, 
because the helices are translated to align hydrophobic centers in a later step of the 
procedure, this uncertainty in TM helical prediction may only lead to local errors in 
atomic structure. 
• For TM4 our prediction adds G at the end and misses N at the start.  The 
crystallographic (φ,ψ) for these N and G residues are (-43.5,-59.6) and (169.8,5.4) 
whereas the value obtained in our final structure are (-93.9,119.6) and (112.5,-118.4). 
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Thus the predictions are fine even though the G and N were misassigned. We are 
considering modifying our procedure to exclude a terminal G.  
• Compared to the crystal structure assignment, our prediction for TM5 adds LVF at 
the end and misses N at the start.  In addition the GQ at the end terminus in the crystal 
structure assignment have (φ,ψ) outside the range for alpha helices.  Thus we consider 
that the terminal GQLVF in the TM2ndS predictions are in error, the largest error of 
any of the predictions. The crystallographic (φ,ψ) for these N and LVF residues are (-
69.3,-51.1), (-48.2,-36.7), (-39.6,-27.1), and (-58.0,-26.5) whereas the values obtained 
in our final structure are (-109.9,-162.4), (-55.1,-47.8), (-63.4,-59.0), and (-81.5,59.3). 
The rhodopsin crystal structure has high B-factors for the intracellular end of TM5 
(just as for helix 3) suggesting caution in making comparisons.  
• For TM6 our prediction adds H at the end and misses EVT at the start.  The 
crystallographic (φ,ψ) for these EVT and H residues are (-57.6,-53.0), (-54.1,-55.7), (-
56.3,-52.3), and (-81.3,48.8) whereas the value obtained in our final structure are (-
74.4,72.3), (-73.1,130.8), (-16.9,-53.0), and (7.1,87.7). Thus the predictions are fine 
despite the misassignments. We are considering modifying our procedure to exclude a 
terminal H. In fact, the H angles in our final structure fall outside our criteria for 
alpha helicity as a result of the MembStruk optimization of the structure.  
• For TM7 our prediction adds P at the start and misses Y at the end.  The 
crystallographic (φ,ψ) for the P and Y residues are (-30.2,-48.1) and (-46.0,-55.0) 
whereas the value for P obtained in our final structure is (-43.6,-23.2). Since the 
current MembStruk protocol does not model the structures of the C and N termini, we 
did include the Y in our structure. Thus the predictions are fine despite the 
 29
misassignments. We are considering modifying our procedure to exclude a terminal 
P, but it is not obvious that a modified method would automatically include the Y. In 
fact, the P angles in our final structure fall outside our criteria for alpha helicity as a 
result of the MembStruk optimization of the structure. 
 Overall, we consider that the predictions agree sufficiently well with the crystal 
structure to be useful in building them into the assembly. In addition, we can see several 
improvements in the capping procedure of TM2ndS that could have decreased the errors 
in predicting which residues near the ends are considered to be helix breakers for capping 
the TM helices.  However, this paper is meant to validate the procedure we have been 
applying to many systems and we did not want to change the procedure on the basis of 
our only independent validation.  
 
Step 2: Assembly and optimization of the seven helical TM bundle:  
 Having predicted the seven TM helix domains using TM2ndS, we next build them 
into the seven helical TM bundle.  This involves two steps: assembly and optimization of 
the relative translation and rotation of the helices. 
Step 2a: Assembly of the Seven TM helices into a bundle: Canonical right-handed 
α-helices are built for each helix using extended side chain conformations. Then the 
helical axes are oriented in space according to the 7.5Å electron density map of frog 
rhodopsin (Schertler et al., 1998).  This 7.5Å electron density map gives only the rough 
relative orientations of the helical axes, with no data on atomic positions. This serves as 
the starting point for optimization of the helices in the helical bundle.  It should be 
emphasized here that no information as to helical translations or rotations was used. 
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Since this electron density map showed no retinal present, it is not clear whether this 
form of rhodopsin is active or inactive. This same information has been used to build 
structures of ~10 other GPCR classes (Vaidehi et al., 2002). In each case the predictions 
of binding site and binding energy agrees well with available experimental data, 
providing some validation for this general approach of constructing the TM bundle of 
GPCRs. However for bovine rhodopsin we can make much more precise comparisons to 
the experimental structures, as reported below.   
Step2b: Optimization of the Relative Translation of the helices in the bundle:  The 
translational and rotational orientation of each helix in the TM bundle is critical to the 
nature and conformation of the binding site in the GPCR. We do not use homology 
methods to predict these quantities because many GPCRs have very remote sequence 
homology to rhodopsin (ranging down to 10%) making it quite risky to base a three- 
dimensional structure on homology modeling using the rhodopsin crystal structure as 
template. Also we do not use atomistic molecular dynamics (MD) and molecular 
mechanics (MM) methods to optimize the structure, because the large barriers between 
various favorable positions can trap the conformation in local minima making such 
approaches ineffective in repositioning the helices.  Instead we developed methods to 
optimize the initial packing by translating and rotating the helices over a grid of 
positions and by using various properties of the amino acids in the sequence to suggest 
initial starting points. This Monte Carlo like systematic conformational search algorithm 
for rotational and translational orientation of the helices allows the system to surmount 
barriers in the conformational space.  
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Our general principle in repositioning the helices is that the outer surface of the 
TM bundle (at least the middle regions) should be hydrophobic in order to have 
stabilizing interactions with the hydrophobic chains of the lipid.  We imagine a midpoint 
plane through the lipid bilayer corresponding to the contact of the hydrophobic chains, 
which we denote as the lipid midpoint plane (LMP). We then assume that the 
hydrophobic regions of the TM bundle will position themselves such that the middle of 
their maximum hydrophobicity lies in this plane.  We tested this concept for the crystal 
structure of bovine rhodopsin as follows.  We determined the hydrophobic center (HPC) 
for each helix as the maximum of the peak of hydrophobicity from the profiles generated 
with various window sizes (since we go an integer number of residues in each direction 
WS is always even). Our criterion for the best fit to experiment is that these 7 positions 
when applied to the crystal structure would all lie in a single plane that could be taken as 
the LMP.   
As shown in Figure 3, the deviation of the calculated hydrophobic centers from 
lying in a single plane in the rhodopsin crystal structure is a minimum for WS 20 and 22.  
Thus Get_Centers calculates the overall hydrophobic center of each TM helix based on 
the average of centers obtained for a range of window sizes near 20. Get_Centers 
determines this range of window sizes as follows. First, each hydrophobic center (HC) is 
calculated for WS=20. Then, the HC are calculated for WS 12-30 (excluding WS=20). 
For each helix Get_Centers determines the window sizes that yield HC less then 5 
residues from the HC calculated at WS=20. For example, consider helix 1 in Table 1. 
Here HC = 18 for WS = 20. For windows sizes 12, 14, 16, 18, 22, 24, 26, 28, 30 we find 
HC = 15, 13, 20, 18, 17, 18, 15, 16, 13. For WS 16, 18, 22, 24 the HC are less than 5 
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from the value at WS=20. Thus we consider that the hydrophobic center calculation is 
stable within this regime of window sizes. The HC calculated for WS 16, 18, 22, 24 for 
the helices 2-7 are also less than 5 residues from the centers at WS=20. Thus, 
Get_Centers averages the HC for window sizes 16, 18, 22, 24 and then it averages these 
values with the HC at WS=20 for each TM helix. Get_Centers takes these values (last 
column of Table 1) as the final TM helix centers. We find that for bovine rhodopsin, 
these seven HPC deviate by a root mean square of 1.04 Å from a common plane. 
Step 2c: Optimization of the rotational orientation: Once the helices are aligned 
along their helical axes according to the calculated hydrophobic centers, the rotational 
orientation of the helices is optimized using either or both of the following steps:   
i) Orienting the net hydrophobic moment of each helix to point toward the membrane 
(Phobic Orientation). In this procedure (denoted as CoarseRot-H), the helical face with 
the maximum hydrophobic moment is calculated for the middle section of each helix, 
denoted as the hydrophobic mid-region (HMR).  The face is the sector angle obtained as 
follows: 1) the central point of the sector angle is the intersection point of the helical axis 
(the active helix that is being rotated) with the common helical plane (LMP). 2) The other 
two points forming the arc are the nearest projections (on the LMP) of the Cα vectors of 
the two adjacent helices. The calculation of the hydrophobic moment vector is restricted 
to this face angle. This allows the predicted hydrophobic moment to be insensitive to 
cases in which the interior of the helix is uncharacteristically hydrophilic (because of 
ligand or water interactions within the bundle). Currently we choose HMR to be the 1/3 
of each helix straddling the predicted hydrophobic center and exhibiting large 
hydrophobicity.  This hydrophobic moment is projected onto the common helical plane 
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(LMP) and oriented exactly opposite to the direction toward the geometric center of the 
TM barrel (GCB).  This criterion is most appropriate for the six helices (excluding TM3) 
having significant contacts with the lipid membrane. The LMP is the plane that most 
closely intersects the hydrophobic centers as described in step 2.2.2b.  The GCB is 
calculated as the center of mass of the positions of the alpha-carbons for each residue in 
the HMR for each helix summed over all seven. This procedure is called Phobic 
Orientation. 
ii) Optimization of the rotational orientation using energy minimization techniques 
(RotMin): In this procedure, each of the seven TMs is optimized through a range of 
rotations and translations one at a time (the active TM) while the other six helices are re-
optimized in response. After each rotation of the main chain (kept rigid) of each helix, the 
side chain positions of all residues for all seven helices in the TMR are optimized 
[currently using SCWRL (Bower et al., 1997)].  The potential energy of the active helix 
is then minimized (for up to 80 steps of conjugate gradients minimization until an RMS 
force of 0.5 kcal/mol/Å is achieved) in the field of all other helices (whose atoms are kept 
fixed). This procedure is carried out for a grid of rotation angles (typically every 5 o for a 
range of +/- 50 o) for the active helix to determine the optimum rotation for the active 
helix. Then we keep the active helix fixed in its optimum rotated conformation and allow 
each of the other six helices to be rotated and optimized. Here the procedure for each of 
the six helices one by one is: (1) rotate the main chain, (2) SCWRL the side chains, (3) 
minimize the potential energy of all atoms in the helix. The optimization of these six 
helices is done iteratively until the entire grid of rotation angles is searched. This method 
is most important for TM3, which is near the center of the GPCR TM barrel and not 
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particularly amphipathic (it has several charged residues leading to a small hydrophobic 
moment). This procedure is called RotMin. 
 For bovine rhodopsin, we used Phobic Orientation for placing the hydrophobic 
moments away from the GCB for all seven helices. Subsequently rotations were 
optimized using RotMin for helices 3 and 5 using small rotation angles of ±2.5o, ±5.0 o, 
and ±8.0o. This optimizes the only salt bridge in the TM region (between residues His211 
and Glu122). Coarse-grain rotation optimization combining both the energy optimization 
and hydrophobic moments is expected to provide better optimized TM helices than either 
one alone.  
Step3:  Optimizing the individual helices:  
 The optimization of the rotational and translational orientation of the helices 
described in the above steps is performed initially on canonical helices (we also apply 
them again to the helices after their optimizations described in step3). To obtain a valid 
description of the backbone conformation for each residue in the helix, including the 
opportunity of G, P, and charged residues to cause a break in a helix, the helices built 
from the step 2 were optimized separately.  In this procedure we  
• first use SCWRL for side chain placement  
• then carry molecular dynamics (MD) (either Cartesian or torsional MD called 
NEIMO [Jain et al., 1993 ; Mathiowetz et al., 1994; Vaidehi et al., 1996]) at 300 K 
for 500 ps,  
• then choose the structure with the lowest total potential energy in the last 250 ps and 
minimize it using conjugate gradients.  
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This optimization step is important to correctly predict the bends and distortions that 
occur in the helix due to helix breakers such as proline and two glycines. The MD also 
carries out an initial optimization of the the side chain conformations, which is later 
further optimized within bundle using Monte Carlo side chain replacement methods. This 
procedure allows each helix to optimize in the field due to the other helices in the 
optimized TM bundle from Step 2.  
Step 4: Addition of lipid bilayer and fine-grain re-optimization of the TM 
bundle: To the final structure from Step 3 MembStruk adds two layers of explicit lipid 
bilayers.  This consists of 52 molecules of dilauroylphosphatidyl choline lipid around the 
TM bundle of seven helices. This was done by inserting the TM bundle into a layer of 
optimized bilayer molecules in which a hole was built for the helix assembly and 
eliminating lipids with bad contacts (atoms closer than 10 Å). Then we used the 
quaternion-based rigid body molecular dynamics (RB-MD) in MPSim(Lim et al., 1997) 
to carry out RB-MD for 50 ps (or until the potential and kinetic energies of the system 
stabilized). In this RB-MD step the helices and the lipid bilayer molecules were treated as 
rigid bodies and we used 1 fs time steps at 300 K. This RB-MD step is important to 
optimize the positions of the lipid molecules with respect the TM bundle and to optimize 
the vertical helical translations, relative helical angles, and rotations of the individual 
helices in explicit lipid bilayers.  
Step 5: Loop building: Following the RB-MD, we added loops to the helices using the 
WHATIF software (Vriend et al., 1990). After the addition of loops, we used SCWRL 
(Bower et al., 1997) to add the side chains for all the residues. The loop conformations 
were optimized by conjugate gradient minimization of the loop conformations while 
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keeping the TM helices fixed. This step also allows the general option of forming 
selected disulfide linkages [e.g., between the cysteines in extracellular 2 (EC-II) loop 
(which are conserved across many GPCRs) and the N-terminal edge of TM3 or EC3]. In 
the case of bovine rhodopsin, the alignment of the 44 sequences from Section 2.21a 
indicates only one pair of fully conserved cysteines on the same side of the membrane 
(extracellular side). The disulfide bond was formed and optimized with equilibrium 
distances lowered in decrements of 2 Å until the bond distance was 2 Å. Then the loop 
was optimized with the default equilibrium disulfide bond distance of 2.07 Å. Annealing 
MD was then used to optimize the EC-II loop at this stage.  This involved 71 cycles in 
each of which the loop atoms were heated from 50 K to 600 K and back to 50 K over a 
period of 4.6 ps. From each cycle the minimum potential energy structure was selected 
and minimized.  We finally used the overall minimum energy structure for subsequent 
steps. During this process the rest of the atoms were kept fixed for the first 330 ps and 
then the side chains within the cavity of the protein in the vicinity of the EC-II loop were 
allowed to move for 100 ps to allow accommodation of the loop. Subsequently a full 
atom conjugate gradient minimization of the protein was performed in vacuum using 
MPSim (Lim et al., 1997). This leads to the final MembStruk predicted structure for 
bovine rhodopsin.  
The crystal structure for the retinal/rhodopsin complex has a well-defined β-sheet 
structure for EC-II, which we speculate to be involved as a mobile gate for entry of 11-
cis-retinal on the extracellular side of rhodopsin. Such a gating mechanism is illustrated 
in Figure 4 in which the helix 3 coupled to this loop by a cysteine bond is the 
“gatekeeper” which responds to signaling structural sub-states of rhodopsin as follows:  
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1) When rhodopsin binds 11-cis-retinal, the ground state conformation of the receptor is 
stabilized, thus shifting helix 3 towards the intracellular side (forming the D(E)RY-
associated salt bridges at that end) and “closing” the EC-II loop. In fact, 11-cis-retinal 
has been shown to be an inverse agonist for G-protein signaling (Okada et al., 2001). 
2) In response to absorption of a photon, the 11-cis retinal isomerizes to the all-trans 
conformation, inducing helix 3 to shift towards the extracellular side. This induction 
of helix 3 movement may be direct or indirect. It may be due to a direct clash of helix 
3 with all-trans-retinal. This is consistent with the result of a cross-linking experiment 
in which the ionone ring of retinal interacts with Ala269 when the receptor is 
activated (Borhan et al., 2000). This may occur because the trans-retinal clashes with 
helix 3 of the ground state rhodopsin crystal structure (Bourne at al., 2000). The 
induction of helix 3 movement may also occur indirectly in the following way: 11cis-
retinal as observed in the crystal structure interacts with aromatic side chains Trp265 
and Tyr268 on helix 6. But all-trans-retinal does not have these stabilizing interaction 
with helix 6, which should decrease the energy barrier for helix 6 rotation [this has 
been observed in preliminary MD calculation we carried out and in reports in the 
literature (Saam et al., 2002)]. 
3) This motion (of helix 3 or helix 6) breaks the DRY-associated salt bridges (Greasley 
et al., 2002) at the intracellular side. Helix 3 may have fewer constraints to 
movement, but since it is coupled by a disulfide linkage to the EC-II loop, movement 
on helix 3 would likely cause an “opening” of the EC-II loop to allow Schiff base 
reversion and exit of the free all-trans-retinal ligand. The breaking of this DRY salt 
bridge would also allow hinge motion (Altenbach et al., 2001: 1 and 2) of helix 6 to 
 38
expand the molecular surface at the cytoplasmic end for G-protein binding. This 
model is consistent with the experimental mutations studies in which the disulfide has 
been shown to be important for ligand binding and receptor activation (Schöneberg et 
al., 2002). 
 Building the loops without the constraint of coupling these cysteines leads to an 
open EC-II loop very different from the crystal structure of bovine rhodopsin.  It is likely 
that both the open loop and closed loop structures play an important role in GPCRs, and 
indeed general observations of GPCRs suggests two distinct forms one of which leads to 
activation of G protein and one of which does not.  We consider that one of these is likely 
the closed form and the other the open form.  It seems likely that the ligand might not be 
able to diffuse into the active site when the loop is closed and hence for most GPCRs 
(other than bovine rhodopsin) we visualize the process of activation as:  
• The GPCR with the open form of EC2 loop can bind selectively to the appropriate 
ligand; 
• Binding of the ligand favors closing of the EC2 loop; 
• After closure of the loop, G protein activation may begin.  
 Thus we have built two structures for bovine rhodopsin (Here the MS denotes that 
the structure was predicted using MembStruk):  
• Apo/closed(MS) has the cysteine coupling observed in the crystal and is the structure 
we compare to experiment after binding the retinal 
• Apo/open(MS) is built without a constraint, forming what we believe would be the 
configuration which binds initially to the ligand.   
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Function prediction for GPCRs  
 Since there are no experimental structures available for any human GPCR, the 
only validation available for the accuracy of predicted structures for human GPCRs is to 
predict the ligand binding sites and the ligand binding energies. The accuracy in the 
predicted binding site can then be judged from site-directed mutagenesis experiments on 
the residues predicted to control selectivity.   An even tougher test is to compare binding 
affinity of ligands to each other and to mutated proteins.  For many GPCRs of 
pharmaceutical interest there is ample experimental data on ligand binding constants as 
well as agonist and antagonist inhibition constants for many GPCRs (for a compilation of 
this literature see http://www.gpcr.org).  
 To carry out such function validations for the predicted structures, it is essential to 
have reliable and efficient procedures for predicting binding site and binding affinities.  
Since the ligand-binding site is completely unknown for most GPCRs, we must scan the 
entire protein to identify likely binding sites and conformation of each ligand, and then 
we must reliably rank the relative binding energies of the various ligands in these sites. 
To do this we employ the HierDock procedure, which has been tested and validated for 
predicting ligand binding sites and ligand binding energies for many globular and 
membrane bound proteins ( Vaidehi et al., 2002; Kekenes-Huskey et al., 2003 accepted; 
Floriano et al., 2003 accepted; Datta et al., 2003;  Datta et al., 2002). These studies show 
that the multi-step hierarchical procedure in HierDock ranging from coarse-grain docking 
to fine-grain MD optimization leads to efficient and accurate predictions for ligand 
binding in proteins.  
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The HierDock method was first described in Floriano et al. 2000, which we label as 
HierDock1.0. The method was improved in Vaidehi et al. 2002, which we label as 
HierDock2.0. In this paper we present an improved version that we label as HierDock2.5. 
The various steps involved in this current procedure are as follows: 
1. Sphere generation. We assume no knowledge of the ligand binding site in GPCRs 
and hence the entire molecular surface of the receptor is scanned to predict the 
energetically preferred ligand binding sites.  The negative of the molecular surface of 
the protein was used to define potential binding regions within the receptor over 
which the various ligand conformations are to be sampled. The void regions are 
mapped with spheres generated over the whole receptor using the Sphgen program in 
DOCK 4.0. No assumptions were made on the nature or the location of the binding 
site in these receptors. For bovine rhodopsin this led to total of 7474 spheres, which 
was partitioned into 13 overlapping docking regions each with a volume of (10Å)3 as 
shown in Figure 5. We excluded from docking regions in contact with the membrane 
or near the intracellular region likely to be involved in binding to the G-protein.  No 
assumptions were made on the nature or the location of the binding site in these 
regions.  
2. Coarse-grain sampling. To locate the most favorable ligand binding site(s), we used 
DOCK 4.0 (Ewing et al., 1997) to generate a set of conformations for binding 11-cis-
retinal (a ligand known to bind to bovine rhodopsin) to each of the 13 regions. For 
this docking step we used a bump filter of 10, a non-distance dependent dielectric 
constant of 1.0, and a cutoff of 10Å for energy evaluation. The ligands were docked 
as non-flexible molecules to generate and score 100 conformations of the ligand in 
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each of the 13 regions. We then rejected any ligand conformation with less than 90% 
of the surface area buried into the protein and ranked the remainder by the ligand-
protein interaction energy using Dreiding FF. The best binding energy conformation 
among the 13 regions was chosen as the putative binding region. Other conformations 
with binding energies within 10 kcal/mol of the best conformation were also chosen 
as possible binding regions.  
3. Construction of putative binding region using a more refined sampling of ligand-
protein interactions.  A set of overlapping boxes were used to enclose the volume 
corresponding to the putative "binding region" (or regions) determined in step 2, 
which is now to be used for a new sampling of ligand-protein conformations similar 
to 2.   
4. Coarse-grain sampling of putative binding regions. To locate the most favorable 
ligand binding site(s), we again used DOCK 4.0 to generate a set of conformations for 
binding 11-cis-retinal (a ligand known to activate bovine rhodopsin) to the putative 
binding region. We again used a bump filter of 10, a non-distance dependent 
dielectric constant of 1.0, and a cutoff of 10 Å for energy evaluation. The ligands 
were docked as non-flexible molecules to generate and score 1000 conformations. 
After eliminating ligands with less than 90% surface burial, we selected the 10% 
(100) with best DOCK4.0 score for further analysis. 
5. Ligand-only minimization. The 100 best conformations selected from step 4 were 
(conjugate gradient) minimized keeping the protein fixed but all atoms of the ligand 
movable. Minimized ligand conformations that satisfied the buried surface area cutoff 
criterion of 75% were kept for the next step. 
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6. Ligand-protein full minimization. The  ligand/protein conformations from step 5 were 
further energy minimized with all atoms (protein, lipid, and ligand) movable using 
conjugate gradients. The structure with the binding energy calculated by equation (1) 
was selected: 
BE1 = Energy (ligand in protein complex) - Energy (free ligand in solvent)            (1) 
Here the energy of the ligand in water is calculated using DREIDING FF and AVGB 
continuum solvation method. Since a substantial part of the complex is in contact 
with the membrane environment, we did not solvate the complex. 
7. Using the best binding conformation from step 6, the side chain conformations for all 
the residues within 5Å of the bound 11cis-retinal conformation were optimized using 
the SCREAM side chain optimization program (Kam et al., unpublished). The 
resulting ligand-protein structure was finally optimized by conjugate gradient 
minimization allowing all atoms to relax. 
8.  Iterative HierDock (optional). The protein from step 7 (optimized with ligand bound) 
was saved. The steps 4-6 were repeated again in order to obtain the best possible 
conformation for the ligand within the protein (with side chains optimized in the 
presence of the ligand). This step was performed for bovine rhodopsin.  
Results and discussion 
We first present the results for the validation of the HierDock protocol on the 
crystal structure of bovine rhodopsin, followed by results on structure and function 
prediction for bovine rhodopsin.  In order to clarify our notation we summarize it here.  
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• Ret(xtal)/closed(xtal) is obtained from the crystal structure by minimizing using the 
Dreiding FF. It deviates from the crystal structure by 0.29Å CRMS. It has retinal 
bound as in the crystal structure and has the closed form of the EC2 loop. The retinal 
conformations differ by 0.22 Å CRMS. This further validates the FF. Since they 
differ so little, the retinal in the non-minimized crystal structure, ret(xtal-noFF), is 
used as the reference structure for the HierDock validation step.  
• Apo/closed(xtal) is obtained from Ret(xtal)/closed(xtal) by removing the retinal and 
adding the proton to Lys296. It was minimized without ligand. It deviates from the 
crystal structure by 0.74Å CRMS.  It is likely that this is a lower bound on the change 
in structure upon removal of the retinal.  For a more complete optimization, we would 
use MD. 
• Ret(HD)/closed(xtal) is the predicted structure for 11-cis retinal obtained by applying 
HierDock to Apo/closed(xtal) and then forming the Schiff base linkage to Lys296 and 
minimizing. The ret(HD) deviates from Ret(xtal) by 0.62Å CRMS. To distinguish the 
error in ligand conformation due to the HierDock procedure from that due to 
MembStruk, the structure Ret(HD)/closed(xtal) will serve as the reference structure to 
compare to the predicted ligand conformations in the MembStruk structures.  
• Apo/closed (MS) is the MembStruk predicted structure of the closed form, without the 
retinal. The TM bundle for this structure deviates by 2.84 Å CRMS main chain atoms 
from Apo/closed(xtal) (4.04 Å CRMS for all TM  atoms, excluding H) 
• Ret(HD)/closed(MS) is the predicted structure for 11-cis retinal in the 
Apo/closed(MS) rhodopsin structure, obtained by applying HierDock to 
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Apo/closed(MS) and then forming the Schiff base linkage to Lys296 and minimizing 
the energy The ret(HD) deviates from Ret(HD)/closed(xtal) by 2.92 Å CRMS. 
• Apo/open(MS) is the MembStruk predicted structure of bovine rhodopsin without the 
retinal. There are no experiments with which to compare.  This structure differs in the 
TM region from Apo/closed(MS) by 0.11 Å. 
• Ret(HD)/open (MS) is the predicted structure for 11-cis retinal in rhodopsin obtained 
by applying HierDock to Apo/open(MS) and then forming the Schiff base linkage to 
Lys296 and minimizing. There are no experiments with which to compare.  The 
retinal differs from that in Ret(HD)/closed (MS) by 1.74 Å. 
Validation for function prediction: HierDock protocol for 11cis-retinal on bovine 
rhodopsin:  
Bovine rhodopsin (a member of the opsin family) is the only GPCR to be 
crystallized in its entirety at a high resolution (2.8Å).  Thus we used this system as a test 
to validate the HierDock protocol for predicting of binding sites of GPCRs.  
To test HierDock, we used the apo/closed(xtal) structure with the retinal removed 
and minimized. First we did a complete HierDock scan as outlined above to predict the 
binding of 11cis-retinal to bovine rhodopsin. The crystal structure of rhodopsin has the 
11cis-retinal covalently bound to Lys 296 (between the aldehyde of 11cis-retinal and the 
N of the Lys), but for docking we cannot have a covalent bond to the crystal.  Thus we 
docked the full 11cis-retinal ligand (containing a full aldehyde group) and considered the 
Lys 296 to be protonated. 
We applied steps 1-2 of the HierDock described above for all 13 overlapping 
regions for step 2 shown in Figure 5.  The initial scan of the entire rhodopsin (step 1 to 2 
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in section 2.3) gave two good binding regions shown as the red boxes in Figure 5.  The 
data for this scanning step are shown in Table 2. The final optimized best binding 
structure for the retinal/rhodopsin complex from step 6 of HierDock deviates by 1.11 Å 
CRMS from the ligand in the crystal structure as seen in Figures 6ab.  The binding site 
(defined as the 7 residues that contribute at least 1 kcal/mol to the bonding) of this ligand 
is shown in Figure 9b. Lys296 has hydrophilic interactions while the other side chains 
have van der Waals interactions. This docked structure has the retinal O 2.72 Å from the 
N of Lys 296.  In addition, the retinal O and the closest H of the protonated Lys296 N are 
just 2.35 Å apart, close enough to form an H-bond (likely an intermediate step before 
Schiff base formation). We then coupled these two units to form the covalent CN bond to 
Lys 296 while eliminating the H2O. After minimizing the full ligand-protein structure, we 
find that the predicted structure for 11cis-retinal bonded to the protein deviates from the 
crystal structure by only 0.62Å CRMS as shown in Figures 6cd. Most of this discrepancy 
results because the FF minimized structure of the retinal has the ionone ring in a chair 
conformation which was retained in our docking procedure, whereas the crystal structure 
has the ionone ring in a half-chair conformation (which we calculate to be  2 kcal/mol 
higher in energy than the chair conformation within the minimized complex). This 
retinal/protein complex minimized with the Dreiding FF [denoted ret(HD)/closed(xtal)] 
serves as the reference structure for comparing the predicted structures in later sections. 
We consider that these results validate the HierDock protocol for a GPCR.  
In addition, we used HierDock to determine the binding site and best scoring 
ligand conformation for all-trans-retinal, with the binding energy calculated using 
equation (1) above. The binding energy for 11cis-retinal was -1 kcal/mol while that for 
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all-trans-retinal was ~31 kcal/mol, a difference of 32 kcal/mol. This compares well with 
the experimental result that the retinal ligand/protein complex stores 34.7 +/-2.2 kcal/mol 
upon isomerization in the protein (Okada et al., 2001). This stored energy might be used 
to induce rigid body helical motions needed for receptor activation and G-protein 
binding. This excellent agreement is probably fortuitous since we have not carried out 
full optimizations of the all trans configuration , but it may be partly because cis and trans 
retinal are neutral isomers of each other with similar solvation energies. 
Structure prediction of rhodopsin using MembStruk  
We used MembStruk3.5 as detailed in section 2.2 to predict the structure of 
bovine rhodopsin using only the protein sequence. For the apo-rhodopsin we predicted 
two structures, one with the open EC-II loop and one with closed EC-II loop. These 
represent two different states of rhodopsin likely to play a role in activation of G-Protein. 
The crystal structure of rhodopsin has a closed EC-II loop with the 11-cis-retinal bound 
to it. To validate this predicted structure, we should compare to the crystal structure for 
apo-rhodopsin (without a bound 11cis-retinal). However, this crystal structure for the apo 
protein is not available.  Thus instead we will compare the predicted structure to the 
minimized crystal structure of bovine rhodopsin after removing the 11cis-retinal.  In 
making these comparisons, we predicted two structures for apo-rhodopsin:  
• the open form where no restrictions were made on the structure of EC-II loop 
[apo/open(MS)] and  
• the closed form where we assumed that EC2 makes the same cysteine linkage as 
observed in the crystal structure [apo/closed(MS)]).  
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The predicted TM domains are compared to the rhodopsin crystal structure in Figure 2 
and discussed in section 2.2.1c   
After optimization of the helices using MD (300 K for 500 ps), most helices yield 
the same bends as in the crystal. Thus helices 2 and 6 undergo significant bending (due to 
Pro267 in helix 6 and due to GLY89 and GLY90 in helix 2), which is consistent with 
spin-labeling EPR experiments (Farrens et al., 1996). In addition, we find that helix 7 
bends near the two prolines, which has also been shown by spin-labeling experiments 
(Altenbach et al., 2001: 1 and 2). We find that helix 1 undergoes significant bending due 
to a GLY/PRO combination, but this has not yet been studied experimentally. Snapshots 
with even more similar bends to the crystal structure (throughout the dynamics) are also 
shown in Figure S2a. The overlays of all snapshots at 2.5 ps intervals in shown in Figure 
S2b. The dynamical nature of the bending can be seen. Such bending at “hinge” sites may 
be important for expanding the molecular surface needed at the cytoplasmic side to allow 
G-protein binding. We find similar “hinge-bending” with MD when the trans isomer is 
bound to the helix assembly. 
The optimized helices were again inserted into a bundle. As a double-check to the 
rotation before the Rotmin step, a 360 degree energy scan was performed more recently 
(Figure S3). The alternate rotation of helix 6 at ~+90 degrees is important, since the helix 
with the most rotation difference than in the crystal structure is helix 6 (~100 degrees). 
This correlates with spin labeling experiments (Farrens et al., 1996) which point to a 
helix 6 rotation on receptor activation. In fact, when analyzing the hydrophobic moment 
orientation for a different number of middle residues from the hydrophobic center (in the 
optimized crystal structure), there are two conformations (Figure S4) of the helix which 
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emerge, corresponding to the two rotations of the active and inactive receptor. For the 
final structure in this current paper, this method was not used on helix 6. 
After the helices were inserted into a bundle again, we carried out RotMin on 
helices 3 and 5, the only helix pair with a potential salt bridge The resulting 7 helix 
bundle was then inserted into a lipid bilayer, and optimized using rigid body molecular 
dynamics as described in step 4 of section 2.2. This step leads to optimization of the 
vertical helical positions, relative helical angles, and rotations of the individual helices 
within a lipid environment. The CRMS difference before and after this rigid body MD is 
1.10Å for all atoms and 0.98Å for main chain atoms. This is consistent with in the 
changes during this optimization step for other GPCRs (Vaidehi et al., 2002). 
After adding the intracellular and extracellular loops, optimizing the side chains, 
and then optimizing the structure in vacuum with the TM helical region fixed (to 
eliminate bad contacts in the loop region), we then optimized the entire structure allowing 
all bonds and angles to change. These ab initio predictions of the structure were carried 
out for both the open and closed forms of the EC-II loop in apo-rhodopsin leading to the 
Apo/open (MS) and Apo/closed(MS) structures where MS denotes a MembStruk derived 
structure and open or closed denotes the open or closed form of the EC-II loop. Although 
the crystal structure has the 11cis-retinal bound, we will compare the predicted apo-
rhodopsin structures to the minimized apo-protein of the crystal structure, 
apo/closed(xray).   
Comparing Apo/closed(MS) to Apo/closed(xray) we find a CRMS difference of 
2.85 Å in the main chain atoms and 4.04 Å for all the atoms in the TM helical region.  
These structures are compared graphically in Figure 7a.  Comparing all residues 
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including loops (but ignoring the residues not present or complete in the x-ray structure), 
the predicted structure differs from the crystal structure by 6.80 Å in the main chain and 
7.80 Å CRMS for all atoms.  The major contribution to this CRMS is the low-resolution 
loop region, which is likely to be quite fluxional and may be very different between 
crystal and solution. Specifically, the predicted topology and phi-psi angles of the EC-II 
loop are consistent with that of a beta-sheet. However, the specific twist of this beta-sheet 
in the xray structure was not predicted well. Although this may be partly due to packing 
effects in the crystal structure, we consider that our prediction of the general topology of 
the EC-II loop to act as a “plug” to restrict retinal binding is adequate but that specific 
interactions with retinal may not be predicted well. In the function prediction results 
discussed below in section 3.3.1, we find that there are no specific favorable interactions 
between the ligand and the EC-II loop before Schiff base bond formation in the crystal 
structure (Figure 9b). Thus the EC-II may function initially primarily as an unspecific 
“plug” to disfavor certain ligand conformations. After Schiff base bond formation, the 
ligand is then stabilized by Glu181 in the EC-II loop (Figure 10A). Thus accurate 
prediction of the atomic structure of the EC-II loop remains an important challenge. 
We find that Apo/open (MS) deviates from Apo/closed(MS) by a CRMS 
difference of 0.11 Å in the main chain atoms and 0.68 Å for all the atoms in the TM 
helical region.  These structures are compared graphically in Figure 7c. This small 
difference in CRMS in the transmembrane region suggests that we need to carry out long 
time scale molecular dynamics in order for the helices to accommodate the EC-II loop 
conformational change. Comparing all residues, the predicted structure differs from the 
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crystal structure by 4.74 Å in the main chain and 5.00 Å CRMS for all atoms.  There is 
no experimental structure apo/open(xray) with which to compare Apo/open (MS).  
HierDock function prediction for Apo_rhod (MS) structures 
 Except for bovine rhodopsin, essentially all applications of HierDock to GPCRs 
must use predicted structures rather than experimental structures.  The question here is: 
given the errors in predicting the GPCR structure (2.8Å CRMS in the TM helical region) 
can we hope to get accurate predictions in the binding site and binding energy? We will 
now test how well HierDock determines the binding site of 11cis-retinal to the predicted 
rhodopsin structures Apo/open (MS) and Apo/closed(MS).  
 Here we repeated the full process described in section 2.3.  The void space for 
both the Apo/open (MS) and Apo/closed(MS) structures were partitioned into fourteen 
7Å x 7Å x 7 Å boxes and scanned for the putative binding site of 11-cis-retinal (using the 
same ab initio FF optimized ligand structure as in section 3.1). Again the molecule 
includes the aldehyde group (no assumed formation of the Schiff’s base).   
Apo/closed(MS) 
Scanning the entire Apo/closed(MS) receptor to find the binding site and binding 
energy for 11-cis-retinal used the steps described in section 2. The best scoring 
conformation for 11cis-retinal and its associated binding site, denoted as NoSB-
ret(HD)/closed(MS) are shown in Figure 9c. Here NoSB indicates the structure without 
the Schiff’s base covalent bond between the aldehyde group of 11cis-retinal and Lys296. 
This conformation (no covalent attachment) differs from Ret(HD)/closed(xtal) by 3.2 Å 
CRMS. We should emphasize that the Apo/closed(MS) structure was constructed purely 
from ab initio predictions with MembStruk, with no input from the x-ray crystal 
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structure.  Thus nowhere did we assume a lysine covalent bond with retinal in any of the 
docking procedures.  Yet, the predicted structure identifies which Lys can bond to the 
retinal, with a 2.85Å between the predicted position of the retinal oxygen and the 
predicted position of the Lys 296 nitrogen.  
Then starting with NoSB-ret(HD)/closed(MS), we formed this Schiff’s base bond 
(eliminating H2O), and optimized the full ligand-protein complex with conjugate gradient 
minimization to obtain the ret(HD)/closed(MS) structure. This differs from 
Ret(HD)/closed(xtal) by 2.92 Å CRMS. These structures are compared in Figures 8ab. 
A second criterion for validity of the predicted binding site is to identify the 
residues interacting most strongly with the ligand, which can be used to predict 
mutational studies for validation and to design antagonists or agonists. Considering the 
binding site as all residues within 5.0Å of the ligand leads to 30 residues for 
Ret(xtal)/closed(xtal). For ret(HD)/closed(MS) we find 26 residues [26 in common with 
Ret(x)/closed(xtal)] and for ret(HD)/closed(xtal) we find 23 residues [15 in common with 
Ret(x)/closed(xtal)] in the binding site. More important is to establish which of these 
residues is responsible for ligand stabilization. Thus we calculated the interactions of all 
amino acid residues within 5Å of the ligand and kept those which interact more favorable 
than –1 kcal/mol interaction energy with the ligand. For ret(xtal)/closed (xtal) this leads 
to the 15 residues shown in Figure 10a.  For ret(HD)/closed(MS) we find 10 residues (8 
in common with Ret(x)/closed(xtal)) shown in Figure 10b and for ret(HD)/closed(xtal) 
we find 14 residues (12 of which in common with Ret(x)/closed(xtal)) shown in Figure 
10c. The interactions energies of the residues are shown in Table S2. The side chains 
 52
identified to be important include Trp265 and Tyr 268, which have been implicated (Lin 
et al., 1996) to modulate the absorption frequency of 11-cis-retinal.  
To provide an idea how the retinal binds prior to Schiff base bond formation, we 
also considered the binding site as all residues within 5.0Å of the ligand before bond 
formation that interact more favorable than –1 kcal/mol interaction energy with the 
ligand. For NoSB-ret(HD)/closed(xtal) this leads to the 7 residues shown in Figure 9b.  
For NoSB-ret(HD)/closed(MS) we find 8 (6 in common with NoSB-ret(HD)/closed(xtal)) 
shown in Figure 9c. The interactions energies of the residues are shown in Table S1. Of 
the top interacting residues (3 residues) in NoSB-ret(HD)/closed(xtal), 2 (Tyr268, 
Lys296) are also shown to rank among the top three in NoSB-ret(HD)/closed(MS). The 
residue which was missed (Thr118) ranked lower in NoSB-ret(HD)/closed(MS) because 
it is actually closer to the retinal (in comparison with the NoSB-ret(HD)/closed(xtal) 
structure), with distances as low as 2.8 Ǻ (whereas an optimal van der Waals distance is 
~3.4 Ǻ) to the polyene chain of retinal.  
In conclusion, we conclude that the MembStruk predicted structure is useful for 
predicting binding sites sufficiently well to direct mutation studies to elucidate the precise 
site. 
Apo/open(MS). 
We scanned the entire Apo/open(MS) receptor to find the binding site and binding 
energy for 11cis-retinal using the steps described in section 2. The best scoring 
conformation for 11cis-retinal and its associated binding site, denoted as NoSB-
ret(HD)/open(MS) are shown in Figure 9d. The predicted structure identifies which Lys 
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can bond to the retinal, with 2.87 Å between the predicted position of the retinal oxygen 
and the predicted position of the Lys 296 nitrogen.  
Then starting with NoSB-ret(HD)/open(MS), we formed this Schiff’s base bond 
(eliminating H2O), and optimized the full ligand-protein complex with conjugate gradient 
minimization to obtain the ret(HD)/open(MS) structure, This is no experimental structure 
with which to compare, but this structure differs from ret(HD)/closed(MS) by 1.7 Å 
CRMS. These structures are compared in Figures 11ab. 
A second criterion for validity of the predicted binding site is in identifying the 
residues close to the ligand to consider for mutational studies and drug design.  
Considering the binding site of NoSB-ret(HD)/open(MS) as all residues within 5.0Å of 
the ligand, the amino acid residues which interact with less than –1 kcal/mol interaction 
energy with the ligand (10 residues) are shown in Figure 9d. Of these, 6 residues are also 
shown to interact with the ligand in the NoSB-ret(HD)/closed(MS) structure discussed in 
Sec. 3.3.1. We also find 4 additional residues (Phe276, Phe208, Val271, Ala272) that do 
not bind with 1 kcal/mol in the NoSB-ret(HD)/closed(MS) structure. This difference 
results from the shift in the retinal binding site upon opening of the EC-II loop. Thus, we 
consider that the retinal bound to the open-loop structure is partially stabilized by van der 
Waals interactions. 
Exploring the signaling mechanism 
Using MembStruk we predicted the two structures apo/open(MS) with the 
extracellular loop 2 (EC-II) in an "open" conformation and apo/closed(MS) with it 
closed.  The crystal structure of rhodopsin has the closed configuration in which EC-II 
has a well-defined β-sheet structure with the 11-cis-retinal bound. We speculate that 
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changes in the structure of this loop are involved in activation of G-protein and in the 
entry of 11-cis-retinal on the extracellular side of rhodopsin. The idea is illustrated in 
Figure 4 in which the helix 3 coupled to this loop by a cysteine bond is the "gatekeeper" 
which responds to signaling structural sub-states of rhodopsin as follows:  
1) Starting with the inactive form ret/closed with 11cis retinal covalently linked to the 
rhodopsin, the response to visible light causes the 11cis retinal to isomerize to all-
trans-retinal, which in turn causes changes in the conformation (Altenbach et al., 
2001: 1 and 2; Altenbach et al., 1996; Farrens et al., 1996) near the retinal that 
eventually leads a structure in which the all-trans retinal is covalently linked to the 
open form with a structure resembling the trans-ret(HD)/open(MS) structure from our 
calculations. 
2) The transformation from closed to open in step 1 is caused by conformational 
changes responsible for activation (perhaps by the direct interaction of the trans 
isomer with helix 3, to induce helix 3 to shift towards the extracellular side, breaking 
the DRY-associated salt bridges at the intracellular side).  
3) Other processes hydrolyze off the trans retinal to form a structure similar to 
apo/open(MS) and then other processes reattach 11cis-retinal to form a structure 
similar to ret(HD)/open(MS) 
4) The ret(HD)/open(MS) relaxes eventually to form ret(HD)/closed(MS), the inactive 
form.  In this process the EC-II loop closes, perhaps caused by the helix 3 shifting 
towards the intracellular side, reforming the DRY-associated salt bridges at that end 
with the final result that closes to form a structure similar to the inactive.  
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Thus by using MembStruk and HierDock we have generated a total of six 
structures (summarized later in section 5.0) for ligand/protein complexes that can now be 
used to explore all the processes involving ligand binding and GPCR activation.  The 
experiment provided just one of these six structures, but the validation with experiment 
allows us to have greater confidence in the five structures for which experimental is not 
available.  
Comparison to other methods 
There have been attempts to model the structure of GPCRs using homology 
modeling methods with either the bacteriorhodopsin or bovine rhodopsin crystal structure 
as template (Strader et al., 1994). Since there is only one known structure, these 
homology applications lead to transmembrane regions very similar to the bovine 
rhodopsin template structure.  Moreover, many important GPCR targets have only low 
homology to bovine rhodopsin making the models particularly unreliable (Archer et al., 
2003). Thus the sequence identity of bovine rhodopsin to dopamine D2 receptor is 17%, 
of serotonin H1A is 14%, and of G2A is 13%, whereas good structures from homology 
models generally require over 45% sequence identity. 
GPCR structures have also been modeled using the properties of conserved 
residues in multiple sequence alignments followed by optimization of the structure using 
distance restraint to maximize the hydrogen bonds (Lomize et al., 1990).Also distance 
restraints from various experiments were used to predict the structure of 
bacteriorhodopsin (Herzyk et al., 1995). Comparing the TM helical region of their 
predicted structure to a bundle of ideal helices (not bent) superimposed on the 
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bacteriorhodopsin electron cryo-microscopy structure, they reported a CRMS of 1.87 Å 
in the C-alphas. 
Shacham et al. claim to have predicted the structure of bovine rhodopsin using an 
approach based on specificity of protein-protein interaction and protein-membrane 
interaction and the amphipathic nature of the helices. However they have not yet 
provided any details of their method or of predictions on other GPCRs.  
 
Summary 
Using MembStruk we predicted the three-dimensional structure of bovine 
rhodopsin protein interacting with 11cis-retinal using only primary sequence information.  
This led to the flowing structures: 
• Apo/closed (MS) is the MembStruk predicted structure of the closed form, without 
the retinal. The transmembrane assembly for this structure deviates from 
Apo/closed(xtal) by 2.84 Å CRMS for the mainchain atoms (4.04 Å CRMS for all 
transmembrane atoms, excluding H). Starting with the crystal structure and 
minimizing using the Dreiding FF leads to a structure that deviates from the crystal 
by 0.29Å CRMS, indicating that the FF leads to a good description. Thus most of the 
2.8 Å CRMS error is due to the MembStruk process. 
• Ret(HD)/closed(MS) is the predicted structure for 11-cis retinal obtained by applying 
HierDock to Apo/closed(MS). This leads to close contact (2.8 Å) between the 
carbonyl of the retinal and the N of Lys296. Forming the Schiff base linkage and 
minimizing leads to the ret(HD) structure that deviates from Ret(HD)/closed(xtal) by 
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2.92 Å CRMS. Carrying out the same HierDock process for the minimized crystal 
structure leads to a predicted structure for 11-cis retinal that deviates from Ret(xtal) 
by 0.62Å CRMS. This indicates that it is errors in the predicted protein structure that 
are responsible for the errors in ligand prediction. 
• Trans-Ret(HD)/closed(MS) is the predicted structure for all-trans retinal obtained by 
converting 11-cis retinal to all trans and allowing the protein to respond. There is no 
experimental structure with which to compare. 
• Apo/open(MS) is the MembStruk predicted structure of without the retinal. There are 
no experiments with which to compare.  This structure differs in the TM region from 
Apo/closed(MS) by 0.11 Å. 
• NoSB-Ret(HD)/open (MS) is the predicted structure for 11-cis retinal obtained by 
applying HierDock to Apo/open(MS). There is no experimental structure with which 
to compare. 
• Ret(HD)/open (MS) is formed from NoSB-Ret(HD)/open(MS) by forming the Schiff 
base linkage to Lys296 and minimizing. There are no experiments with which to 
compare.  The retinal differs from that in Ret(HD)/closed(MS) by 1.74 Å. 
The validation with experiment is sufficiently good that we can now start to 
explore the mechanisms by carrying out long time scale molecular dynamics and Monte 
Carlo calculations on these various forms to learn more about the mechanism of 
activation. Comparisons of the structures and energetics for these systems provide 
information that might be useful for understanding the mechanisms of binding and 
activation in rhodopsin in particular and GPCRs in general.  
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We have noted above several steps for which we anticipate substantial 
improvements and we are continuing to improve the methods. For example, the 
individual optimization of the helices can be performed under a more constrained 
environment by performing torsional dynamics of each helix in the presence of other 
helices or by performing torsional dynamics of all helices simultaneously. Also for 
improved accuracy in predicting the structures and for predicting the ligand binding 
energy, we intent to take into account the differential solvent dielectric environment 
between membrane, hydrophilic and the interfacial dielectric constants (Spassov et al., 
2002).  
Conclusions 
These applications of TM2ndS, MembStruk, and HierDock to bovine rhodopsin 
validate these techniques for predicting both the structure of membrane-bound proteins 
and the binding site of ligands to these proteins.  The predictions from such studies can 
be used to design experiments to test details of the structures, which might lead to 
improved structures.  This could lead to structures, more accurate than any of these 
techniques individually. The HierDock and MembStruk techniques validated here should 
also be useful for applications to other GPCRs, particularly for targeting agonists and 
antagonists against specific subtypes. 
In addition, these studies open the door to examination of the mechanism for 
activation (structural and energy changes) of signaling. Obtaining independent structures 
for each of the major steps involved in binding and activation (e.g., the six structures 
discussed for retinal-rhodopsin) provides the basis for computational studies and for 
experiments that should provide a basis for detailed examination of each step. 
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Table 1: The last column shows the positions of the hydrophobic center (HC) 
predicted for each TM by TM2ndS for various window sizes. The first row (shaded in 
gray) has the window sizes chosen to calculate this hydrophobic center. Here position 
1 corresponds to the first residue in the capped sequence in Figure 2. 
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Table 2: Results from the coarse-grain docking step of HierDock to predict the binding 
site (s) in apo/closed(xray). The energies of the top 5% after ranking (level 2 of 
HierDock) are shown for each box. Among all boxes, the best coarse-grain score is 
underlined. The scores within 100 kcal/mol of the top score are shown in bold. 
Box  Top 5 % after coarse-grain ranking 
1 2596, 2941, 2991, 3011, 4281 
2 4440, 4621, 4625, 5509, 5513 
3 2338, 2375, 2409, 2566, 2571 
4 5844, 5961, 6006, 6244, 6278 
5 None passed buried surface criteria 
6 102, 118, 131, 136, 208 
7 1366, 1370, 1374, 1374, 1379 
8 No conformations generated from DOCK 
9 12026 
10 82, 139, 153, 377, 380 
11 2348, 2348, 2566, 2843, 2843 
12 No conformations generated from DOCK 
13 551, 734, 931, 1110, 1226 
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Figure Legends 
Figure 1: Hydrophobicity profile from TM2ndS for bovine rhodopsin at window size 
WS=14. The pink line (at 0.07) is the base_mod (described  in 2.2.1b) used as the 
baseline in identifying hydrophobic regions. The predicted TM domains are indicated by 
the yellow lines (after capping).  The cyan lines show the predictions prior to helix 
capping. Each tick mark indicates the sequence number for the alignment based on 
bovine rhodopsin (100 residues per panel).  The residues at every 5th position are 
indicated below each panel. The partition of helix 7 into two parts results from the 
hydrophilic residues near its center. 
 
Figure 2: The transmembrane helical predictions (labeled as after capping) from 
TM2ndS compared with helix ranges from the bovine rhodopsin xray crystal structure. In 
addition the predictions before TM2ndS capping are shown. Those residues in the crystal 
structure which fall outside the range of alpha helicity (using analysis described in Sec. 
2.2.1c) are indicated in lowercase letters. 
 
Figure 3: The RMS deviation for various window sizes (WS) of the central residues 
predicted from TM2ndS for Bovine rhodopsin compared to the best fit plane to the 
crystal structure minimized without ligand, Apo/closed(xtal). This suggests that the best 
WS is 16 to 22. 
 
Figure 4: Schematic for a possible signaling mechanism in rhodopsin. Note that the 
movement of helix 3 (caused by interaction with the trans isomer of retinal) exposes the 
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DRY sequence to G-protein activation and as a result closes the EC2 loop to maintain the 
ligand inside the bundle sequence. 
 
Figure 5: The thirteen regions shown as boxes used in scanning the entire protein for the 
11cis-retinal putative binding site. The 2 boxes chosen as binding sites by HierDock are 
shown in red.  (a) front view with N-terminus at the bottom (b) top view obtained by 
rotating by 90 degrees about the horizontal-axis in a) so that the N terminus is out of the 
page. These two orientations are used for all structures shown in this paper. 
 
Figure 6abcd: Validation of HierDock: (a) Front view of the 11cis-retinal conformation 
determined by HierDock for ret(HD)/closed(xray) (CPK color) compared to the 
published crystal structure (green). The CRMS difference in the ligand structures is 1.1 
Å. (b) Top view of Figure a. This shows that predicted position of the retinal aldehyde 
oxygen is 2.8 Å from the N of LYS296, which is short enough for an H-bond. (c) Top 
view showing the result of making the Schiff base bond of 11cis-retinal to LYS296 in 
Figure a and minimizing the resulting structure (blue), compared with the 
crystallographic ligand structure (red).  The CRMS difference between these ligand 
structures is 0.62 Å. (d) Top view of Figure c. 
 
Figure 7: (a) Comparison of the predicted structure (orange) Apo/closed(MS) with the 
experimental structure (blue) apo/closed(xray).  They differ in the TM helical region by 
CRMS=2.84 Å.  
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(b) Comparison of the predicted Apo/closed(MS) structure (orange) with the predicted 
Apo/open(MS) structure (cyan).  They differ in the TM helical region by 0.11 Å.  
 
Figure 8: MembStruk validation using the closed EC-II loop a) The HierDock predicted 
conformation of 11cis-retinal (CPK color) in the MembStruk predicted apo/closed(MS) 
structure, denoted NoSB-ret(HD)/closed(MS). Note that the aldehyde oxygen is 2.85 Å 
from the N of LYS296. b) In violet: The retinal structure after forming this Schiff base 
bond of 11cis-retinal to Lys296 and optimizing to form ret(HD)/closed(MS). In blue: 
retHD/closed(xtal). These ligand structures were found to differ by 2.9 Å CRMS. 
 
Figure 9abcd: Comparison of predicted binding sites for retinal [those residues within 5 
Å of retinal which interact strongly with the ligand (contributions to binding greater than 
1 kcal/mol)] before Schiff base bond formation in the three rhodopsin structures.  
a) All three structures and ligand conformations are shown. The colors blue, grey, 
orange correspond respectively to those structures analyzed in b-d.  
b) NoSB-Ret(HD)/closed(xtal) structure. Here we see that seven residues bind more 
strongly than 1 kcal/mol. 
c) NoSB-Ret(HD)/ closed (MS). Here we see that five of the seven residues in 
Figure (b) are predicted (only Phe208 and Hsp211, both rather weakly bound). 
We also find three additional residues (Phe212, Ile275, Ala117) that do not bind 
with 1 kcal/mol in b. 
d) NoSB-Ret(HD)/open(MS). Here we see that six of the seven residues in Figure 
(c) bind more strongly than 1 kcal/mol. We also find four additional residues that 
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do not bind with 1 kcal/mol in b. This difference results from the shift in the 
retinal binding site upon closure of the EC-II loop. 
The side chains in common with the NoSB-Ret(HD)/closed(xtal) structure (in Figure 
b) or with NoSB-Ret(HD)/closed(MS) (in Figure c) within the binding site around the 
11cis-retinal are labeled with larger font. 
 
Figure 10abc: Comparison of predicted binding sites of retinal with Schiff base bond 
formed. We considered residues within a 5 Å shell of the ligand (excluding the Lys296 to 
which the retinal is bound) and determined those which contribute at least 1 kcal/mol of 
stabilization energy for the three rhodopsin structures.   
a) Ret(xtal)/closed(xtal) structure. Here we see that 15 residues bind more strongly than 
1 kcal/mol. 
b) Ret(HD)/closed(xtal). Here we see that 12 of the 15 residues in Figure (a) are 
predicted to bind strongly (Ala117 and His211 still contribute positively to bonding 
but are now rather weakly bound [<1 kcal/mol]). We find 2 additional residues 
(Cys187, Ala269) that did not bind with 1 kcal/mol in a. 
c) Ret(HD)/ closed (MS). Here we find 8 of the 15 residues in Figure (a) still bind 
strongly. We also find 2 additional residues (Ile275, Ala269) that did not bind with 1 
kcal/mol in a. 
A larger font is used to label the side chains in common with the Ret(xtal)/closed(xtal) 
structure within the binding site around the 11cis-retinal. 
 
Figure 11: MembStruk validation using the open EC-II loop:  
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a) The HierDock predicted conformation (CPK color) of 11cis-retinal in the MembStruk 
predicted structure to form the NoSB-Ret(HD)/open(MS) structure. Note that the 
aldehyde oxygen is 2.87 Å from the N of LYS296; which is short enough to form a 
hydrogen bond.  
b) The Ret(HD)/open(MS) structure after forming the Schiff base bond (green), 
compared with the structure (violet) of 11cis-retinal in ret(HD)/closed(MS).These ligand 
structures differ by 1.7 Å CRMS. The EC-II loop may function to position the retinal 
ligand into its final conformation as found in the rhodopsin crystal structure. 
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Figure S1:  The sequences (43 Blast entries shown) used to generate the multiple 
sequence alignment with bovine rhodopsin. 
sp|P28682|OPSB_CHICK Blue-sensitive opsin (Blue cone photorecept...   
357   2e-98 
sp|P51472|OPSB_ASTFA BLUE-SENSITIVE OPSIN (BLUE CONE PHOTORECEPT...   
347   2e-95 
sp|P32310|OPSB_CARAU Blue-sensitive opsin (Blue cone photorecept...   
337   2e-92 
sp|P87365|OPSB_ORYLA BLUE-SENSITIVE OPSIN (BLUE CONE PHOTORECEPT...   
330   2e-90 
sp|Q9W6A8|OPSB_BRARE Blue-sensitive opsin (Blue cone photorecept...   
324   2e-88 
sp|P51473|OPSV_XENLA Violet-sensitive opsin (Violet cone photore...   
307   2e-83 
sp|P51475|OPSP_CHICK Pinopsin (Pineal opsin) (P-opsin) (Pineal g...   
302   6e-82 
sp|P28684|OPSV_CHICK Violet-sensitive opsin (Violet cone photore...   
300   2e-81 
sp|P51476|OPSP_COLLI PINEAL OPSIN (P-OPSIN) (PINEAL GLAND-SPECIF...   
295   1e-79 
sp|O13092|OPSB_SAIBB Blue-sensitive opsin (Blue cone photorecept...   
290   3e-78 
sp|P51491|OPSB_MOUSE Blue-sensitive opsin (Blue cone photorecept...   
290   4e-78 
sp|Q90309|OPSU_CARAU ULTRAVIOLET-SENSITIVE OPSIN (ULTRAVIOLET CO...   
287   2e-77 
sp|P03999|OPSB_HUMAN Blue-sensitive opsin (Blue cone photorecept...   
285   1e-76 
sp|Q9W6A9|OPSU_BRARE Ultraviolet-sensitive opsin (Ultraviolet co...   
283   3e-76 
sp|Q63652|OPSB_RAT Blue-sensitive opsin (Blue cone photoreceptor...   
283   5e-76 
sp|P51490|OPSB_BOVIN Blue-sensitive opsin (Blue cone photorecept...   
277   3e-74 
sp|P87368|OPSV_ORYLA PUTATIVE VIOLET-SENSITIVE OPSIN (VIOLET CON...   
276   4e-74 
sp|O42490|OPSP_PETMA PINEAL OPSIN (P-OPSIN) (PINEAL GLAND-SPECIF...   
273   3e-73 
sp|P04001|OPSG_HUMAN Green-sensitive opsin (Green cone photorece...   
269   5e-72 
sp|Q95170|OPSR_CAPHI Red-sensitive opsin (Red cone photoreceptor...   
268   2e-71 
sp|O18913|OPSR_FELCA Red-sensitive opsin (Red cone photoreceptor...   
267   3e-71 
sp|P35358|OPSG_GECGE Green-sensitive opsin P521 (Green photorece...   
266   4e-71 
sp|P87367|OPSR_ORYLA RED-SENSITIVE OPSIN (RED CONE PHOTORECEPTOR...   
266   6e-71 
sp|O18910|OPSG_RABIT Green-sensitive opsin (Green cone photorece...   
265   8e-71 
sp|P04000|OPSR_HUMAN Red-sensitive opsin (Red cone photoreceptor...   
265   1e-70 
sp|O35476|OPSG_RAT Green-sensitive opsin (Green cone photorecept...   
264   2e-70 
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sp|P34989|OPSL_CALJA Opsin, longwave 563 nm                           
263   3e-70 
sp|Q9W6A7|OPSR_BRARE Red-sensitive opsin (Red cone photoreceptor...   
263   4e-70 
sp|O35478|OPSG_SCICA Green-sensitive opsin (Green cone photorece...   
262   8e-70 
sp|Q9R024|OPSG_CAVPO Green-sensitive opsin (Green cone photorece...   
262   8e-70 
sp|O35599|OPSG_MOUSE Green-sensitive opsin (Green cone photorece...   
261   1e-69 
sp|P32313|OPSR_CARAU Red-sensitive opsin (Red cone photoreceptor...   
259   7e-69 
sp|P22332|OPSR_ASTFA RED-SENSITIVE OPSIN (RED CONE PHOTORECEPTOR...   
258   9e-69 
sp|P41592|OPSR_ANOCA Red-sensitive opsin (Red cone photoreceptor...   
258   2e-68 
sp|O12948|OPSR_XENLA RED-SENSITIVE OPSIN (RED CONE PHOTORECEPTOR...   
257   2e-68 
sp|P22329|OPSR_CHICK Red-sensitive opsin (Red cone photoreceptor...   
253   3e-67 
sp|P22330|OPSG_ASTFA Green-sensitive opsin 1 (Green cone photore...   
246   6e-65 
sp|P22331|OPSH_ASTFA Green-sensitive opsin 2 (Green cone photore...   
244   1e-64 
sp|O42266|OPSP_ICTPU PARAPINOPSIN                                     
229   6e-60 
sp|O18912|OPSR_HORSE Red-sensitive opsin (Red cone photoreceptor...   
222   7e-58 
sp|O18911|OPSG_ODOVI Green-sensitive opsin (Green cone photorece...   
222   7e-58 
sp|O18914|OPSR_CANFA Red-sensitive opsin (Red cone photoreceptor...   
218   1e-56 
sp|O13018|OPSO_SALSA Vertebrate ancient opsin                         
218   2e-56 
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Table S1: Residues within a 5 Å shell (of retinal without Schiff base bond formed) which 
interact more favorably than an interaction energy of –1 kcal/mol with the ligand are 
shown in order of decreasing interaction. The interaction energy values are shown in 
parentheses. 
NoSB-
Ret(HD)/closed(xtal) 
NoSB-Ret(HD)/ 
closed (MS) 
NoSB-
Ret(HD)/open(MS) 
Thr118 (-4.6) 
Tyr268 (-3.9) 
Lys296 (-2.6) 
Hsp211 (-1.8) 
Glu122 (-1.4) 
Phe208 (-1.4) 
Met207 (-1.2) 
Lys296 (-9.6) 
Glu122 (-3.0) 
Tyr268 (-2.6) 
Ala117 (-1.9) 
Thr118 (-1.9) 
Ile275 (-1.6) 
Met207 (-1.1) 
Phe212 (-1.0) 
Lys296 (-7.3) 
Tyr268 (-3.4) 
Glu122 (-2.9) 
Ala272 (-2.7) 
Ile275 (-2.5) 
Ala117 (-2.2) 
Val271 (-1.9) 
Met207 (-1.4) 
Phe208 (-1.3) 
Phe276 (-1.1) 
 
Table S2: Residues within a 5 Å shell (of retinal with Schiff base bond formed) which 
interact more favorably than an interaction energy of –1 kcal/mol with the ligand are 
shown in order of decreasing interaction. The interaction energy values are shown in 
parentheses. 
Ret(xtal)/closed(xtal) Ret(HD)/closed(xtal) Ret(HD)/closed(MS) 
Glu122 (-21.9) 
Glu113 (-20.3) 
Glu181 (-18.0) 
Trp265 (-6.5) 
Tyr268 (-4.8) 
Thr118 (-3.9) 
Ala292 (-2.9) 
Ala117 (-2.3) 
Phe208 (-2.0) 
His211 (-1.8) 
Phe212 (-1.7) 
Gly114 (-1.6) 
Met207 (-1.6) 
Phe261 (-1.4) 
Phe293 (-1.1) 
Glu122 (-19.8) 
Glu113 (-18.0) 
Glu181 (-14.9) 
Trp265 (-6.8) 
Thr118 (-5.2) 
Tyr268 (-5.2) 
Met207 (-2.7) 
Ala292 (-2.3) 
Phe212 (-1.9) 
Phe208 (-1.8) 
Gly114 (-1.8) 
Cys187 (-1.3) 
Phe261 (-1.2) 
Ala269 (-1.2) 
Glu122 (-18.2) 
Thr118 (-4.0) 
Tyr268 (-4.0) 
Phe208 (-3.2) 
Met207 (-1.2) 
Trp265 (-1.1) 
Gly114 (-1.1) 
Ala269 (-1.1) 
Phe212 (-1.0) 
Ile275 (-1.0) 
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Figure S2: A graphical comparison of the individual helices from the optimized 
experimental structure apo/closed(xray)  (white) and that created by the step 3 helical 
optimization of the MembStruk protocol (cyan at 100ps or after temperature stabilization, 
orange is best match to the crystal in all the simulation). Each helix is oriented with the 
N-terminus at the top. Note the large bends in the crystal helices 2 and 6 due to proline 
residues. B) The entire dynamics simulation after temperature stabilization or 100 ps 
(whichever was later) was analyzed for all helices. The helices at 2.5 ps intervals are 
overlayed. Helices 2 and 6 undergo the most bending at specific “hinge” residues, as has 
been confirmed by EPR studies. This  points to the inherently dynamical nature of these 
helices needed for the receptor activation process and G-protein binding. 
A) 
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 Figure S3: The 360 degree energy scans for the 7 helices of the predicted 
rhodopsin structure after step 3 of the MembStruk procedure. The arrow for 
helix 6 indicates the alternate rotation which corresponds more closely to the
ground state conformation of the crystal structure.  
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Figure S4: The two alternate rotations of helix 6 found by analysis of the 
hydrophobic moment using the “phobic face” method of MembStruk. In 
green is indicated this moment using 19 middle residues, and in red is 
indicated the moment using 15 middle residues. The alternate rotations 
correspond to the active and inactive forms of the receptor. 
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Figure S5: A screenshot of part of the graphical user interface for TM2ndS.  
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Chapter 3: High accuracy transmembrane helix predictions using 
TM2ndS 
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Abstract 
 
 
The MembStruk was designed to predict the 3-D structures of GPCRs based on 
sequence alone from first principles. The first step of this method is the accurate 
determination of transmembrane helices from sequence using the TM2ndS protocol. This 
study validates TM2ndS for automatic high residue accuracy secondary structure 
predictions on the set of high-resolution membrane protein crystal structures (MPtopo 
database). In addition, the method is compared to top TM helical prediction methods. It 
emerges as one of the two top methods in terms of residue accuracy, and the top 
“untrained” method. This general method thus demonstrates great generalizability to 
membrane proteins of unknown structure and of various specific 3-D topologies. 
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Introduction 
Membrane proteins are involved in many important biological processes, from ion 
transport to the immune response. In particular, G-protein-coupled receptors (GPCRs) are 
a superfamily of 7-helical transmembrane (TM) proteins which are a target for ~50 % of 
pharmaceutical drugs (Flower 1999). Despite this, there is a high-resolution structure for 
only 1 GPCR, and in general <1% of proteins with solved structures are membrane 
proteins (Chen 2002). In order to design receptor-specific drugs with minimal cross 
reactivity to other receptor subtypes, it is probably best to apply a structure-based design 
procedure. Because of the scarcity of atomic level structures, however, theoretical 
methods need to be developed to meet this need. We have thus developed a first 
principles method to obtain structures for GPCRs named MembStruk which has been 
previously described (Floriano 2000; Vaidehi 2002; Trabanino 2003). 
The first step of the MembStruk procedure is the prediction of TM helical regions 
from sequence. There are a variety of other programs available for TM helical 
predictions. DAS (Cserzo 1997) and TopPred2 (Sipos 1993) use hydrophobicity plots. 
SOSUI (Hirokawa 1998) and TMHMM (Sonnhammer 1998) use preference functions 
derived from known protein transmembrane helical locations. HMMTOP (Tusnady 1998) 
is similar to TMHMM in that it uses a hidden Markov model method. PHDhtm (Rost 
1996) uses a neural network scheme with information of sequence relationships and 
differences. The performance of these methods have been compared (Moller 2001), 
which found TMHMM to score best. The criteria did not include per-residue accuracy 
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however, and a recent study (Chen 2002) found there to be no clearly better method for 
all criteria. 
As described in detail in Trabanino, 2003, and validated for the only GPCR with a 
reference crystal structure available, bovine rhodopsin (Palczewski 2000), MembStruk is 
a first principles method which applies general rules and uses no structural information 
from databases to aid in obtaining structures. The first step in this procedure reflects this. 
Within MembStruk, the determination of transmembrane helices from sequence alone is 
accomplished by the TM2ndS procedure. It is a hydrophobicity based method which uses 
multiple-sequence alignments, window scanning, and a robust baseline definition method 
to aid in obtaining TM regions, which are later capped by general rules of  helix 
termination. As such, this method was developed without a training set of membrane 
proteins, with the intention of retaining its general applicability to proteins of unknown 
structure. In this paper, we present the results for TM helical predictions on a database of 
membrane proteins known as MPtopo (Jayasinghe 2001). As this method is applied to 
GPCR’s, where the number of helices is known beforehand, the focus of the method is 
the accurate determination of TM helical regions (in terms of residues correctly 
predicted), although the accuracy in terms of number of TM helical regions is also 
analyzed (for possible future use in data mining of membrane proteins). In addition, since 
the primary goal is accurate TM helical residue predictions, the proteins in the MPtopo 
database were analyzed in terms of their phi-psi angles and crystal structure B-factors in 
order to provide the most accurate reference for the comparison to predictions. 
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Materials and methods 
Preparing the reference experimental helix data 
For analysis of the performance of TM helical prediction methods, there is a 
website (Kernytsky 2003) which automatically analyzes methods and compares with 
others using a common criteria. This resource was used to compare TM2ndS to to other 
top methods, and the results will be discussed later. Also, since TM2ndS is primarily 
aimed at accurate TM helical residue determination, we chose to analyze the high-
resolution experimental database of MPtopo to precisely determine the true helical 
regions and use this as a reference for our analysis. 
The MPtopo (Jayasinghe 2001) database includes accurate TM helical ranges 
identified from PDB structure assignments as well as visual observation to assign TM 
regions. However, for the purposes of this study, the helix definitions of this database 
needed to be refined further. We used a criteria for alpha helicity as residues with phi-psi 
angles in the following ranges: -37 < φ < -77 and -27 < ψ< -67. Residues which fell 
outside these ranges were considered non-helical. A helix was considered broken if a 
stretch of two of these non-helical residues was found. In addition, the crystallographic 
temperature B-factors were considered in assigning TM helical regions. Any residue in 
which the average of backbone B-factors was over 70 was considered uncertain, and any 
prediction (or missed prediction) in this region was still considered valid.  
 
The TM2ndS method 
The method for TM helical prediction known as TM2ndS was described in detail 
in Trabanino, 2003. The procedure could be divided into three parts: 
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a) A multiple sequence alignment using Clustalw (Thompson 
1994) of a set of sequences obtained from a Blast (Altschul 
1990; Altschul 1997) search of a query sequence is obtained. 
Sequences above bit score 200 but non-identical (E value less 
than e-100) were used in the alignment. An ideal set of sequences 
would be one in which there is uniform distribution across the 
bit score bins.   
b) The hydrophobicity assigned by the Eisenberg scale (Eisenberg 
1982) was first averaged across sequences in the alignment, and 
then across a window size of residues. The hydrophobicity scale 
was derived from combining values from various partitioning 
studies of residues between aqueous and apolar environments. 
The window size used for analysis was 14. TM regions are 
detected as peaks  which satisfy criteria of area >=0.4 and length 
>6 but <=50. The baseline for these peak determinations is 
obtained as follows: 1) the average over the region excluding the 
N and C terminus was obtained 2) then the baseline is increased 
by 0.12 in increments of 0.01 and kept as the new baseline 
base_mod if more peaks were determined at this modified 
baseline.  
This baseline determination method is different than that 
described in Trabanino, 2003 since that method focused on 
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GPCRs and thus looked for 7 helices. The method of modifying 
the original baseline was found to better resolve small 
interhelical  loops, which has been a significant problem for 
prediction methods (Chen 2002). 
It should be noted that TM2ndS regularly applies a local 
average for peaks of low intensity in the case of GPCRs. These 
peaks would correspond to relatively polar helices which are 
stabilized in the membrane by interaction with other helices 
(Popot 1990). However, for the current study, this local average 
was not applied since it is better applied when the number of 
helices is known beforehand, as in GPCRs. 
c) Once the coarse TM regions were predicted, the regions were 
capped using general rules of helix breaking residues and 
retaining a loop size of at least 6 for all cases. 
An important feature of this method is the baseline determination. Proteins are 
essentially thermodynamically equilibrated structures (White 2001). Thus, this final 
baseline may be interpreted physically as a ∆G=0 value above which residues are 
thermodynamically stable in the transmembrane and below which they are not. This 
baseline is unique to the particular protein to which it is being applied, with its individual 
environmental factors (water clusters, ions, hydrophobic or hydrophilic ligand or 
interhelical interactions, membrane composition) that may change the relative stability of 
any particular residue.  
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Results and discussion 
TM helical region identification 
Since this method is to be currently applied to GPCRs, we focused attention on 
helices of certain length, namely, those in which the high-resolution experimental lengths 
were >=20 and <=34. Overall, the MPtopo database was made up of 24 protein 
complexes with 208 helices. Of these, 164 helices are of  length >=20 and <=34. 
TM2ndS correctly identified 158 of these helices (96.3 %) with overlap of at least 15 
residues. In addition, 182 helices were predicted with 158 (86.8% true positive) of these 
correctly overlapping at least 15 residues. 
There are some problems with the structures of the proteins in this database. Thus, 
of these 24 protein complexes, 5 chains were excluded from the residue accuracy 
analysis. They were 1JSQ (6 helices) since it has only C-alpha coordinates, preventing 
phi-psi analysis, 1MSR (1 helix) since it is a theoretical model, and 1BGY chain E (1 
helix) since it is missing residues in assigned TM helical region. Also, the proteins 1OCC 
chain B and 1PRC chain H were excluded due the fact that their first or last peaks were 
too close (less than half a peak length) away from the beginning or end of the sequence. 
This would not allow a good quality baseline to be determined. These cases were 
identified automatically by TM2ndS. 
After these exclusions, 154 helices remained. TM2ndS correctly identified 148 of 
these helices (96.1 %) with overlap of at least 15 residues (Table 1). In addition, 162 
helices were predicted with 148 (91.3% true positive) of these correctly overlapping at 
least 15 residues. Interestingly, if one excludes those helices predicted to be too long or 
 110
short (>34 or <20), then 148 helices are predicted with 139 of these overlapping in at 
least 15 residues (93.9%). Thus, there may be more false positives amongst helices which 
are predicted to be too short or too long. It should be noted that many of these false 
positives were due to signal peptides and non-TM hydrophobic regions, which is 
generally a problem with hydrophobicity-based methods (Lao 2002). 
It should be noted that predictions were also obtained without an alignment of 
multiple sequences. In this case, TM2ndS correctly identified 150 of the 156 helices (96.1 
%) with overlap of at least 15 residues (Table 2). But 155 helices were predicted with 148 
(95.5% true positive) of these correctly overlapping at least 15 residues. Thus, for the 
purposes of data mining of membrane proteins from the genome, TM2ndS may perform 
better with one sequence instead of an alignment. However, as expected, the residue error 
was larger for analysis with one sequence (Johnson 1999). Thus the multiple sequence 
alignment method was used for evaluation of residue accuracy for this method. 
Assuming that the TM helices are identified correctly (which would be the case in 
predictions for GPCRs, where 7 TM helices are known to exist), what is the error in 
determining the precise TM helical ranges?  
 
TM helical region residue accuracy 
Some of the TM2ndS predicted sequences (for those proteins in which all the 
lengths of the crystal and predicted  helices were >=20 and <=34) before and after 
capping are shown in Figure 1 (placed after references because of length). The 
predictions for all helices (which have lengths of the crystal reference helix of >=20 and 
<=34) in the database are analyzed are shown in Figure S1 (supplemental material after 
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references). In addition, the experimental TM helix sequences are shown. Those residues 
which did not fit the criteria for alpha helicity (in phi-psi angles) are indicated in italics, 
while those which have B-factors over 70 are indicated in bold. 
After analyzing the phi-psi and B-factors of the crystal structures, the residue 
accuracy errors were as follows. For all 148 helices (96.1 % of total helices as discussed 
in Sec. 3.1) which were predicted with overlap of >=15, the average error in residues was 
5.39. This would be equivalent to an average error of 2.70 on each side of the TM 
helices. Of these helices, 127 (85.8%) had errors of <= 7. The average residue error for 
these was 4.18, corresponding to an error of 2.09 on either side.  
As seen in Figure 2, the distribution of these errors is largely clustered around 
smaller values. The distributions of errors in the N-terminal, C-terminal, and both sides of 
the helices are shown in this figure. 
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Figure 2: The N-terminal, C-terminal , and combined errors in TM 
helix prediction for TM2ndS. 
 
 
 
Number of helices with certain residue error on N-
terminii
0
5
10
15
20
25
30
35
40
0.0
0
1.1
8
2.3
6
3.5
5
4.7
3
5.9
1
7.0
9
8.2
7
9.4
5
10
.64
11
.82 Mo
re
Residue error
 
Number of helices with certain residue error on C- 
terminii
0
10
20
30
40
0.0
0
1.0
0
2.0
0
3.0
0
4.0
0
5.0
0
6.0
0
7.0
0
8.0
0
9.0
0
10
.00 Mo
re
Residue error
 
 113
Number of helices with certain residue error on both 
terminii
0
5
10
15
20
25
30
0.0
0
1.6
4
3.2
7
4.9
1
6.5
5
8.1
8
9.8
2
11
.45
13
.09
14
.73
16
.36 Mo
re
Residue error
 
The purpose of such high precision is to maintain the correct secondary structure 
for segments of the sequence which may be involved in ligand binding or other critical 
function. As such, these small errors in the TM helical predictions would lead to only 
local errors in the protein structure prediction of MembStruk. This is because MembStruk 
has a translation protocol implemented which aligned helices by their hydrophobic 
centers, thus positioning the binding site residues of any given ligand correctly. 
 
Gap check 
There are a few certain outlier cases where errors may exceed 10. Such cases may 
require a better list of sequences for the alignment (more uniform distribution of 
homologies). In addition, a careful analysis of the profile changes with window size may 
lead to more accurate predictions. These outlier cases occur mostly in bacterial proteins, 
which have vastly different membrane compositions from the GPCRs in humans for 
example. The much greater membrane protein to lipid ratio in bacteria (3:1 as opposed to 
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1:1 in humans) and thus the higher association with other proteins contribute to this 
difference. So, it may not be wise to make the method more specific to do well for this 
database with a great number of bacterial proteins. Nevertheless, the analysis of gaps in 
the alignment may provide another check for the helical predictions. This is demonstrated 
for 4 cases, two which have larger than 10 error and two with smaller than 10 error (to 
evaluate the generality of this second-pass approach). In this gap check, an alignment of 
sequences down to low homologies (25-30%) is performed. This alignment is then 
checked for gaps about the TM2ndS TM helical prediction. These gaps would define an 
upper limit to the capping of the helix when they do not form a loop which is to small and 
when they do not enter the region defined by the raw (before capping) TM prediction. 
The cases of helices 2 and 5 of 1BRX and 3, 6 for 1OCC were analyzed by this approach. 
The alignments in these regions are shown in Figure 3. 
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Figure 3: The alignments of sequences down to lower homologies for a) 1BRX 
and b) 1OCCR chain C, demonstrating the gap check method. The gap check TM 
helix is in bold while the crystal structure TM helix in underlined. 
a) 
 
HELIX 2 
1BRX                                -QAQITGRPEWIWLALG----------TALMGLGTLYFLVKGMGVSDPDA
gi|15790468|ref|NP_280292.1|        -QAQITGRPEWIWLALG----------TALMGLGTLYFLVKGMGVSDPDA 
gi|3023375|sp|P96787|BAC3_HALS      -DLLGDGRPETLWLGIG----------TLLMLIGTFYFLVRGWGVTDKDA 
gi|114807|sp|P19585|BAC1_HALS1      -DLLGDGRPETLWLGIG----------TLLMLIGTFYFIVKGWGVTDKEA 
gi|231626|sp|P29563|BAC2_HALS2      -DLLNDGRPETLWLGIG----------TLLMLIGTFYFIARGWGVTDKEA 
gi|2829812|sp|P94854|BACR_HALV      ---MPAPEGEAIWLWLG----------TAGMFLGMLYFIARGWGETDSRR 
gi|2499386|sp|Q57101|BACR_HALA      ---MPEPGSEAIWLWLG----------TAGMFLGMLYFIARGWGETDSRR 
gi|2499387|sp|Q53496|BACR_HALS      -MSTYVPGGESIFLWVG----------TAGMFLGMLYFIARGWSVSDQRR 
gi|14194473|sp|O93740|BACR_HAL      -PMAATVGPESIWLWIG----------TIGMTLGTLYFVGRGRGVRDRKM 
gi|461611|sp|P33971|BACR_HALHP      -----------IWLWLG----------TAGMFLGMLYFIARGWGETDSRR 
gi|461612|sp|P33972|BACR_HALHS      -------------LWLG----------TAGMFLGMLYFIARGWGETDGRR 
gi|461610|sp|P33969|BACR_HALHM      --------------GIG----------TLLMLIGTFYFIARGWGVTDKKA 
gi|1168614|sp|P42197|BACT_HALV      ------MATITTWFTLG----------LLGELLGTAVLAY-GYTLVPEET 
gi|461609|sp|P33742|BACH_HALSS      -EAVQSDTLLASSLWIN----------IALAGLSILLFVYMGRNVEDPRA 
gi|2499383|sp|Q48315|BACH_HALH      -QEIQSNFLLNSSIWVN----------IALAGVVILLFVAMGRDIESPRA 
gi|2499384|sp|Q48314|BACH_HALH      -QEIQSNFLLNSSIWVN----------IALAGVVILLFVAMGRDLESPRA 
gi|14194475|sp|O93742|BACH_HAL      -EAIQGDTLLASSLWIN----------IALAGLSILLFVYMGRNLEDPRA 
gi|114809|sp|P15647|BACH_NATPH      -EFVLNDPLLASSLYIN----------IALAGLSILLFVFMTRGLDDPRA 
gi|2829811|sp|P94853|BACH_HALV      -GEIQSNFLLNSSLWVN----------IALAGVVILLFVAMGRELESSRA 
gi|15790684|ref|NP_280508.1|        -------MALTTWFWVG------------AVGMLAGTVLPIRDCIRHPSH 
gi|15789491|ref|NP_279315.1|        -AAVRENALLSSSLWVN----------VALAGIAILVFVYMGRTIRPGRP 
gi|461608|sp|P33970|BACH_HALHM      ---------------------------IALAGLSILLFVYMGRNVEDPRA 
gi|14194474|sp|O93741|BACH_HAL      -TQIRTDTLLHSSLWVN----------IALAGLSILVFLYMARTVRANRA 
gi|1168615|sp|P42196|BACT_NATP      ------MVGLTTLFWLG----------AIGMLVGTLAFAWAGRDAGSGE- 
gi|15790610|ref|NP_280434.1|        ------MDAVATAYLGG----------AVALIVGVAFVWLLYRSLDGSPH 
gi|2499388|sp|Q48334|BAC3_HALV      ------MDAVAVVYGIT----------AAGFAVGVAIVGYLYASLEGSEE 
gi|461613|sp|P33743|BACS_HALSS      -----MTGAVSAAYWIA----------AVAFLVGLGITAALYAKLGESED 
gi|14194476|sp|O93743|BACS_HAL      -----MTGAVTSAYWLA----------AVAFLIGVGITAALYAKLEGSRA 
gi|6685436|sp|O74631|F123_CORV      -ATFHLSTHGSDWLWAA-----------FSVFGVSLLTVVAWTFTRPRGA 
gi|6319528|ref|NP_009610.1|         GADFHITSRGSDWLFTV---------FCVNLLFGVILVPL--MFRKPVKD 
gi|1729881|sp|P51564|TCR8_PASM      -NSLATHYGVLLALYAT----------MQVIFAPILGRLSDKYGRKPILL 
gi|11467412|ref|NP_043269.1|        CSKLATLLRWLTHFWLFFG-------LMVLISASGFTSYEEHRDVLYYFK 
gi|16763593|ref|NP_459208.1|        -FMAAVVGTLTGLVGVAFEK--A-VSWVQNMRIGALVQVADHAFLLWPLA 
gi|1708329|sp|P53706|HST6_CANA      IKEDTDNEKLMGVLAILRYC--S-STINGKSLLGFGILLAIFQGVSSPVF 
gi|16759194|ref|NP_454811.1|        -FMAAVVGTLTGLVGVAFEK--T-VSWVQNMRIGALVQVADHAFLLWPLA 
gi|15594598|ref|NP_212387.1|        FFLKEQLKAIKAELGIGDKKSSD-LEKLKTKLKALELKGEPLEVVEKELE 
gi|2501369|sp|Q47085|CBRB_ERWC      GALWHPDPLNVSHILVTS---------TRLSRTLIAIVVGAGLAVAGALM 
gi|17568741|ref|NP_509364.1|        SIMYPKPQEKEALKDVMVFILVLGFIALIGFIYTVIEMVSRGESLKHIII 
gi|15604244|ref|NP_220760.1|        SIKDSFVVTLISSEVLS-----F-IKLWGEMPMGVLFVILYSKLCNIMTT 
 
 
 
       (continued)                                                                                
Gap chosen for cap 
 
1BRX                                KKFYAITTLVPAIAFTMYLSMLLG-------------------------- 
gi|15790468|ref|NP_280292.1|        KKFYAITTLVPAIAFTMYLSMLLG-------------------------- 
gi|3023375|sp|P96787|BAC3_HALS      REYYAVTILVPGIASAAYLSMFFG-------------------------- 
gi|114807|sp|P19585|BAC1_HALS1      REYYSITILVPGIASAAYLSMFFG-------------------------- 
gi|231626|sp|P29563|BAC2_HALS2      REYYAITILVPGIASAAYLAMFFG-------------------------- 
gi|2829812|sp|P94854|BACR_HALV      QKFYIATILITAIAFVNYLAMALG-------------------------- 
gi|2499386|sp|Q57101|BACR_HALA      QKFYIATILITAIAFVNYLAMALG-------------------------- 
gi|2499387|sp|Q53496|BACR_HALS      QKFYIATIMIAAIAFVNYLSMALG-------------------------- 
gi|14194473|sp|O93740|BACR_HAL      QEFYIITIFITTIAAAMYFAMATG-------------------------- 
gi|461611|sp|P33971|BACR_HALHP      QKFYIATILITAIAFVNYLAMALG-------------------------- 
gi|461612|sp|P33972|BACR_HALHS      QKFYIATILITAIAFVNYLAMALG-------------------------- 
gi|461610|sp|P33969|BACR_HALHM      REYYAITILVPGIASAAYLSMFFG-------------------------- 
gi|1168614|sp|P42197|BACT_HALV      RKRYLLLIAIPGIAIVAYALMALG-------------------------- 
gi|461609|sp|P33742|BACH_HALSS      QLIFVATLMVPLVSISSYTGLVSG-------------------------- 
gi|2499383|sp|Q48315|BACH_HALH      KLIWVATMLVPLVSISSYAGLASG-------------------------- 
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gi|2499384|sp|Q48314|BACH_HALH      KLIWVATMLVPLVSISSYAGLASG-------------------------- 
gi|14194475|sp|O93742|BACH_HAL      QLIFVATLMVPLVSISSYTGLVSG-------------------------- 
gi|114809|sp|P15647|BACH_NATPH      KLIAVSTILVPVVSIASYTGLASG-------------------------- 
gi|2829811|sp|P94853|BACH_HALV      KLIWVATMLVPLVSISSYAGLASG-------------------------- 
gi|15790684|ref|NP_280508.1|        RRYDLVLAGITGLAAIAYTTMGLG-------------------------- 
gi|15789491|ref|NP_279315.1|        RLIWGATLMIPLVSISSYLGLLSG-------------------------- 
gi|461608|sp|P33970|BACH_HALHM      QLIFVATLMVPLVSISSYTGLVSG-------------------------- 
gi|14194474|sp|O93741|BACH_HAL      RLIVGATLMIPLVSLSSYLGLVTG-------------------------- 
gi|1168615|sp|P42196|BACT_NATP      RRYYVTLVGISGIAAVAYVVMALG-------------------------- 
gi|15790610|ref|NP_280434.1|        QSALAPLAIIPVFAGLSYVGMAYD-------------------------- 
gi|2499388|sp|Q48334|BAC3_HALV      RSILAALALIPGFAGISYVAMAFG-------------------------- 
gi|461613|sp|P33743|BACS_HALSS      RGRLAALAVIPGFAGLAYAGMALG-------------------------- 
gi|14194476|sp|O93743|BACS_HAL      RTRLAALAVIPGFAGLSYVGMALG-------------------------- 
gi|6685436|sp|O74631|F123_CORV      RLFHQIAIVVLTTGSLAYFSMASD-------------------------- 
gi|6319528|ref|NP_009610.1|         RFVYYTAIAPNLFMSIAYFTMASN-------------------------- 
gi|1729881|sp|P51564|TCR8_PASM      FSLLGAALDYLLMAFSTTLWMLYIG------------------------- 
gi|11467412|ref|NP_043269.1|        RQFVFCLIGIVISNILMHFPLTLL-------------------------- 
gi|16763593|ref|NP_459208.1|        FILSALLAMVGYFLVRKFAPEAGG-------------------------- 
gi|1708329|sp|P53706|HST6_CANA      SYCFSKLLSTSLDSSIGLNSTQKI-------------------------- 
gi|16759194|ref|NP_454811.1|        FILSALLAMVGYFLVRKFAPEAGG-------------------------- 
gi|15594598|ref|NP_212387.1|        KFSLLETSSAEYIVVRNYLELITEL------------------------- 
gi|2501369|sp|Q47085|CBRB_ERWC      QVLTRNPLASPGLFGINAGAMFFLI------------------------- 
gi|17568741|ref|NP_509364.1|        RSLDIITIVVPPALPAAMSVGIINANSRLKKKKIFCTSPTTVNVCGLINV 
gi|15604244|ref|NP_220760.1|        EQVFRIITSTFLFFFAIFGFILFP-------------------------- 
 
 
Helix too short and no alternative, so not considered for gap check   
 
Helix 5 
1BRX                                ------------------YRFVWWAISTAAMLYILY-------------- 
gi|15790468|ref|NP_280292.1|        ------------------YRFVWWAISTAAMLYILY-------------- 
gi|3023375|sp|P96787|BAC3_HALS      ------------------ARYSWWLFSTICMIVVLY-------------- 
gi|114807|sp|P19585|BAC1_HALS1      ------------------ARYTWWLFSTICMIVVLY-------------- 
gi|231626|sp|P29563|BAC2_HALS2      ------------------ARYTWWLFSTIAFLFVLY-------------- 
gi|2829812|sp|P94854|BACR_HALV      ----------------GAERLVWWGISTAFLLVLLY-------------- 
gi|2499386|sp|Q57101|BACR_HALA      ----------------GAERLVWWGISTAFLLVLLY-------------- 
gi|2499387|sp|Q53496|BACR_HALS      ----------------GAERLVWWGISTGFLLVLLY-------------- 
gi|14194473|sp|O93740|BACR_HAL      ------------------TRIAWWAISTGALLALLY-------------- 
gi|461611|sp|P33971|BACR_HALHP      ----------------GAERLVWWGISTAFLLVLLY-------------- 
gi|461612|sp|P33972|BACR_HALHS      ----------------GAERLVWWGISTAFLLVLLY-------------- 
gi|461610|sp|P33969|BACR_HALHM      ------------------ARYTWWLFSTIAFLFVLY-------------- 
gi|1168614|sp|P42197|BACT_HALV      -------------------SYALFAVGGALFGGVIY-------------- 
gi|461609|sp|P33742|BACH_HALSS      -----------------LLRWVWYAISCAFFVVVLY-------------- 
gi|2499383|sp|Q48315|BACH_HALH      -----------------LLRWVFYGISCAFFVAVLY-------------- 
gi|2499384|sp|Q48314|BACH_HALH      -----------------LLRWVFYGISCAFFVAVLY-------------- 
gi|14194475|sp|O93742|BACH_HAL      -----------------LLRWVWYVISCAFFVVVLY-------------- 
gi|114809|sp|P15647|BACH_NATPH      -----------------LMRWFWYAISCACFLVVLY-------------- 
gi|2829811|sp|P94853|BACH_HALV      -----------------LLRWVFYGISCAFFIAVLY-------------- 
gi|15790684|ref|NP_280508.1|        -------------------RWLFFAVGAAGYAALLY-------------- 
gi|15789491|ref|NP_279315.1|        -----------------LFRWAFYAISCAFFVVVLS-------------- 
gi|461608|sp|P33970|BACH_HALHM      -----------------LLRWVWYGISCAFFVVVLY-------------- 
gi|14194474|sp|O93741|BACH_HAL      -----------------AFRWAFYLVSTAFFVVVLY-------------- 
gi|1168615|sp|P42196|BACT_NATP      -------------------RYALFGMGAVAFLGLVY-------------- 
gi|15790610|ref|NP_280434.1|        -------------------KWALFGVSSIFHLSLFA-------------- 
gi|2499388|sp|Q48334|BAC3_HALV      -------------------KWVLFGVSTVFHVSLFA-------------- 
gi|461613|sp|P33743|BACS_HALSS      -------------------KWVLFGVSSIFHVTLFA-------------- 
gi|14194476|sp|O93743|BACS_HAL      -------------------KWALFGVSALFHVSLFA-------------- 
gi|6685436|sp|O74631|F123_CORV      -------------------KWGYYTFGVSALFYIWY-------------- 
gi|6319528|ref|NP_009610.1|         -------------------KWGYYTIGIGAAIVVCI-------------- 
gi|1729881|sp|P51564|TCR8_PASM      -----------------NTVTVFFKKSLYFWLATYFI------------- 
gi|11467412|ref|NP_043269.1|        ----------------ANFPWKYLLGTVFVGLSMAIT------------- 
gi|16763593|ref|NP_459208.1|        ----------------PQFRYNLISIKAVFTGVIMSS------------- 
gi|1708329|sp|P53706|HST6_CANA      ----------------IVSGWKLALVGISFVPLVLLV------------- 
gi|16759194|ref|NP_454811.1|        ----------------PQFRYNLISIKAVFTGVIMSS------------- 
gi|15594598|ref|NP_212387.1|        EV------LDPEQNVRFRDHYLDLPFDISNVFFILTANS-VETIPRPLLN 
gi|2501369|sp|Q47085|CBRB_ERWC      ----------------ADRELADGAAADGLLLAALVG------------- 
gi|17568741|ref|NP_509364.1|        HLNFAKALKTPRDIMESELEFLGLIVMENRLKDVTLSVINELSVANIRCV 
gi|15604244|ref|NP_220760.1|        ----------------DTNEILLKSFITVILISGLIC------------- 
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b) 
Helix 3 
1OCC3                               NPSPWPLTGALSALLMTSGLTMWFH--------FNSMTLLMIGLTTNMLT 
gi|28381353|sp|P00415|COX3_BOV      NPSPWPLTGALSALLMTSGLTMWFH--------FNSMTLLMIGLTTNMLT 
gi|5921862|sp|O47701|COX3_ANTM      NPSPWPLTGALSALLMTSGLTMWFH--------FNSMTLLTLGLTTNMLT 
gi|5921876|sp|O47695|COX3_OURO      NPSPWPLTGALSALLMTSGLIMWFH--------FNSTTLLMLGLTTNMLT 
gi|5921877|sp|O47692|COX3_PELC      NPSPWPLTGALSALLMTSGLIMWFH--------FNSTTLLMLGLTTNMLT 
gi|5921888|sp|O47687|COX3_TRAS      NPSPWPLTGALSALLMTSGLTMWFH--------FNSMILLMLGLTTNMLT 
gi|5921861|sp|O47702|COX3_ANTC      NPSPWPLTGALSALLMTSGLIMWFH--------FNSTTLLMLGLTTNMLT 
gi|5921866|sp|O47708|COX3_GAZC      NPSPWPLTGALSALLMTSGLIMWFH--------FNSTTLLMLGLTTNMLT 
gi|5921865|sp|O47694|COX3_DAML      NPSPWPLTGALSALLMTSGLIMWFH--------FNSMTLLMLGLTTNMLT 
gi|5921885|sp|O47685|COX3_TRAI      NPSPWPLTGALSALLMTSGLTMWFH--------YNSTILLMLGLTTNMLT 
gi|6166023|sp|O48346|COX3_GAZG      NPSPWPLTGALSALLMTSGLIMWFH--------FNSTTLLMLGLTTNMLT 
gi|5921864|sp|O47693|COX3_CEPN      NPSPWPLTGALSALLMTSGLIMWFH--------FNSTALLMLGLTTNMLT 
gi|5921873|sp|O47700|COX3_LITW      NPSPWPLTGALSALLMTSGLIMWFH--------FNSTTLLMLGLTTNMLT 
gi|6166022|sp|O48308|COX3_GAZD      NPSPWPLTGALSALLMTSGLIMWFH--------FNSTTLLMLGLTTNMLT 
. 
. 
gi|5834878|ref|NP_006947.1|COX      SLSSYPILIFCSSLGFTSSLVVFFKNG-IFG-------GLLFCLFSIFLV 
 
Helix 6 
1OCC3                               MYQWWRDVIRESTFQGHHTPAVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|28381353|sp|P00415|COX3_BOV      MYQWWRDVIRESTFQGHHTPAVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|5921862|sp|O47701|COX3_ANTM      MYQWWRDIIRESTFQGHHTPNVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|5921876|sp|O47695|COX3_OURO      MYQWWRDVIRESTFQGHHTPTVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|5921877|sp|O47692|COX3_PELC      MYQWWRDIIRESTFQGHHTPSVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|5921888|sp|O47687|COX3_TRAS      MYQWWRDIIRESTFQGHHTPVVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|5921861|sp|O47702|COX3_ANTC      MYQWWRDVIRESTFQGHHTPNVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|5921866|sp|O47708|COX3_GAZC      MYQWWRDVVRESTFQGHHTPNVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|5921865|sp|O47694|COX3_DAML      MYQWWRDIIRESTFQGHHTSAVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|5921885|sp|O47685|COX3_TRAI      MYQWWRDIIRESTFQGHHTPTVQKGLRYGMILFIISEVLFFTGFFWAFYH 
gi|6166023|sp|O48346|COX3_GAZG      MYQWWRDVIRESTFQGHHTPNVQKGLRYGMILFIISEVLFFTGFFWAFYH 
Gap not chosen because would make helix too short . 
. 
gi|5834931|ref|NP_008087.1|COX      -MLWFRDIIRESTFQGMHSMFITNFLKFSMILFILSELMFFISFFWTFFH 
. 
gi|1169062|sp|P41775|COX3_MYTE      TFSWWRDLIREGDIG-
FHTRFVIKSFRDCVALFILSEVMFFFTFFWTFFH 
 
 
Gap chosen  
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Interestingly, if these same alignments with low homology sequences are used as 
input for TM2ndS prediction, some of the larger errors are reduced. For 1BRX, TM 
helices 2 and 5: 
Helix 2 
KFYAITTLVPAIAFTMYLSMLLG    (previous error 15, now error is 5) 
Helix 5 
RFVWWAISTAAMLYILY too short so would use default prediction 
 
And for 1OCCR: 
Helix 3 
GMILFIISEVLFFTGFFWAFYHSSLAPTPELG same error  
Helix 6 
DGVYGSTFFVATGFHGLHVIIGSTFLIVCFFR same error 
 
So these additional approaches may provide a second check for the TM2ndS 
default predictions as well as provide alternate predictions which may be improvements 
in some cases. 
 
Comparison to other methods 
 As mentioned previously, TM2ndS was compared to other top TM helix 
prediction methods by “static benchmarking” of the Rost group (developers of the PHD 
prediction method). This comparison is made using the same set of proteins and the same 
scoring method. The results for the TM helix residue accuracy are shown in Figure 4. Of 
all these methods, only TM2ndS and PHD performed over 75% (horizontal line) for both 
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the Q2Tobs (low value indicates underprediction of TM helix lengths) and Q2Tprd (low 
value indicates overprediction of lengths) whose definitions are given below: 
*Q2T(obs)=residues correctly predicted in TM helices/residues observed in TM helices 
 
*Q2T(prd)=residues correctly predicted in TM helices/residues predicted in TM helices 
 
The high values for both scores indicates a stable and accurate prediction. And of 
these two methods, only TM2ndS is based on hydrophobicity and general rules. It was 
not developed using the training set of membrane proteins, which is the case for other 
methods such as PHD. This indicates the general applicability of TM2ndS, especially in 
the case of GPCRs where there is a scarcity of information available. 
Figure 4: Histogram comparing the residue accuracy performance of the top 
TM helical prediction methods. 
Comparison of TM helical region prediction performance
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Thus for most cases, the TM2ndS residue accuracy is good enough to give 
confidence in predictions for unknown cases. It should be reiterated that these helices 
were not used in “training” the method. TM2ndS is based on hydrophobicity and general 
rules, which contribute to its generalizability. 
 
Conclusion 
TM2ndS is based on a first principles hydrophobicity analysis, with a robust 
baseline calculation, and general rules for the termination of the helix. As such, it is a 
general method for TM helix identification which is extendable to all membrane proteins 
of known structure. The residue accuracy of the predictions increases when the number of 
helices is known beforehand. But nevertheless, this study reports the high TM helix 
identification accuracy of 96.1% with a minimum required overlap of 15 residues, a 
stringent criteria in comparison to previous such analyses. Using this same criteria, the 
false positives were 8.7%. When using one sequence in the analysis (instead of a multiple 
sequence alignment), the number for true positives and false positives were 96.1% and 
95.5%, respectively. For the purposes of genome mining, this modification of TM2ndS 
may be used. 
This method is currently incorporated into MembStruk and as such is targeted 
towards the predictions for GPCRs, for which the number of helices is known 
beforehand, and in which case the focus is on high residue accuracy to permit correct 
function prediction. The average error in the predictions for the TM helical proteins was 
5.39 (corresponding to a 2.70 average error on any particular helix terminus accuracy). 
For 85.8% of the sequences, the average errors are 4.18 (2.09 on any side). The outlier 
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cases would very likely be improved by providing alignments with better sequence 
enrichment and by observing trends at different window sizes as used for GPCRs.  
Because of the translation protocol of MembStruk, the small errors in the current 
TM helical predictions would lead to small local structure errors in the 3-D structure 
predictions. Thus based on this automatic method, the predictions are of sufficiently good 
accuracy to allow correct determination of correct ligand binding.  
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Table 1: Data on true positives as well as false positives for the TM2ndS analysis using a 
multiple sequence alignment 
 Reference crystal 
structure helices 
Predictions 
Number  total 154 162 
Number predicted to 
overlap with >=15 
residues 
148 148 
Percents 96.1 (true +) 91.3 
 
Table 2: Data on true positives as well as false positives for the TM2ndS analysis 
without using a multiple sequence alignment (one sequence used in analysis) 
 Reference crystal 
structure helices 
Predictions 
Number  total 156 155 
Number predicted to 
overlap with >=15 
residues 
150 148 
Percents 96.1 (true +) 95.5 
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Figure 1: A set of TM helix predictions before and after capping compared with the 
ranges from the MPtopo crystal structure database (for those proteins in which all 
the lengths of the crystal and predicted  helices were >=20 and <=34). Those 
residues which did not fit the criteria for alpha helicity (in phi-psi angles) are 
indicated in italics, while those which have B-factors over 70 are indicated in 
bold.  
 
 
Figure S1: A set of TM helix predictions before and after capping compared with the 
ranges from the MPtopo crystal structure database helices (which have lengths of 
the crystal reference helix of >=20 and <=34, “GPCR ranges”). Those residues 
which did not fit the criteria for alpha helicity (in phi-psi angles) are indicated in 
italics, while those which have B-factors over 70 are indicated in bold. Those 
helices which were predicted to be larger than 34 are indicated with a *. Those 
helices predicted to be smaller than 20 are indicated with **. Underlined residues 
have missing backbone atoms so that phi-psi angles cannot be calculated. 
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Figure 1: 
 
The protein of pdb code 1H68 chain A (bacteria) 
TM Helix 1 
     LFWLGAIGMLVGTL 
VGLTTLFWLGAIGMLVGTLAFAWAG 
 GLTTLFWLGAIGMLVGTLAFAWAG 
 
TM Helix 2 
         GISGIAAVAYVVMALGVG 
      TLVGISGIAAVAYVVMALGVGWVP 
ERRYYVTLVGISGIAAVAYVVMAL 
 
TM Helix 3 
         TTPLIVYFLGL 
   YIDWILTTPLIVYFLGLLAGLDS 
APRYIDWILTTPLIVYFLGLLAG 
 
TM Helix 4 
            TLNTVVMLAGFAGA 
       VITLNTVVMLAGFAGAMVPGIE 
DSREFGIVITLNTVVMLAGFAGAMV 
 
TM Helix 5 
         MGAVAFLGLVYYLV 
         MGAVAFLGLVYYLVGPMTESASQ 
  ERYALFGMGAVAFLGLVYYLVGPMTESAS 
 
TM Helix 6 
                 LWAIYPFIWLLGPPGVALL 
           RNLTVILWAIYPFIWLLGPPGVALL 
SSGIKSLYVRLRNLTVILWAIYPFIWLLG 
 
TM Helix 7 
 LTPTVDVALIVYLDLVTKVGF 
       VALIVYLDLVTKVGFGFIALD 
  TPTVDVALIVYLDLVTKVGFGFIALDAAATL
 
 
The protein of pdb code 1BGY1 chain C (bovine) 
TM Helix 1 
  WNFGSLLGICLILQILTGLFL 
 WWNFGSLLGICLILQILTGLFLA 
SWWNFGSLLGICLILQILTGLFL 
 
TM Helix 2 
           ASMFFICLYMHVG 
      MHANGASMFFICLYMHVGRGLYY 
GWIIRYMHANGASMFFICLYMHVGRGLYY 
 
TM Helix 3 
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       VILLLTVMATAFMGYVLPWGQMSFW 
      GVILLLTVMATAFMGYVLPWGQM 
LETWNIGVILLLTVMATAFMGYVL 
 
TM Helix 4 
        AFHFILPFIIMAIAMVHLLF 
      FFAFHFILPFIIMAIAMVHLLFLH 
KATLTRFFAFHFILPFIIMAIAMVHLLFLHE 
 
TM Helix 5 
     ILGALLLILALMLLVLFA 
   KDILGALLLILALMLLVLFAPD 
YTIKDILGALLLILALMLLVLF 
 
TM Helix 6 
    GVLALAFSILILALIP 
NKLGGVLALAFSILILALIPLLHT 
 KLGGVLALAFSILILALIPLL 
 
TM Helix 7 
      FWALVADLLTLTW 
PLSQCLFWALVADLLTLTWIGGQP 
PLSQCLFWALVADLLTLTWIGG 
 
TM Helix 8 
    TIGQLASVLYFLLILVLMPTAG 
  
HPYITIGQLASVLYFLLILVLMPTAGTIENKL 
  TIGQLASVLYFLLILVLMPTAG 
 
 
The protein of pdb code 1BGY5 chain J (bovine) 
TM Helix 1 
  TSTFALTIVVGALLFER 
RRTSTFALTIVVGALLFERAF 
    TSTFALTIVVGALLFERAFDQGADAIYEHIN 
 
 
The protein of pdb code 1BRX chain A (bacteria) 
TM Helix 1 
   WLALGTALMGLGTLYFL 
EWIWLALGTALMGLGTLYFLVKG 
EWIWLALGTALMGLGTLYFLVKG 
 
TM Helix 2 
          TTLVPAIAFTMYLSMLLGYGLTMV 
          TTLVPAIAFTMYLSMLLGYGLTMV 
DPDAKKFYAITTLVPAIAFTMYLSMLLG 
 
TM Helix 3 
         TPLLLLDL 
 RYADWLFTTPLLLLDLALLVDADQ 
ARYADWLFTTPLLLLDLALLV 
 
TM Helix 4 
        VGADGIMIGTGLVGALTKVYS 
       LVGADGIMIGTGLVGALTKVYS 
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DQGTILALVGADGIMIGTGLVGAL 
 
TM Helix 5 
     WAISTAAMLYILYVLFF 
 RFVWWAISTAAMLYILYVLFFGFT 
YRFVWWAISTAAMLYILYVLFFG 
 
TM Helix 6 
               VVLWSAYPVVWLIGSEGAGI 
       FKVLRNVTVVLWSAYPVVWLIGS 
RPEVASTFKVLRNVTVVLWSAYPVVWLIG 
 
TM Helix 7 
 VPLNIETLLFMVLDVSAKVG 
 VPLNIETLLFMVLDVSAKVGF 
  PLNIETLLFMVLDVSAKVGFGLILLR 
 
 
 
The protein of pdb code 1OCC4 chain D (bovine) 
TM Helix 1 
   TVVGAAMFFIGFTALLLIWEKHYVYG 
   TVVGAAMFFIGFTALLLIWEKHYVYG 
EWKTVVGAAMFFIGFTALLLIWEKHYV 
 
 
The protein of pdb code 1OCC5 chain G (bovine) 
TM Helix 1 
  TWRFLTFGLALPSVALCTLNS 
  TWRFLTFGLALPSVALCTLNSWLH 
ARTWRFLTFGLALPSVALCTLNSWL 
 
 
 
 
The protein of pdb code 1OCC7 chain J (bovine) 
TM Helix 1 
             CLGGTLYSLYCLG 
       RVTMTLCLGGTLYSLYCLGWASF 
ATDNILYRVTMTLCLGGTLYSLYCLGWAS 
 
 
 
The protein of pdb code 1OCC8 chain K (bovine) 
TM Helix 1 
         LASGATFCVAVWVYMATQIGIE 
         LASGATFCVAVWVYMATQIGIE 
FHDKYGNAVLASGATFCVAVWVYMATQ 
 
 
 
The protein of pdb code 1OCC9 chain L (bovine) 
TM Helix 1 
       MTLFFGSGFAAPFF 
  RLLAMMTLFFGSGFAAPFFIVRH 
KWRLLAMMTLFFGSGFAAPFFIVRHQL 
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The protein of pdb code 1OCC10 chain M (bovine) 
TM Helix 1 
       LSVTFLSFLLPAGWVL 
    AIGLSVTFLSFLLPAGWVLYHL 
PKEQAIGLSVTFLSFLLPAGWVLYH 
The protein of pdb code 1AR12 chain B (bacteria) 
TM Helix 1 
    QWLDHFVLYIITAVTIFVCLLLLIC 
     QWLDHFVLYIITAVTIFVCLLLLICIVR 
LAHDQQWLDHFVLYIITAVTIFVCLLLLICIVR 
 
TM Helix 2 
  IEVIWTLVPVLILVAIGAFSLPIL 
   IEVIWTLVPVLILVAIGAFSLPIL 
NTPIEVIWTLVPVLILVAIGAFSLPILFRSQE 
 
 
The protein of pdb code 1EHK2 chain B (bacteria) 
TM Helix 1 
           EKGWLAFSLAMLFVFIALIAYTLATHTAGV 
           EKGWLAFSLAMLFVFIALIAYTLATHTAGV 
EHKAHKAILAYEKGWLAFSLAMLFVFIALIAYTLA 
 
 
 
The protein of pdb code 1FUM1 chain D (bacteria) 
TM Helix 1 
       LFGAGGMWSAIIAPVMILLVGILLPLGLFP 
       LFGAGGMWSAIIAPVMILLVGILLPLGLFP 
DEPVFWGLFGAGGMWSAIIAPVMILLV 
 
TM Helix 2 
        FIGRVFLFLMIVLPL 
RVLAFAQSFIGRVFLFLMIVLPLWCGL 
        FIGRVFLFLMIVLPLWCGLHRMHHAMHDL 
 
 
 
The protein of pdb code 1FUM2 chain C (bacteria) 
TM Helix 1 
             AVWFSIELIFGLF 
        GTAVPAVWFSIELIFGLFALKNG 
YRFYMLREGTAVPAVWFSIELIFGLFAL 
 
TM Helix 2 
   DFLQNPVIVIINLITLAA 
GFVDFLQNPVIVIINLITLAAALLH 
        PVIVIINLITLAAALLHTKTWFELA 
 
TM Helix 3 
     KSLWAVTVVATIVIL 
  PIIKSLWAVTVVATIVILFVALY 
PEPIIKSLWAVTVVATIVILFVAL 
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The protein of pdb code 1E12 chain A (bacteria) 
TM Helix 1 
       SLWVNVALAGIAILVFV 
ENALLSSSLWVNVALAGIAILVFVYMG 
 NALLSSSLWVNVALAGIAILVFVYMG 
 
TM Helix 2 
       ATLMIPLVSISSYLGLLSGLTVGM 
      GATLMIPLVSISSYLGLLSGLTVGM 
RPRLIWGATLMIPLVSISSYLGLL 
 
TM Helix 3 
         STPMILLALGLLADVDLGS 
  RYLTWALSTPMILLALGLLADVDLGS 
WGRYLTWALSTPMILLALGLLA 
 
TM Helix 4 
      VIAADIGMCVTGLAAAM 
      VIAADIGMCVTGLAAAMTTSA 
LGSLFTVIAADIGMCVTGLAAAMT 
 
TM Helix 5 
      FYAISCAFFVVVLSALVTD 
      FYAISCAFFVVVLSALVTDWAAS 
LLFRWAFYAISCAFFVVVLSALV 
 
TM Helix 6 
      LRVLTVVLWLGYPIVWAVGVEGLALVQSVGVT 
      LRVLTVVLWLGYPIVWAVGVEGLALVQSVGVT 
AEIFDTLRVLTVVLWLGYPIVWAV 
 
TM Helix 7 
           DVFAKYVFAFI 
 GVTSWAYSVLDVFAKYVFAFILLRWV 
VGVTSWAYSVLDVFAKYVFAFILLRWVAN 
 
 
 
The protein of pdb code 1BL8 chain A (bacteria) 
TM Helix 1 
   AGAATVLLVIVLLAGSYL 
WRAAGAATVLLVIVLLAGSYLAVLAE 
  AAGAATVLLVIVLLAGSYLAVLAER 
 
TM Helix 2 
 WGRCVAVVVMVAGITSFGLVTAALA 
 WGRCVAVVVMVAGITSFGLVTAALATWFVG 
 WGRCVAVVVMVAGITSFGLVTAALATW 
 
 
 
The protein of pdb code 1KZU1 chain A (bacteria) 
TM Helix 1 
       ALLGSVTVIAILVHLAIL 
     IPALLGSVTVIAILVHLAILSH 
NPAIGIPALLGSVTVIAILVHLAILS 
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The protein of pdb code 1KZU2 chain B (bacteria) 
TM Helix 1 
         RVFLGLALVAHFLAFS 
      DGTRVFLGLALVAHFLAFSATP 
LHKYVIDGTRVFLGLALVAHFLAFSA 
 
 
 
The protein of pdb code 1LGH1 chain A (?) 
TM Helix 1 
 PSTWLPVIWIVATVVAIAVHAAV 
 PSTWLPVIWIVATVVAIAVHAAV 
NPSTWLPVIWIVATVVAIAVHAAVLAA 
 
 
 
The protein of pdb code 1LGH2 chain B (?) 
TM Helix 1 
                   IILAAVAHVLV 
            KTTFSAFIILAAVAHVLVWVWKP 
TEEEAIAVHDQFKTTFSAFIILAAVAHVLVWVWK 
 
 
 
The protein of pdb code 1MSL chain B (bacteria TB) 
TM Helix 1 
   IVDLAVAVVIGTAFTAL 
RGNIVDLAVAVVIGTAFTALVTK 
    VDLAVAVVIGTAFTALVTKFTDSIITPLI 
 
TM Helix 2 
 QTIDLNVLLSAAINFFLIAFAVYFLVVL 
 QTIDLNVLLSAAINFFLIAFAVYFLVVLP 
     LNVLLSAAINFFLIAFAVYFL 
 
 
 
The protein of pdb code 2RCR1 chain H (bacteria) 
TM Helix 1 
 FGNFDLASLAIYSFWIFLAGLIYYL 
 FGNFDLASLAIYSFWIFLAGLIYYLQTE 
       ASLAIYSFWIFLAGLIYYLQTENMREGY 
 
 
 
The protein of pdb code 1EHK chain C (bacteria) 
TM Helix 1 
         LVLTLTILVFWLGV 
   GALAVILVLTLTILVFWLGVYAVFFAR 
KPKGALAVILVLTLTILVFWLGVYAVFFAR 
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Figure S1: 
 
 
The protein of pdb code 1KPK chain A (bacteria) 
TM Helix 2 
ADHAFLLWPLAFILSALLAMVGYFL 
ADHAFLLWPLAFILSALLAMVGYFL 
     LLWPLAFILSALLAMVGYFLVRK 
 
TM Helix 8 
      IKAVFTGVIMSSI 
RYNLISIKAVFTGVIMSSIVFRIF 
    ISIKAVFTGVIMSSIVFRIFN 
 
TM Helix 9 
  NTLWLYLILGIIFGVVGPVFNS 
PVNTLWLYLILGIIFGVVGPVFNSLVLR 
      LYLILGIIFGVVGPVFNSLVLRTQDMFQRF 
 
TM Helix 13 
 CFSSGAPGGIFAPMLALGTLLGTAFGMAAAVLFP 
 CFSSGAPGGIFAPMLALGTLLGTAFGMAAAVL 
          IFAPMLALGTLLGTAFGMAAAV 
 
 
 
The protein of pdb code 1L7V chain A (bacteria) 
TM Helix 1 
               LSVLMLLALLLSLCAG 
          RWLLCLSVLMLLALLLSLCAGEQWI 
LARQQQRQNIRWLLCLSVLMLLALLLSLC 
 
TM Helix 2 
        LLVGAALAISGAV 
   
RLPRTLAVLLVGAALAISGAVMQA 
RTLAVLLVGAALAISGAVMQALFE 
 
TM Helix 3 ** 
        VSNGAGVGLIAAVLLGQGQLPN 
    GLLGVSNGAGVGLIAAVLLG 
LAEPGLLGVSNGAGVGLIAAVL 
 
TM Helix 4 
 NWALGLCAIAGALIITL 
 NWALGLCAIAGALIITLILLRFA 
  WALGLCAIAGALIITLILLRFARRHL 
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TM Helix 9 
 ALAGASALLLADIVA 
      SALLPGCALAGASALLLADIVAR 
        LLPGCALAGASALLLADIVARLA 
 
 
 
The protein of pdb code 1H68 chain A (bacteria) 
TM Helix 1 
     LFWLGAIGMLVGTL 
VGLTTLFWLGAIGMLVGTLAFAWAG 
 GLTTLFWLGAIGMLVGTLAFAWAG 
 
TM Helix 2 
         GISGIAAVAYVVMALGVG 
      TLVGISGIAAVAYVVMALGVGWVP 
ERRYYVTLVGISGIAAVAYVVMAL 
 
TM Helix 3 
         TTPLIVYFLGL 
   YIDWILTTPLIVYFLGLLAGLDS 
APRYIDWILTTPLIVYFLGLLAG 
 
TM Helix 4 
            TLNTVVMLAGFAGA 
       VITLNTVVMLAGFAGAMVPGIE 
DSREFGIVITLNTVVMLAGFAGAMV 
 
TM Helix 5 
         MGAVAFLGLVYYLV 
         MGAVAFLGLVYYLVGPMTESASQ 
  ERYALFGMGAVAFLGLVYYLVGPMTESAS 
 
TM Helix 6 
                 LWAIYPFIWLLGPPGVALL 
           RNLTVILWAIYPFIWLLGPPGVALL 
SSGIKSLYVRLRNLTVILWAIYPFIWLLG 
 
TM Helix 7 
 LTPTVDVALIVYLDLVTKVGF 
       VALIVYLDLVTKVGFGFIALD 
  TPTVDVALIVYLDLVTKVGFGFIALDAAATL
 
 
 
The protein of pdb code 1FQY chain A (human) 
TM Helix 1 
   WRAVVAEFLATTLFVFISIGSALG 
   WRAVVAEFLATTLFVFISIGSALG 
KLFWRAVVAEFLATTLFVFISIGSALGFK 
 
TM Helix 4 
 LMYIIAQCVGAIVATAILSGIT 
 LMYIIAQCVGAIVATAILSGITS 
 LMYIIAQCVGAIVATAILSGI 
 
TM Helix 8 
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  WIFWVGPFIGGALAVLIYDFIL 
 HWIFWVGPFIGGALAVLIYDFIL 
NHWIFWVGPFIGGALAVLIYD 
 
 
 
The protein of pdb code 1A91 chain A (bacteria) 
TM Helix 2 
          GLVDAIPMIAVGLGLY 
        VMGLVDAIPMIAVGLGLYVMFAV 
LLRTQFFIVMGLVDAIPMIAVGLGLYVMFA 
 
 
 
The protein of pdb code 1BGY1 chain C (bovine) 
TM Helix 1 
  WNFGSLLGICLILQILTGLFL 
 WWNFGSLLGICLILQILTGLFLA 
SWWNFGSLLGICLILQILTGLFL 
 
TM Helix 2 
           ASMFFICLYMHVG 
      MHANGASMFFICLYMHVGRGLYY 
GWIIRYMHANGASMFFICLYMHVGRGLYY 
 
TM Helix 3 
       VILLLTVMATAFMGYVLPWGQMSFW 
      GVILLLTVMATAFMGYVLPWGQM 
LETWNIGVILLLTVMATAFMGYVL 
 
TM Helix 4 
        AFHFILPFIIMAIAMVHLLF 
      FFAFHFILPFIIMAIAMVHLLFLH 
KATLTRFFAFHFILPFIIMAIAMVHLLFLHE 
 
TM Helix 5 
     ILGALLLILALMLLVLFA 
   KDILGALLLILALMLLVLFAPD 
YTIKDILGALLLILALMLLVLF 
 
TM Helix 6 
    GVLALAFSILILALIP 
NKLGGVLALAFSILILALIPLLHT 
 KLGGVLALAFSILILALIPLL 
 
TM Helix 7 
      FWALVADLLTLTW 
PLSQCLFWALVADLLTLTWIGGQP 
PLSQCLFWALVADLLTLTWIGG 
 
TM Helix 8 
    TIGQLASVLYFLLILVLMPTAG 
    TIGQLASVLYFLLILVLMPTAG 
HPYITIGQLASVLYFLLILVLMPTAGTIENKL 
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The protein of pdb code 1BGY2 
 
 
 
 
 
The protein of pdb code 1BGY4 
 
 
The protein of pdb code 1BGY5 chain J (bovine) 
TM Helix 1 
  TSTFALTIVVGALLFER 
RRTSTFALTIVVGALLFERAF 
  TSTFALTIVVGALLFERAFDQGADAIYEHIN 
 
 
 
The protein of pdb code 1BGY6 
 
 
The protein of pdb code 1BRX chain A (bacteria) 
TM Helix 1 
   WLALGTALMGLGTLYFL 
EWIWLALGTALMGLGTLYFLVKG 
EWIWLALGTALMGLGTLYFLVKG 
 
TM Helix 2 
          TTLVPAIAFTMYLSMLLGYGLTMV 
          TTLVPAIAFTMYLSMLLGYGLTMV 
DPDAKKFYAITTLVPAIAFTMYLSMLLG 
 
TM Helix 3 
         TPLLLLDL 
 RYADWLFTTPLLLLDLALLVDADQ 
ARYADWLFTTPLLLLDLALLV 
 
TM Helix 4 
        VGADGIMIGTGLVGALTKVYS 
       LVGADGIMIGTGLVGALTKVYS 
DQGTILALVGADGIMIGTGLVGAL 
 
TM Helix 5 
     WAISTAAMLYILYVLFF 
 RFVWWAISTAAMLYILYVLFFGFT 
YRFVWWAISTAAMLYILYVLFFG 
 
TM Helix 6 
               VVLWSAYPVVWLIGSEGAGI 
       FKVLRNVTVVLWSAYPVVWLIGS 
RPEVASTFKVLRNVTVVLWSAYPVVWLIG 
 
TM Helix 7 
 VPLNIETLLFMVLDVSAKVG 
 VPLNIETLLFMVLDVSAKVGF 
  PLNIETLLFMVLDVSAKVGFGLILLR 
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The protein of pdb code 1EUL chain A (rabbit) 
TM Helix 1 
WELVIEQFEDLLVRILLLAACISFVLAWFEEG 
 WELVIEQFEDLLVRILLLAACISFVLAWFEEG 
     IEQFEDLLVRILLLAACISFVLAWFEE 
 
TM Helix 2 
 AFVEPFVILLILIANAIVGVWQERN 
 AFVEPFVILLILIANAIVGVWQERN 
   VEPFVILLILIANAIVGVWQERNAENAIEAL 
 
TM Helix 3 * 
  LQQKLDEFGEQLSKVISLICVAVWLINIGHFNDPVHG 
  LQQKLDEFGEQLSKVISLICVAVWLINIGHFNDPVHG 
TPLQQKLDEFGEQLSKVISLICVAVWLI 
 
TM Helix 6 
 ALIPVQLLWVNLVTDGLPATALGFNPP 
 ALIPVQLLWVNLVTDGLPATALGFNPP 
   IPVQLLWVNLVTDGLPATALGF 
 
TM Helix 7 * 
  WLFFRYMAIGGYVGAATVGAAAWWFMYAEDGPGVTYH 
  WLFFRYMAIGGYVGAATVGAAAWWFMYAEDGPGVTYH 
SGWLFFRYMAIGGYVGAATVGAA 
 
 
 
The protein of pdb code 1OCC1 chain A (bovine mito) 
TM Helix 1 
     TLYLLFGAWAGMVGTALSLLI 
    GTLYLLFGAWAGMVGTALSLLIR 
HKDIGTLYLLFGAWAGMVGTALSLLIRAE 
 
TM Helix 4 
 GASVDLTIFSLHLAGVSSILGAINFITTIIN 
 GASVDLTIFSLHLAGVSSILGAINFITTIINM 
  ASVDLTIFSLHLAGVSSILGAINFITTIIN 
 
TM Helix 5 
 QTPLFVWSVMITAVLLLLSLPVLAAGITML 
 QTPLFVWSVMITAVLLLLSLPVLAAGITML 
    LFVWSVMITAVLLLLSLPVLAAGITMLLTD 
 
TM Helix 6 
 ILYQHLFWFFGHPEVYILILPGFGMISHI 
 ILYQHLFWFFGHPEVYILILPGFGMISHI 
          FGHPEVYILILPGFGMISHIVTYY 
 
TM Helix 8 
      FTSATMIIAIPTGVKVFSWLATLH 
   RAYFTSATMIIAIPTGVKVFSWLATLH 
VDTRAYFTSATMIIAIPTGVKVFSWLATL 
 
TM Helix 9 
 PAMMWALGFIFLFTVGGLTGIVLANSSLD 
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 PAMMWALGFIFLFTVGGLTGIVLANSSLD 
 PAMMWALGFIFLFTVGGLTGIV 
 
TM Helix 10 
 YYVVAHFHYVLSMGAVFAIMGGFVHWFPL 
TYYVVAHFHYVLSMGAVFAIMGGFVHWFPL 
 YYVVAHFHYVLSMGAVFAIMGGFVHWFPLF 
 
TM Helix 11 
 TWAKIHFAIMFVGVNMTFFPQHFL 
 TWAKIHFAIMFVGVNMTFFPQHFL 
DTWAKIHFAIMFVGVNMTFFPQHFLGL 
 
TM Helix 12 
 PDAYTMWNTISSMGSFISLTAVMLMVFIIWEAF 
 PDAYTMWNTISSMGSFISLTAVMLMVFIIWEAF 
    YTMWNTISSMGSFISLTAVMLMVFIIWEAFAS 
 
 
 
 
 
The protein of pdb code 1OCC3 chain C (bovine mito) 
TM Helix 2 
 FNSMTLLMIGLTTNML 
 FNSMTLLMIGLTTNMLTMYQWWR 
     TLLMIGLTTNMLTMYQWWRDVIREST 
 
TM Helix 3 
           ILFIISEVLFFTGFFWAFYHSSLAPTPELG 
         GMILFIISEVLFFTGFFWAFYHSSLAPTPELG 
PAVQKGLRYGMILFIISEVLFFTGFFWAFYHSS 
 
TM Helix 4 
   PLLNTSVLLASGVSITW 
LEVPLLNTSVLLASGVSITWAHH 
  VPLLNTSVLLASGVSITWAHHSLM 
 
TM Helix 5 
   MLQALFITITLGVYFTLLQ 
   MLQALFITITLGVYFTLLQASE 
RKHMLQALFITITLGVYFTLLQASEYYE 
 
TM Helix 6 
 DGVYGSTFFVATGFHGLHVIIGSTFLIVCF 
 DGVYGSTFFVATGFHGLHVIIGSTFLIVCFFR 
  GVYGSTFFVATGFHGLHVIIGSTFLIVCFFRQL 
 
TM Helix 7 
    AGAWYWHFVDVVWLFLYVSIYWWGS 
    AGAWYWHFVDVVWLFLYVSIYWWG 
FGFEAGAWYWHFVDVVWLFLYVSI 
 
 
 
The protein of pdb code 1OCC4 chain D (bovine) 
TM Helix 1 
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   TVVGAAMFFIGFTALLLIWEKHYVYG 
   TVVGAAMFFIGFTALLLIWEKHYVYG 
EWKTVVGAAMFFIGFTALLLIWEKHYV 
 
 
 
The protein of pdb code 1OCC5 chain G (bovine) 
TM Helix 1 
  TWRFLTFGLALPSVALCTLNS 
  TWRFLTFGLALPSVALCTLNSWLH 
ARTWRFLTFGLALPSVALCTLNSWL 
 
 
 
The protein of pdb code 1OCC6 
 
 
The protein of pdb code 1OCC7 chain J (bovine) 
TM Helix 1 
             CLGGTLYSLYCLG 
       RVTMTLCLGGTLYSLYCLGWASF 
ATDNILYRVTMTLCLGGTLYSLYCLGWAS 
 
 
 
The protein of pdb code 1OCC8 chain K (bovine) 
TM Helix 1 
         LASGATFCVAVWVYMATQIGIE 
         LASGATFCVAVWVYMATQIGIE 
FHDKYGNAVLASGATFCVAVWVYMATQ 
 
 
 
The protein of pdb code 1OCC9 chain L (bovine) 
TM Helix 1 
       MTLFFGSGFAAPFF 
  RLLAMMTLFFGSGFAAPFFIVRH 
KWRLLAMMTLFFGSGFAAPFFIVRHQL 
 
 
 
The protein of pdb code 1OCC10 chain M (bovine) 
TM Helix 1 
       LSVTFLSFLLPAGWVL 
    AIGLSVTFLSFLLPAGWVLYHL 
PKEQAIGLSVTFLSFLLPAGWVLYH 
 
 
 
The protein of pdb code 1AR11 chain A (bacteria) 
TM Helix 1 
      ILYLFTAGIVGLISVCFTVY 
    IGILYLFTAGIVGLISVCFTVYMR 
NHKDIGILYLFTAGIVGLISVCFTVYMRMELQH 
 
TM Helix 3 
      WMYVCGVALGVASLL 
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LNNLSYWMYVCGVALGVASLLAPGG 
LNNLSYWMYVCGVALGVASLLA 
 
TM Helix 4 
    SMDLAIFAVHVSGASSILGAINIIT 
    SMDLAIFAVHVSGASSILGAINIITTFLNMR 
    SMDLAIFAVHVSGASSILGAINIITTFLN 
 
TM Helix 5 
 KVPLFAWSVFITAWLILLSLPVLAGAIT 
 KVPLFAWSVFITAWLILLSLPVLAGAIT 
   PLFAWSVFITAWLILLSLPVLAGAITMLLMDRNF 
 
TM Helix 8 
       MLATMTIAVPTGIKVFSWIAT 
   QAYFMLATMTIAVPTGIKVFSWIATMW 
LTQQAYFMLATMTIAVPTGIKVFSWIATM 
 
TM Helix 9 
KTPMLWAFGFLFLFTVGGVTGVVLSQAPLD 
KTPMLWAFGFLFLFTVGGVTGVVLSQAP 
KTPMLWAFGFLFLFTVGGVTGVVLSQ 
 
TM Helix 10 
 YHDTYYVVAHFHYVMSLGAVFGIFAGVYYWIGKM 
   DTYYVVAHFHYVMSLGAVFGIFAGVYYWIGKM 
   DTYYVVAHFHYVMSLGAVFGIFAGVYY 
 
TM Helix 11 
   AGQLHFWMMFIGSNLIFFPQHFL 
   AGQLHFWMMFIGSNLIFFPQHFL 
PEWAGQLHFWMMFIGSNLIFFPQHFLGR 
 
TM Helix 12  
      NISSIGAYISFASFLFFIG 
EFAYWNNISSIGAYISFASFLFFIG 
  AYWNNISSIGAYISFASFLFFIGIVFYTLFA 
 
 
 
The protein of pdb code 1AR12 chain B (bacteria) 
TM Helix 1 
    QWLDHFVLYIITAVTIFVCLLLLIC 
     QWLDHFVLYIITAVTIFVCLLLLICIVR 
LAHDQQWLDHFVLYIITAVTIFVCLLLLICIVR 
 
TM Helix 2 
  IEVIWTLVPVLILVAIGAFSLPIL 
   IEVIWTLVPVLILVAIGAFSLPIL 
NTPIEVIWTLVPVLILVAIGAFSLPILFRSQE 
 
 
 
The protein of pdb code 1QLE chain C (bacteria) 
TM Helix 1 
    FGAIGAFVMLTGAVAWMKGITFFGL 
IWPFFGAIGAFVMLTGAVAWMKG 
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IWPFFGAIGAFVMLTGAVAWM 
 
TM Helix 2 
 LPVEGPWMFLIGLVGVLY 
 LPVEGPWMFLIGLVGVLYVMFGW 
      PWMFLIGLVGVLYVMFGWWADVVNEGETG 
 
TM Helix 4 
    INTLILLLSGVAVTW 
HLPLINTLILLLSGVAVTWAHHA 
HLPLINTLILLLSGVAVTWAHHAFVLE 
 
TM Helix 5 
        IVAVILGVCFTG 
  TTINGLIVAVILGVCFTGLQAYEY 
RKTTINGLIVAVILGVCFTGLQAYEYSHA 
 
TM Helix 6 
      FYMATGFHGAHVIIGTIFLFV 
    GAFYMATGFHGAHVIIGTIFLFVCLIR 
TVYAGAFYMATGFHGAHVIIGTIFLFVCLIRLLK 
 
TM Helix 7 
       AWYWHFVDVVWLFLFVVIYIWGR 
       AWYWHFVDVVWLFLFVVIYIWG 
HVGFEAAAWYWHFVDVVWLFLFVVIYIWG 
 
 
 
The protein of pdb code 1EHK1 chain A (bacteria) 
TM Helix 1 
       FLVLGFLALIVGSLFGPF 
  KATLYFLVLGFLALIVGSLFGPFQAL 
EKKATLYFLVLGFLALIVGSLFGPFQALNYGN 
 
TM Helix 2 
      LHGVLNAIVFTQLFAQAI 
   GLTLHGVLNAIVFTQLFAQAIMVYLP 
YYQGLTLHGVLNAIVFTQLFAQAIMVYLPAREL 
 
TM Helix 3 
    WLSWWMAFIGLVVAALPLLANEAT 
 GLMWLSWWMAFIGLVVAALPLLANEAT 
MGLMWLSWWMAFIGLVVAALPLL 
 
TM Helix 4 
   AFYLGASVFVLSTWVSIY 
GHWAFYLGASVFVLSTWVSIYIVLD 
  WAFYLGASVFVLSTWVSIYIVLDLWRRWKAA 
 
TM Helix 5 * 
 LVTYMAVVFWLMWFLASLGLVLEAVLFLLPWSFGLVEG 
 LVTYMAVVFWLMWFLASLGLVLEAVLFLLPWSFGLVEG 
 LVTYMAVVFWLMWFLASLGLVLEAVLFLLPWS 
 
TM Helix 6 
          TGHPIVYFWLLPAYAIIYT 
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        WWTGHPIVYFWLLPAYAIIYTILP 
PLVARTLFWWTGHPIVYFWLLPAYAIIYTILPKQ 
 
TM Helix 7 
    RLAFLLFLLLSTPVG 
DPMARLAFLLFLLLSTPVGFHHQ 
DPMARLAFLLFLLLSTPVGFHH 
 
TM Helix 8 
      HSVLTLFVAVPSLMTAFTVAA 
     IHSVLTLFVAVPSLMTAFTVAASLE 
PTWKMIHSVLTLFVAVPSLMTAFTVAASLEFAGRL 
 
TM Helix 9 
 AFVAPVLGLLGFIPGGAGGIVNASF 
 AFVAPVLGLLGFIPGGAGGIVNASFTLD 
PAFVAPVLGLLGFIPGGAGGIVN 
 
TM Helix 11 
          VWLWFLGMMIMAVGLHWA 
      GLAVVWLWFLGMMIMAVGLHWAGLL 
DAQRRLGLAVVWLWFLGMMIMAVGLHWAGL 
 
TM Helix 12 
    VPMVFNVLAGIVLLVALLLFIYGLF 
    VPMVFNVLAGIVLLVALLLFIYGLF 
PHAAVPMVFNVLAGIVLLVALLLFIYGLFSVLL 
 
TM Helix 13 
 RIGFWFAVAAILVVLAYGPTLV 
 RIGFWFAVAAILVVLAYGPTLV 
  IGFWFAVAAILVVLAYGPTLVQLF 
 
 
 
The protein of pdb code 1EHK2 chain B (bacteria) 
TM Helix 1 
           EKGWLAFSLAMLFVFIALIAYTLATHTAGV 
      
EHKAHKAILAYEKGWLAFSLAMLFVFIALIAYTLA 
     EKGWLAFSLAMLFVFIALIAYTLATHTAGV 
 
 
 
The protein of pdb code 1FUM1 chain D (bacteria) 
TM Helix 1 
       LFGAGGMWSAIIAPVMILLVGILLPLGLFP 
       LFGAGGMWSAIIAPVMILLVGILLPLGLFP 
DEPVFWGLFGAGGMWSAIIAPVMILLV 
 
TM Helix 2 
        FIGRVFLFLMIVLPL 
RVLAFAQSFIGRVFLFLMIVLPLWCGL 
        FIGRVFLFLMIVLPLWCGLHRMHHAMHDL 
 
 
 
The protein of pdb code 1FUM2 chain C (bacteria) 
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TM Helix 1 
             AVWFSIELIFGLF 
        GTAVPAVWFSIELIFGLFALKNG 
YRFYMLREGTAVPAVWFSIELIFGLFAL 
 
TM Helix 2 
   DFLQNPVIVIINLITLAA 
GFVDFLQNPVIVIINLITLAAALLH 
        PVIVIINLITLAAALLHTKTWFELA 
 
TM Helix 3 
     KSLWAVTVVATIVIL 
  PIIKSLWAVTVVATIVILFVALY 
PEPIIKSLWAVTVVATIVILFVAL 
 
 
 
The protein of pdb code 1QLA chain C (?) 
TM Helix 1 
       WQSATGLFLGLFMIGHMFFVSTILLGDN 
     DWWQSATGLFLGLFMIGHMFFVSTILLGDN 
MPAKLDWWQSATGLFLGLFMIGHMFFVSTIL 
 
TM Helix 2 
 FEGGKPIVVSFLAAFVFAVFIAHAFLAM 
 FEGGKPIVVSFLAAFVFAVFIAHAFLAMR 
       IVVSFLAAFVFAVFIAHAFLAMRK 
 
TM Helix 3 
      WIQAMTGFAMFFLGSVHLYIMMTQPQ 
 DTTLWWIQAMTGFAMFFLGSVHLYIMMTQPQ 
GDTTLWWIQAMTGFAMFFLGSVHLYIMMT 
 
TM Helix 4 
  EWMWPLYLVLLFAVELHGSV 
VSEWMWPLYLVLLFAVELHGSVGL 
     WPLYLVLLFAVELHGSVGLYRLAVKW 
 
 
 
The protein of pdb code 1FX8 chain A (bacteria) 
TM Helix 1 
        EFLGTGLLIFFGVGCVAALKVA 
      IAEFLGTGLLIFFGVGCVAALKV 
TLKGQCIAEFLGTGLLIFFGVGCVAALKVA 
 
TM Helix 2 ** 
 GQWEISVIWGLGVAMAIYLTAGV 
  QWEISVIWGLGVAMAIYLTA 
 GQWEISVIWGLGVAMAIYLTA 
 
TM Helix 4 
      VSQVAGAFCAAALVYGLYY 
      VSQVAGAFCAAALVYGLYYNLFFD 
KVIPFIVSQVAGAFCAAALVYGLY 
 
TM Helix 5 
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     QAFAVEMVITAILMGLILA 
HINFVQAFAVEMVITAILMGLILALTD 
  NFVQAFAVEMVITAILMGLILALTDD 
 
TM Helix 8 
    LVPLFGPIVGAIV 
IPYFLVPLFGPIVGAIVGAFA 
  YFLVPLFGPIVGAIVGAFAYRKL 
 
 
 
 
The protein of pdb code 1E12 chain A (bacteria) 
TM Helix 1 
       SLWVNVALAGIAILVFV 
ENALLSSSLWVNVALAGIAILVFVYMG 
 NALLSSSLWVNVALAGIAILVFVYMG 
 
TM Helix 2 
       ATLMIPLVSISSYLGLLSGLTVGM 
      GATLMIPLVSISSYLGLLSGLTVGM 
RPRLIWGATLMIPLVSISSYLGLL 
 
TM Helix 3 
         STPMILLALGLLADVDLGS 
  RYLTWALSTPMILLALGLLADVDLGS 
WGRYLTWALSTPMILLALGLLA 
 
TM Helix 4 
      VIAADIGMCVTGLAAAM 
      VIAADIGMCVTGLAAAMTTSA 
LGSLFTVIAADIGMCVTGLAAAMT 
 
TM Helix 5 
      FYAISCAFFVVVLSALVTD 
      FYAISCAFFVVVLSALVTDWAAS 
LLFRWAFYAISCAFFVVVLSALV 
 
TM Helix 6 
      LRVLTVVLWLGYPIVWAVGVEGLALVQSVGVT 
      LRVLTVVLWLGYPIVWAVGVEGLALVQSVGVT 
AEIFDTLRVLTVVLWLGYPIVWAV 
 
TM Helix 7 
           DVFAKYVFAFI 
 GVTSWAYSVLDVFAKYVFAFILLRWV 
VGVTSWAYSVLDVFAKYVFAFILLRWVAN 
 
 
 
The protein of pdb code 1BL8 chain A (bacteria) 
TM Helix 1 
   AGAATVLLVIVLLAGSYL 
WRAAGAATVLLVIVLLAGSYLAVLAE 
  AAGAATVLLVIVLLAGSYLAVLAER 
 
TM Helix 2 
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 WGRCVAVVVMVAGITSFGLVTAALA 
 WGRCVAVVVMVAGITSFGLVTAALATWFVG 
 WGRCVAVVVMVAGITSFGLVTAALATW 
 
 
 
The protein of pdb code 1KZU1 chain A (bacteria) 
TM Helix 1 
       ALLGSVTVIAILVHLAIL 
     IPALLGSVTVIAILVHLAILSH 
NPAIGIPALLGSVTVIAILVHLAILS 
 
 
 
The protein of pdb code 1KZU2 chain B (bacteria) 
TM Helix 1 
         RVFLGLALVAHFLAFS 
      DGTRVFLGLALVAHFLAFSATP 
LHKYVIDGTRVFLGLALVAHFLAFSA 
 
 
 
The protein of pdb code 1LGH1 chain A (?) 
TM Helix 1 
 PSTWLPVIWIVATVVAIAVHAAV 
 PSTWLPVIWIVATVVAIAVHAAV 
NPSTWLPVIWIVATVVAIAVHAAVLAA 
 
 
 
The protein of pdb code 1LGH2 chain B (?) 
TM Helix 1 
                   IILAAVAHVLV 
            KTTFSAFIILAAVAHVLVWVWKP 
TEEEAIAVHDQFKTTFSAFIILAAVAHVLVWVWK 
 
 
 
The protein of pdb code 1MSL chain B (bacteria TB) 
TM Helix 1 
   IVDLAVAVVIGTAFTAL 
RGNIVDLAVAVVIGTAFTALVTK 
    VDLAVAVVIGTAFTALVTKFTDSIITPLI 
 
TM Helix 2 
 QTIDLNVLLSAAINFFLIAFAVYFLVVL 
 QTIDLNVLLSAAINFFLIAFAVYFLVVLP 
     LNVLLSAAINFFLIAFAVYFL 
 
 
 
The protein of pdb code 2RCR1 chain H (bacteria) 
TM Helix 1 
 FGNFDLASLAIYSFWIFLAGLIYYL 
 FGNFDLASLAIYSFWIFLAGLIYYLQTE 
       ASLAIYSFWIFLAGLIYYLQTENMREGY 
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The protein of pdb code 2RCR2 chain L (bacteria) 
TM Helix 1 * 
GGNLFDFWVGPFYVGFFGVATFFFAALGIILIAWSAVL 
 GGNLFDFWVGPFYVGFFGVATFFFAALGIILIAWSAVL 
              VGFFGVATFFFAALGIILIAWSAV 
 
TM Helix 2 
 APLAKGGLWQIITICATGA 
GGAPLAKGGLWQIITICATGAFV 
       GGLWQIITICATGAFVSWALREVEICRK 
 
TM Helix 3 
 HIPFAFAFAILAYLTLVLFRPVMMG 
  HIPFAFAFAILAYLTLVLFRPVMMG 
GYHIPFAFAFAILAYLTLVLFRPVMM 
 
TM Helix 4 
   HMIAISFFFTNALALALHGALV 
   AHMIAISFFFTNALALALHGALVL 
YNPAHMIAISFFFTNALALALHGALVLSAA 
 
TM Helix 5 
 TLGIHRLGLLLSLSAVFFSALCMIITGTIW 
  TLGIHRLGLLLSLSAVFFSALCMIITGTIW 
IGTLGIHRLGLLLSLSAVFFSALCMII 
 
 
 
The protein of pdb code 2RCR3 chain M (bacteria) 
TM Helix 1 * 
  NAQLGPIYLGSLGVLSLFSGLMWFFTIGIWFWYQAGW 
  NAQLGPIYLGSLGVLSLFSGLMWFFTIGIWFWYQAGW 
         YLGSLGVLSLFSGLMWFFTIGIWFWY 
 
TM Helix 3 
    HTAWAFLSAIWLWMVLGFIRPILMG 
    HTAWAFLSAIWLWMVLGFIRPILMG 
GMGKHTAWAFLSAIWLWMVLGFIRPI 
 
TM Helix 4 
    PFHGLSIAFLYGSALLFAMHGATIL 
    PFHGLSIAFLYGSALLFAMHGATIL 
LFYNPFHGLSIAFLYGSALLFAMHGATI 
 
TM Helix 5 
         RWAIWMAVLVTLTGGIGILLSGTVVD 
         RWAIWMAVLVTLTGGIGILLSGTVVD 
FNATMEGIHRWAIWMAVLVTLTGGIGI 
 
 
 
 
 
The protein of pdb code 1PRC2 chain L (bacteria) 
TM Helix 1 * 
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 GDLFDFWVGPYFVGFFGVSAIFFIFLGVSLIGYAASQ 
 GDLFDFWVGPYFVGFFGVSAIFFIFLGVSLIGYAASQ 
             VGFFGVSAIFFIFLGVSLIGYAAS 
 
TM Helix 2 
  APLLEGGFWQAITVCALGAF 
GAAPLLEGGFWQAITVCALGAFIS 
       GGFWQAITVCALGAFISWMLREVEISRKL 
 
TM Helix 3 
  HVPLAFCVPIFMFCVLQVFRPLLLG 
  HVPLAFCVPIFMFCVLQVFRPLLLG 
GWHVPLAFCVPIFMFCVLQVFRPLLL 
 
TM Helix 4 
    HMSSVSFLFVNAMALGLHGGLI 
   GHMSSVSFLFVNAMALGLHGGLIL 
YNPGHMSSVSFLFVNAMALGLHGGLILSVA 
 
TM Helix 5 
  ALSIHRLGLFLASNIFLTGAFGTIASGPFW 
  ALSIHRLGLFLASNIFLTGAFGTIASGPFW 
IGALSIHRLGLFLASNIFLTGAFGTIA 
 
 
 
The protein of pdb code 1PRC3 chain M (bacteria) 
TM Helix 1 * 
 AQIGPIYLGASGIAAFAFGSTAILIILFNMAAEVHF 
 AQIGPIYLGASGIAAFAFGSTAILIILFNMAAEVHF 
        LGASGIAAFAFGSTAILIILFNMAAEV 
 
TM Helix 2 
 PLHDGGWWLMAGLFMTLSLGSW 
 PLHDGGWWLMAGLFMTLSLGSW 
    DGGWWLMAGLFMTLSLGSWWIRVYSRARAL 
 
TM Helix 3 
  HIAWNFAAAIFFVLCIGCIHPTLVG 
  HIAWNFAAAIFFVLCIGCIHPTLVG 
GTHIAWNFAAAIFFVLCIGCIHPTLV 
 
TM Helix 4 
  PWHGFSIGFAYGCGLLFAAHGATIL 
  PWHGFSIGFAYGCGLLFAAHGATIL 
YCPWHGFSIGFAYGCGLLFAAHGATILAV 
 
TM Helix 5 
       RWGWFFSLMVMVSASVGILLTGTFVD 
       RWGWFFSLMVMVSASVGILLTGTFVD 
ATIESVHRWGWFFSLMVMVSASVGILL 
 
 
 
The protein of pdb code 1F88 chain A (bovine) 
TM Helix 1 
 EPWQFSMLAAYMFLLIMLGFPINFLTL 
 149
 EPWQFSMLAAYMFLLIMLGFPINFLTLYVTVQH 
 EPWQFSMLAAYMFLLIMLGFPINFLTLYVTVQH 
 
TM Helix 2 
      LLNLAVADLFMVFGGFTTTLYTSLHGYFV 
  LNYILLNLAVADLFMVFGGFTTTLYTSLHG 
TPLNYILLNLAVADLFMVFGGFTTTLYTSLHG 
 
TM Helix 4 
     IMGVAFTWVMALACAAPPLV 
   HAIMGVAFTWVMALACAAPPLVGW 
GENHAIMGVAFTWVMALACAAPPLV 
 
TM Helix 5 
   SFVIYMFVVHFIIPLIVIFFCYGQLV 
  ESFVIYMFVVHFIIPLIVIFFCYGQLV 
NNESFVIYMFVVHFIIPLIVIFFCYGQL 
 
TM Helix 6 
          IIMVIAFLICWLPYAGVAFYIFTHQGSDF 
       RMVIIMVIAFLICWLPYAGVAFYIFTHQ 
KAEKEVTRMVIIMVIAFLICWLPYAGVAFYIFTH 
 
TM Helix 7 
 PIFMTIPAFFA 
 PIFMTIPAFFAKTSAVYNPVI 
GPIFMTIPAFFAKTSAVYNPVIYIMMN 
 
 
 
The protein of pdb code 1EHK chain C (bacteria) 
TM Helix 1 
         LVLTLTILVFWLGV 
   GALAVILVLTLTILVFWLGVYAVFFAR 
KPKGALAVILVLTLTILVFWLGVYAVFFAR 
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Chapter 4: The prediction of the transmembrane hydrophobic 
center 
 151
Abstract 
 
In the prediction of structure of G-protein-coupled receptors (GPCR’s) using the 
MembStruk, the accurate determination of the hydrophobic center of each helix is one of 
the critical steps. This paper demonstrates how this calculated value corresponds to the 
physical membrane bilayer center and evaluates its accuracy and generality to bovine 
rhodopsin and well as three other bacterial 7-helical proteins of known structure. The 
predicted hydrophobic centers (HC) for bovine rhodopsin fit to a plane with a 0.78 Å 
RMS error. In addition, experiments corroborate this HC as the actual physical center of 
the membrane bilayer. These results support the use of this HC to initially orient helices 
and to provide the center for the calculation of the hydrophobic moment used in 
rotational orientation of the helices. 
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Introduction 
The MembStruk protocol (Floriano et al., 2000; Vaidehi et al., 2002; Trabanino et 
al., 2004) uses mostly first principles in determining the structures of GPCRs. It has been 
applied successfully in various cases (Floriano et al., 2004; Freddolino et al., 2004; 
Kalani et al., 2004), yielding good correlation to binding, mutation, activation, and 
structural data. In various critical steps, the accurate independent prediction of structural 
features such as the TM (transmembrane) helical extent, the hydrophobic center, and the 
helix rotations distinguish this method from homology modeling or structure building 
with distance constraints from experiments (Strader et al., 1994; Herzyk et al., 1995). 
Such first principles determination of these values may be a large part of the reason for its 
success, since GPCRs of low homology to rhodopsin (10-20%) can be built. 
A transmembrane helix may be thought of as a buoy within a sea of lipid bilayer. 
Probably one of the most important driving forces for orienting this helix within this 
bilayer is the hydrophobic effect, positioning the most hydrophobic residues at or near the 
lipid bilayer center. 
Usually, experimental TM protein structures do not directly yield information as 
to the membrane interfaces or the membrane center. However, recently the electron 
cryomicroscopy structure of bovine rhodopsin was determined from two-dimensional 
crystals of p221 21 symmetry (Krebs et al., 2003). In this crystal, the adjacent rhodopsin 
molecules were oriented upside down with respect to one another. This allowed the 
determination of the orientation of the molecule with respect to the membrane bilayer. 
Thus the hydrophobic center plane of the molecule can be roughly described, as shown in 
Figure 1. 
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Figure 1: The membrane plane relative to the bovine rhodopsin cryo-EM 
structure. Figure: (Krebs et al., 2003) 
 
 
 
b  
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In addition, the non-crystallographic
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Methods 
The procedure for the determination of the hydrophobic center by the get_centers 
protocol in TM2ndS has been previously described in detail (Trabanino et al., 2004). It 
will now currently be described in greater detail in the context of the TM proteins of 
bovine rhodopsin (pdb code 1F88) and bacteriorhodopsin (pdb code 1CSM). 
The hydrophobic profiles for window sizes 12-30 are generated by TM2ndS as 
described previously (Trabanino et al., 2004). Essentially, the profile is a plot of the 
average hydrophobicity (using the Eisenberg scale in this case) over a certain number of 
residues, designated as the window size. The profile for window size 14 for bovine 
rhodopsin is shown in Figure 2. 
 Figure 2: The TM2ndS hydrophobic profile at window size 14. 
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The maxima of these 7 peaks are used to determine the hydrophobic center. Since 
the maxima are actually averages over a window size, these indicate the maximum 
hydrophobic buoys for each helix. The positions vary across window size, as shown in 
Trabanino et al, 2004 and the fit to a common plane seems to be best for window size 
close to 20 (Figure 3). 
 Figure 3: The value of the fit to a plane for the predicted HCs at 
different window sizes in bovine rhodopsin. 
 
 
The hydrophobic profiles for window size 12-24 are shown in Figure 4. The 
variations in the peak maxima are readily seen. The variations of these maxima from 
window size 20 are analyzed by TM2ndS to determine a stable region of stability for the 
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HC, as shown in Table 1. These values are averaged to yield one HC for each helix. This 
protocol was run on bovine rhodopsin and three bacterial 7-helical proteins. 
 
 
Figure 4: The overlayed hydrophobic profiles for window sizes 12-24. 
Table 1: The raw predicted HC’s at each window size for bovine 
rhodopsin. 
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Results and discussion 
 
The positions of the predicted HC for each helix in bovine rhodopsin are shown in 
Figure 5. Interestingly, these HC residues lie on a common plane with a fit of 0.79 Å. 
And when comparing to the experimentally determined membrane bilayer plane by cryo-
EM in Figure 1, the planes actually correspond quite closely. 
 
 
Figure 5: The residue positions of the HC’s relative to the 
experimental cryo-EM bilayer center in bovine rhodopsin. 
 
 Fit to plane=0.78 Å 
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The HC variations across window sizes are different in the case of bacteriorhodopsin as 
shown in Table 2. 
Table 2: The raw values of the HC’s at each window size for 
bacteriorhodopsin. 1CSM fit to plane = 1.78 Å 
 
 
Window sizes 12-30 
 
    12 11 14 14 13 7  6  9  10 11
3  6  10 12 9  10 9  11 13 12  
   12 12 13 11 12 22 8  18 24 24  
   4  8  9  7  7  7  12 11 12 13  
   17 13 12 11 13 13 9  7  7  8  
   15 14 15 16 20 19 20 21 20 22  
H
el
ix
 
      6  6  5  17 15 2  1  13 12 11 
 
 
The bacteriorhodopsin structure consists generally of shorter helices and of more charged 
residues. Also, unlike the bovine rhodopsin case, the variations across window sizes are 
localized into more than one window range. For example, for helix 6, the window sizes 
12-18 comprise a stable region for the HC value quite different than the range for bovine 
rhodopsin (16-24 as in Table 1). So for cases where there is more than one range of HC 
stability, the range with the lower value is chosen. The fit to a common plane was 1.78 Å. 
This was applied in the cases of helix 2,3, and 6. Interestingly, a similar trend was 
observed for the other two bacterial 7-helical proteins halorhodopsin and sensory 
rhodopsin II (pdb codes 1E12 and 1H68), as shown in Tables 3 and 4. 
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Table 3: The raw values of the HC’s at each window size for 
halorhodopsin. 1E12 (mutated protein) fit to plane = 2.7 Å 
 
 
Window sizes 12-30  
 
 
19 20 17 18 14 15 
5  5  6  7  8  9  10 11 12 13  
15 14 13 10  
H
el
ix
 13 12 11 11 21 22 23 24 25 26  
12 5  6  7  8  6  7  11 3  2  
12 11 9 
12 10 11 15 16 14 15 16 17 18  
 8  9  10 6  8  4  3  
    17 16 15 14 12 11 11 9  8  8 
 
 
 Table 4: The raw values of the HC’s at each window size for 
sensory rhodopsin.  1H68 Fit to plane= 2.4 Å  
 
Window sizes 12-30 
 
11 14 14 15 11 12 12 13 14 15  
14 15 15 11 13 14 14 13 12 17  
H
el
ix
 
15 11 13 11 11 12 8  8  18 17  
13 14 6  9  8  10 9  21 21 22  
4  3  6  6  7  7  9  1  1  2  
11 10 11 14 15 14 17 16 20 20  
    19 11 10 10 9  12 13 5  6  5 
 
 The presence of charged and non-charged polar residues within the TM regions of 
these proton pumps and ion channels lead to more difficulty in finding a hydrophobic 
center than in the case of bovine rhodopsin. The presence of these residues also leads to 
interactions with other helices and with the phosphate heads of lipids which may 
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constrain the helices in a vertical orientation that deviates from the predicted orientation 
(which assumes independent helix properties). In addition, the 1E12 protein is a 
bioengineered protein with a mutation in a critical position at the beginning of helix 7, so 
results for it are difficult to interpret. One other thing to note is that these bacterial 7-
helical proteins bind to all-trans-retinal and thus may correspond to “activated” states of 
the receptor when comparing to bovine rhodopsin. This may lead to shifts in some helices 
from the bilayer center. 
 How exactly does the predicted HC correspond to the bilayer center? The output of 
the get_centers program gives the HC variation with window size in Figure 5, and the 
default predicted HC as compared with that determined by site-directed spin labeling 
studies (Altenbach et al., 1994) . Thus, the predicted vertical orientation of at least the 
helix 4 of bacteriorhodopsin agrees well with the experimental HC (results of experiment 
shown in Figure 6). 
 
 
 
 
4 8 
7 7 
For 
 
DQGT
 Figure 5: get_centers output showing the HC values across window sizes
and the values chosen for the final HC calculation in bacteriorhodopsin. 
Also, the experimental HC (bold) and the predicted HC (underlined) are 
compared. 
9 7 7 7 12 11 12 13 
 
helix 4 the hydrophobic center index is 7 
ILALVGADG I MIGTGLVGAL 
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Figure 6: The experimental results for HC determination for 
bacteriorhodopsin (a) with spin labeled sites indicated (b). Figure: 
(Altenbach et al., 1994) 
 
 How well can a hydrophobic center be predicted in an ion channel? As previously 
mentioned, the immersion depth of spin labeled sites was predicted for KcsA (Gross et 
al., 1999) and the mechanosensitive channel (Perozo et al., 2001).  The data for KcsA, as 
shown in Figure 7, is incomplete due to poor labeling of some sites near the center of the 
membrane. The get_centers output is shown in Figure 8, together with the predicted and 
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experimental HC determinations. In this case, there is a 3 residue difference, although 
this exact value is not discernible due to the incomplete experimental data. 
 However, for the case of the MscL (mechanosensitive channel), the data is complete, 
as shown in Figure 9. There is a 3-residue difference between the predicted HC and the 
experimental immersion depth maximum, as shown in Figure 10. There are two ranges of 
HC stability, although not as distinct as in the previous cases of bacterial 7-helical 
proteins.  
 It should be noted at this point that this experimental immersion depth determination 
labels the protein on the membrane-exposed face of the helix. Thus, the maximum value 
of the plot may not correspond exactly to the residue position at the center of the 
membrane. That maximum value may be up to a turn away from the actual HC position. 
In addition, unlike the case of bacteriorhodopsin, the experiments were carried out in 
dodecyl maltoside (as opposed to phosphatidylcholine in the case of bacteriorhodopsin). 
 Since the current focus of MembStruk is to predict structures of GPCRs, the accurate 
determination of the HC in the case of bovine rhodopsin is encouraging. Even the 
uncertainties and errors of up to 3 residues in the cases of the other bacterial ion transport 
proteins would be low enough to initially position the helices for optimization in bundle 
and explicit lipid bilayer, an important fine optimization within the MembStruk protocol. 
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Figure 7: Experimental  results for the HC determination in KcsA. 
Figure: (Gross et al., 1999)  
 
Incomplete data 
 
 
 
Figure 8: get_centers output showing the HC values across window sizes and the 
values chosen for the final HC calculation in KcsA. Also, the experimental HC 
(bold) and the predicted HC (underlined) are compared. 
11 12 12 14 15 18 17 17 15 15 
11 12 12 14 15 18 17 17 15 15  
For helix 2 the hydrophobic center index is 14.6 
 
WGRCVAVVVMVAGITSF GLV TAALATW 
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Figure 9: Experimental  results for the HC determination in MscL. 
Figure: (Perozo et al., 2001) 
 
 
 
 
 
Figure 10: get_centers output showing the HC values across window sizes and the 
values chosen for the final HC calculation in MscL. Also, the experimental HC 
(bold) and the predicted HC (underlined) are compared. 
 
21 22 20 20 17 18 17 16 16 16 
20 20 17  
For helix 2 the hydrophobic center index is 19 
 
LNVLLSAAINFFLIAFAVYFL
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Conclusion 
 
 The get_centers protocol for obtaining the hydrophobic center positions based on 
sequence information alone provides the ability to build structure independent structures 
of GPCRs with low homology to bovine rhodopsin. Its excellent agreement with 
experiment in the case of bovine rhodopsin increases confidence in its application in the 
case of GPCRs, which have fewer number of polar residues than ion channels and proton 
pumps. Nevertheless, the fact that the method still performs reasonably well for such 
cases allows for the method’s applicability in building structures of such non-GPCR 
membrane proteins, in conjunction with the fine optimizations of the MembStruk 
protocol. 
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Chapter 5: Data mining of GPCRs and classification of human 
GPCRs 
 170
Abstract 
 
 The field of bioinformatics in the context of G-protein-coupled receptors 
(GPCRs) is of utmost pharmaceutical interest as the discovery and classification of 
GPCRs would improve the search for new targets and analyze drug cross-reactivity. 
Using TM2ndS, the search for 7-helical proteins was conducted on the Riken mouse 
cDNA collection. Virtually all the GPCRs in the database were detected, and some 
unclassified sequences were also found. In addition, the TM2ndS program was used to 
predict the TM helical regions and hydrophobic centers (HC) for all the human GPCRs 
which are SwissProt entries. A graphical user interface and database scheme has been 
devised to later be able to search this database for possible homologues. Using this 
database, the 7 core TM (transmembrane) regions of the human GPCR were used for 
classifying the GPCRs bases on individual TM homology. Some interesting 
translocations of family members across families in different TMs were noted. 
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Introduction 
 
As GPCRs are important pharmaceutical targets, their informational analysis is 
necessary for determining cross-reactivity and potential new targets for a certain drug. A 
recent bioinformatics study of endogenous GPCRs were classified (Vassilatis et al., 
2003) based on a combination of ligand type and class (A,B,D,F/S based on shared 
sequence motifs), as well as sequence homology. It was found that a majority (60%) of 
the endoGPCRs clustered by ligand type (neurotransmitter, lipid, peptide), which allows 
possible prediction of ligands for orphan GPCRs. The orphan GPCRs were determined 
by homology to known GPCRs. 
Various other schemes for classification of GPCRs have been tried, such as binary 
loop topology patterns (Inoue et al., 2004), “fingerprint” motifs amongst families 
(Fredriksson et al., 2003), and combinations of sequence similarity and “fingerprint” 
pattern analysis (Papasaikas et al., 2003). Nevertheless, bioinformatics for GPCRs 
remains an important field of research (Gaulton et al., 2003; Yanbin et al., 2003). 
This current study was aimed at data-mining of unknown GPCRs by direct 
secondary structure prediction using TM2ndS (Trabanino et al., 2004) TM helix 
prediction program. For initial testing, the annotated mouse cDNA Riken library 
(Consortium, 2001) was used to determine known and previously unknown GPCRs based 
on the presence of 7 helices. 
In addition, the TM helices and hydrophobic centers were determined for 
endogenous human GPCRs in the high-quality SwissProt database. The family 
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relationships for TM core sequence similarity were determined and yield interesting 
changes to the traditionally accepted relationships. 
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Methods 
 
Data mining of GPCRs by secondary structure prediction 
 
The annotated cDNA mouse collection by Riken (from Riken Mouse Gene 
Encyclopedia Project) was translated to protein in all six reading frames. The largest 
coding sequence found was used as input into TM2ndS. This program either predicts TM 
helical regions based primarily on hydrophobicity using one sequence or an ensemble of 
homologues to the sequence of interest. This sequence ensemble is obtained using Blast 
(Altschul et al., 1990; Altschul et al., 1997). The use of the sequence ensemble is 
important for accurate TM helical prediction, not TM identification. Further, because this 
study was aimed at analyzing 20,000 clones, the first option was chosen. In this case, the 
TM2ndS program searched for 7 helices over a range of window sizes. A flow chart of 
the procedure is shown in Figure 1. 
Figure 1: A flow chart of the data mining procedure using TM2ndS.  
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GPCR TM helix and hydrophobic center database creation 
 
For the purpose of obtaining TM core (HC +- 10 residues) information, the set of 
all human GPCRs with SwissProt database entries excluding the olfactory receptors was 
obtained from GPCR.ORG (www.gpcr.org). The SwissProt sequence database was 
chosen because it consists of higher quality well-annotated sequences. Then TM2ndS 
v2.0 was run on this set to obtain TM helix and hydrophobic center predictions. This run 
used an ensemble of sequences from a Blast search with bit score 200 or over with 
respect to the query sequence. 
 Using those TM cores obtained from the first round of TM2ndS, the individual 
TM cores were each used as queries for individual Blast searches for homologues to these 
sequences. This new ensemble was then used to obtain refined TM2ndS helix and 
hydrophobic center predictions. All the files for the first round and second round of 
TM2ndS were saved for subsequent incorporation into a database. The initial code for the 
SQL tables is shown below: 
//saves predictions and centers after one round of TM2ndS for one entry 
create table t1 
( id number, 
  swissprot_id number not null, 
  description varchar2(1000), 
  simple_desc varchar2(100), 
  tm1_c varchar2(200), 
  tm2_c varchar2(200), 
  tm3_c varchar2(200), 
  tm4_c varchar2(200), 
  tm5_c varchar2(200), 
  tm6_c varchar2(200), 
  tm7_c varchar2(200), 
  hc1_c number, 
  hc2_c number, 
  hc3_c number, 
  hc4_c number, 
  hc5_c number, 
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  hc6_c number, 
  hc7_c number, 
  tm1_i varchar2(200), 
  tm2_i varchar2(200), 
  tm3_i varchar2(200), 
  tm4_i varchar2(200), 
  tm5_i varchar2(200), 
  tm6_i varchar2(200), 
  tm7_i varchar2(200), 
  hc1_i number, 
  hc2_i number, 
  hc3_i number, 
  hc4_i number, 
  hc5_i number, 
  hc6_i number, 
  hc7_i number, 
  constraint t1_pk primary key (id), 
  constraint t1_swissprot_uk unique(swissprot_id) 
); 
 
create index t1_swissprot_idx on t1(swissprot_id); 
 
 
//saves pairwise alignment after first round of TM2ndS 
create table t2 
( 
  id1 number, 
  id2 number, 
  seq varchar2(200), 
  constraint t2_pk primary key (id1, id2), 
  constraint t2_fk1 foreign key (id1) references t1 (id), 
  constraint t2_fk2 foreign key (id2) references t1 (id) 
); 
 
//saves alignment and other info after iterative step on all 7 helices 
create table t3  
( 
  id1 number, 
  idx number, 
  id2 number, 
  seq varchar2(200), 
  constraint t3_pk primary key (id1, idx, id2), 
  constraint t3_fk1 foreign key (id1) references t1 (id), 
  constraint t3_fk2 foreign key (id2) references t1 (id), 
--  constraint t3_idx check (idx between 1 and 7) 
); 
 176
 
Some snapshots of the graphical user interface which may later access this 
database is shown in Figure 2. 
 
 Figure 2: The GUI design for accessing the TM helix and HC database. 
 
 
 
Classification of human GPCRs based on TM core homology 
The TM helical and hydrophobic center predictions for D2 dopamine receptor 
were used to align the 7 TM cores with the rest of the 267 endogenous human GPCRs 
(descriptions are shown in Figure S1). The profile alignments were performed using 
Clustalw (Thompson et al., 1994) with high gap penalties (9) for the TM core regions. 
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The tree diagram was generated for each TM core using RETREE (Felsenstein, 1989; 
BioNavigator, by Entigen Corporation) using the output from Clustalw.  
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Results and discussion 
Data mining GPCRs on cDNA library 
 Some of the true positive hits obtained are shown in Figure 3. Over 90% of the 
GPCRs in the cDNA library were found. Those which were not detected were actually 
fragments of the full genes, a problem with the cDNA method. This may arise from error 
in reverse transcription which may have introduced premature “stop” codons or from 
partially degraded mRNA from which cDNA was obtained.  
 Unfortunately of the >20,000 clones they obtained, they only classified 361 as 
signal transduction proteins. Of these only ~30-40 are classified as GPCR's. The other 
GPCR's are either missing from the library or are unclassified. This database is thus not 
complete. 
 In addition, a large number of false positives was obtained, owing probably to the 
window scanning of TM2ndS. In the newer version 2.0, the predictions are conducted 
only at window 14, and as discussed in Chapter 3, this leads to over 90% scoring for TM 
region distinction. This newer method may be applied on the complete human genome 
(Celera or GenBank). 
Classification of human GPCRs 
 The 7 D2 dopamine TM core regions were aligned to the rest of the 267 
sequences for non-olfactory human GPCRs. The relationship tree diagrams are shown in 
Figure 4. Higher resolution versions are in the Appendix. 
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The GPCRs have previously been classified into four families based on the classification 
scheme of GPCRDB (www.gpcr.org). These are Class A,B,C,F/S (Frizzled/Smoothened). 
In this study, this classification is not assumed so even proteins across these classes are 
classified according to their TM core homology. Representative of each class are 
indicated in Figure 4 (muscarinic or ACM, EDG, chemokine, and rhodopsin for class A; 
BAI, PTT, and VIP for class B; MGR or metabotropic glutamate for class C;  FZ or 
frizzled for class F/S).  
 The diagrams have indicated large family divisions and smaller family 
subdivisions for each of the seven TM cores. One thing to note is that with the exception 
of helices 2, 3, 4, the proteins of class B, C, and F/S fall into the same families or 
subfamilies.  
 In the case of the class A proteins, the muscarinic receptors (ACM) fall in the 
same subfamily as the aminergic receptors for all TM’s except 5, 6, 7 indicating possible 
residues which may be able to distinguish binding of drugs in these proteins. This 
information may be useful in reducing cross-reactivity of drugs. 
 The chemokine receptors fall into separate subfamilies as the aminergic receptors, 
indicating that there are structural differences in the receptors which may be taken 
advantage of when designing drugs with reduced cross-reactivity across these types. The 
chemokine receptors interestingly fall in the same subfamily as the muscarinic receptors 
for TM core 6, which correlates with the cross-reactivity seen in BX471 (Hesselgesser et 
al., 1998), an antagonist for which the binding site (which involves helix 6) will be 
 180
discussed in Chapter 9. The EDG lipid receptors fall into different subclasses as the 
aminergic receptors for TM’s 1,4,5,7.  
 Interestingly, for TM 4 some of the adrenergics, serotonin, and dopamines, fall 
into separate families as the main aminergic group, indicating variation in this TM even 
in functionally related proteins. 
 In addition to these insights into cross-selectivity, endogenous ligands for orphan 
receptors may be determined based on the known TM interactions of classified GPCRs. 
In addition, new data mined GPCRs may be classified by a similar method. 
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Conclusions 
 Because of their general pharmaceutical importance, the bioinformatics field as 
applied to GPCRs is of utmost importance in ascertaining possible cross-selectivity and 
discovering new GPCRs. This current study has delved into methods for mining GPCRs 
based on direct secondary structure prediction. In addition, since our group is also 
currently working on the determination of the 3D structures of GPCRs, the organization 
of this data together with TM helical and hydrophobic center predictions has been 
initiated. As an integral process in this information organization for relevant data 
extraction, the known human GPCRs have been classified based on homology in the true 
TM core regions as defined by the hydrophobic center (discussed in Chapter 4) 
predictions. This, together with binding site information (i.e. which helices are involved) 
for drugs, would provide an abundance of information for designing new drugs with 
controlled cross-reactivities for many receptors at once. In addition, the deorphanization 
of new data mined GPCRs may be achieved by determining their relationships with 
classified GPCRs. 
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Figure 3: Some true positive hits from the data mining search using TM2ndS. 
*1200004B16     endothelial differentiation sphingolipid G-protein-
coupled receptor 1   MGD     MGI:1096355     ISS 
*1300015C04     purinergic receptor P2Y, G-protein coupled 2    MGD     
MGI:105107      ISS 
*1300018H12     toll-like receptor 2    MGD     MGI:1346060     ISS 
*1700025D19     homolog to putative G protein-coupled receptor  NCBI-nr 
7657136 ISS 
*1810047I05     L-CCR.  SPTR    O70171  ISS 
*2900079B22     7 transmembrane receptor (rhodopsin family) containing 
protein  Pfam    PF00001 ISS 
*4833409N04     prostaglandin F receptor        MGD     MGI:97796       
ISS 
*4921504D23     homolog to KIAA0001 gene product; putative G-protein-
coupled receptor; G protein coupled receptor for UDP-glucose       
LocusLink       9934    ISS 
*4933424L13     IQ motif containing GTPase activating protein 1 MGD     
MGI:1352757     ISS 
*4933433E02     similar to OLFACTORY RECEPTOR.  SPTR    Q9QZ18  ISS 
*1200012O13     cholecystokinin A receptor      MGD     MGI:99478       
ISS 
*2010001L06     7 transmembrane receptor containing protein     Pfam    
PF00001 ISS 
*2210420B03     endothelial differentiation, G-protein-coupled receptor 
6       MGD     MGI:1333809     ISS 
*3732413I11     homolog to MULTIPLE MEMBRANE SPANNING RECEPTOR TRC8 
(PATCHED RELATED PROTEIN TRC8).     SPTR    O75485  ISS 
*4632401H02     chemokine (C-C) receptor 10     MGD     MGI:1341902     
ISS 
*4930401I05     MAS1 oncogene   MGD     MGI:96918       ISS 
*4930500J03     related to NMDA1 PROTEIN (N-METHYL-D-ASPARTATE 
RECEPTOR-ASSOCIATED PROTEIN).    SPTR    Q9V6H7  ISS 
*4932441H21     similar to OLFACTORY RECEPTOR.  SPTR    Q9QZ18  ISS 
*4933403I07     follicle stimulating hormone receptor   MGD     
MGI:95583       ISS 
*5430432J15     purinergic receptor P2Y, G-protein coupled 2    MGD     
MGI:105107      ISS 
*6330420K13     homolog to CHEMOKINE RECEPTOR-LIKE 2 (G-PROTEIN-COUPLED 
RECEPTOR GPR41).        SPTR    O08878  ISS  
 
Figure 4: Tree diagrams displaying the relationships between TM cores of 
human GPCRs. The longer horizontal lines indicate families while the shorter 
lines indicate sub-families. Some GPCR types are named as well, in order to 
monitor the changes in the relationships for the different TM cores. 
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Figure S1: The gi’s, sp ID’s, and descriptions of the classified proteins. The 
empty lines are sequences which were not analyzed because they are non-
SwissProt. 
 
0 12644225  | sp | P35346 | SSR5_HUMAN Somatostatin receptor type 5 
(SS5R) 
1 401130  | sp | P31391 | SSR4_HUMAN Somatostatin receptor type 4 
(SS4R) 
2 417815  | sp | P32745 | SSR3_HUMAN Somatostatin receptor type 3 
(SS3R) (SSR-28) 
 
 
 
 
7 1705896  | sp | P51681 | CKR5_HUMAN C-C chemokine receptor type 5 (C-
C CKR-5) (CC-CKR-5) (CCR-5) (CCR5) (HIV-1 fusion co-receptor) (CHEMR13) 
(CD195 antigen) 
 
9 1352454  | sp | P25025 | IL8B_HUMAN High affinity interleukin-8 
receptor B (IL-8R B) (CXCR-2) (GRO/MGSA receptor) (IL-8 receptor type 
2) (CDw128b) 
 
 
 
 
 
 
16 401124  | sp | P30872 | SSR1_HUMAN Somatostatin receptor type 1 
(SS1R) (SRIF-2) 
17 416802  | sp | P32246 | CKR1_HUMAN C-C chemokine receptor type 1 (C-
C CKR-1) (CC-CKR-1) (CCR-1) (CCR1) (Macrophage inflammatory protein-1 
alpha receptor) (MIP-1alpha-R) (RANTES-R) (HM145) (LD78 receptor) 
 
19 124356  | sp | P25024 | IL8A_HUMAN High affinity interleukin-8 
receptor A (IL-8R A) (IL-8 receptor type 1) (CXCR-1) (CDw128a) 
20 2829400  | sp | P49682 | CCR3_HUMAN C-X-C chemokine receptor type 3 
(CXC-R3) (CXCR-3) (CKR-L2) (CD183 antigen) 
 
22 1168245  | sp | P35368 | A1AB_HUMAN Alpha-1B adrenergic receptor 
(Alpha 1B-adrenoceptor) 
 
24 730229  | sp | P41145 | OPRK_HUMAN Kappa-type opioid receptor (KOR-
1) 
 
 
27 1168246  | sp | P35348 | A1AA_HUMAN Alpha-1A adrenergic receptor 
(Alpha 1A-adrenoceptor) (Alpha-1C adrenergic receptor) 
 
 
 
31 1705894  | sp | P51679 | CKR4_HUMAN C-C chemokine receptor type 4 
(C-C CKR-4) (CC-CKR-4) (CCR-4) (CCR4) (K5-5) 
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32 1346165  | sp | P48146 | GPR8_HUMAN Probable G protein-coupled 
receptor GPR8 
33 1168243  | sp | P25100 | A1AD_HUMAN Alpha-1D adrenergic receptor 
(Alpha 1D-adrenoceptor) (Alpha-1A adrenergic receptor) 
34 401126  | sp | P30874 | SSR2_HUMAN Somatostatin receptor type 2 
(SS2R) (SRIF-1) 
35 1168965  | sp | P41597 | CKR2_HUMAN C-C chemokine receptor type 2 
(C-C CKR-2) (CC-CKR-2) (CCR-2) (CCR2) (Monocyte chemoattractant protein 
1 receptor) (MCP-1-R) (CCR2) 
36 3123242  | sp | P41143 | OPRD_HUMAN Delta-type opioid receptor (DOR-
1) 
 
38 2851402  | sp | P35372 | OPRM_HUMAN Mu-type opioid receptor (MOR-1) 
 
 
41 1705892  | sp | P51677 | CKR3_HUMAN C-C chemokine receptor type 3 
(C-C CKR-3) (CC-CKR-3) (CCR-3) (CCR3) (CKR3) (Eosinophil eotaxin 
receptor) 
42 21264488  | sp | P41231 | P2Y2_HUMAN P2Y purinoceptor 2 (P2Y2) (P2U 
purinoceptor 1) (P2U1) (ATP receptor) (Purinergic receptor) 
43 3023883  | sp | O00155 | GP25_HUMAN Probable G protein-coupled 
receptor GPR25 
44 400654  | sp | P30991 | CCR4_HUMAN C-X-C chemokine receptor type 4 
(CXC-R4) (CXCR-4) (Stromal cell-derived factor 1 receptor) (SDF-1 
receptor) (Fusin) (Leukocyte-derived seven transmembrane domain 
receptor) (LESTR) (LCR1) (FB22) (NPYRL) (HM89) (CD184 antigen) 
45 1346163  | sp | P48145 | GPR7_HUMAN Probable G protein-coupled 
receptor GPR7 
46 543823  | sp | P35414 | APJ_HUMAN Apelin receptor (G protein-coupled 
receptor APJ) (Angiotensin receptor-like 1) (HG11) 
 
48 1351394  | sp | P49238 | C3X1_HUMAN CX3C chemokine receptor 1 (C-X3-
C CKR-1) (CX3CR1) (Fractalkine receptor) (GPR13) (V28) (Beta chemokine 
receptor-like 1) (CMK-BRL-1) (CMKBLR1) 
49 6016096  | sp | O60755 | GALT_HUMAN Galanin receptor type 3 (GAL3-R) 
(GALR3) 
50 1707884  | sp | P51685 | CKR8_HUMAN C-C chemokine receptor type 8 
(C-C CKR-8) (CC-CKR-8) (CCR-8) (GPR-CY6) (GPRCY6) (Chemokine receptor-
like 1) (CKR-L1) (TER1) (CMKBRL2) (CC-chemokine receptor CHEMR1) 
 
52 1352335  | sp | P32248 | CKR7_HUMAN C-C chemokine receptor type 7 
precursor (C-C CKR-7) (CC-CKR-7) (CCR-7) (MIP-3 beta receptor) (EBV-
induced G protein-coupled receptor 1) (EBI1) (BLR2) 
 
54 6016094  | sp | O43603 | GALS_HUMAN Galanin receptor type 2 (GAL2-R) 
(GALR2) 
55 3041713  | sp | Q15722 | L4R1_HUMAN Leukotriene B4 receptor 1 (LTB4-
R) (P2Y purinoceptor 7) (P2Y7) (Chemoattractant receptor-like 1) 
56 416718  | sp | P32302 | CCR5_HUMAN C-X-C chemokine receptor type 5 
(CXC-R5) (CXCR-5) (Burkitt'S lymphoma receptor 1) (Monocyte-derived 
receptor 15) (MDR15) 
57 1709524  | sp | P51582 | P2Y4_HUMAN P2Y purinoceptor 4 (P2Y4) 
(Uridine nucleotide receptor) (UNR) (P2P) 
58 231519  | sp | P30556 | AG2R_HUMAN Type-1 angiotensin II receptor 
(AT1) (AT1AR) 
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60 1346093  | sp | P47211 | GALR_HUMAN Galanin receptor type 1 (GAL1-R) 
(GALR1) 
61 399504  | sp | P25090 | FML1_HUMAN FMLP-related receptor I (FMLP-R-
I) (Lipoxin A4 receptor) (LXA4 receptor) (RFP) (HM63) 
 
 
 
65 2495002  | sp | Q13725 | AG2S_HUMAN Type-1B angiotensin II receptor 
(AT1B) (AT1BR) 
66 20141395  | sp | P49683 | GP10_HUMAN Prolactin-releasing peptide 
receptor (PrRP receptor) (PrRPR) (G protein-coupled receptor GPR10) 
(hGR3) 
67 1703214  | sp | P50052 | AG22_HUMAN Type-2 angiotensin II receptor 
(AT2) 
68 112821  | sp | P28222 | 5H1B_HUMAN 5-hydroxytryptamine 1B receptor 
(5-HT-1B) (Serotonin receptor) (5-HT-1D-beta) (Serotonin 1D beta 
receptor) (S12) 
 
70 417029  | sp | P32239 | GASR_HUMAN Gastrin/cholecystokinin type B 
receptor (CCK-B receptor) (CCK-BR) 
71 2506481  | sp | P30411 | BRB2_HUMAN B2 bradykinin receptor (BK-2 
receptor) (B2R) 
72 1730237  | sp | P51686 | CKR9_HUMAN C-C chemokine receptor type 9 
(C-C CKR-9) (CC-CKR-9) (CCR-9) (GPR-9-6) 
 
74 115262  | sp | P21730 | C5AR_HUMAN C5a anaphylatoxin chemotactic 
receptor (C5a-R) (CD88 antigen) 
75 730230  | sp | P41146 | OPRX_HUMAN Nociceptin receptor (Orphanin FQ 
receptor) (Kappa-type 3 opioid receptor) (KOR-3) 
76 21264435  | sp | Q13304 | GP17_HUMAN Probable P2Y purinoceptor GPR17 
(P2Y-like receptor) (R12) 
 
78 19857032  | sp | P21452 | NK2R_HUMAN Substance-K receptor (SKR) 
(Neurokinin A receptor) (NK-2 receptor) (NK-2R) 
 
 
 
82 112819  | sp | P28221 | 5H1D_HUMAN 5-hydroxytryptamine 1D receptor 
(5-HT-1D) (Serotonin receptor) (5-HT-1D-alpha) 
83 13878599  | sp | Q9GZQ6 | NFF1_HUMAN Neuropeptide FF receptor 1 
(RFamide-related peptide receptor OT7T022) 
84 3024351  | sp | O00254 | PAR3_HUMAN Proteinase activated receptor 3 
precursor (PAR-3) (Thrombin receptor-like 2) (Coagulation factor II 
receptor-like 2) 
 
86 120427  | sp | P21462 | FMLR_HUMAN fMet-Leu-Phe receptor (fMLP 
receptor) (N-formyl peptide receptor) (FPR) (N-formylpeptide 
chemoattractant receptor) 
 
 
89 1346170  | sp | P49685 | GP15_HUMAN G protein-coupled receptor GPR15 
(BOB) 
90 20139074  | sp | Q96RI0 | PAR4_HUMAN Proteinase activated receptor 4 
precursor (PAR-4) (Thrombin receptor-like 3) (Coagulation factor II 
receptor-like 3) 
91 2495018  | sp | Q15077 | P2Y6_HUMAN P2Y purinoceptor 6 (P2Y6) 
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92 2506480  | sp | P46663 | BRB1_HUMAN B1 bradykinin receptor (BK-1 
receptor) (B1R) 
93 1170008  | sp | P46094 | CXC1_HUMAN Chemokine XC receptor 1 (XC 
chemokine receptor 1) (Lymphotactin receptor) (G protein-coupled 
receptor GPR5) 
94 8247919  | sp | P46092 | CKRA_HUMAN C-C chemokine receptor type 10 
(C-C CKR-10) (CC-CKR-10) (CCR-10) (G-protein-coupled receptor 2) 
 
 
97 132207  | sp | P25106 | RDC1_HUMAN G protein-coupled receptor RDC1 
homolog 
98 17380487  | sp | Q99788 | CML1_HUMAN Chemokine receptor-like 1 (G-
protein-coupled receptor DEZ) (G protein-coupled receptor ChemR23) 
99 8488960  | sp | P34969 | 5H7_HUMAN 5-hydroxytryptamine 7 receptor 
(5-HT-7) (5-HT-X) (Serotonin receptor) (5HT7) 
100 461604  | sp | P13945 | B3AR_HUMAN Beta-3 adrenergic receptor 
101 3121816  | sp | O00574 | CCR6_HUMAN C-X-C chemokine receptor type 6 
(CXC-R6) (CXCR-6) (G protein-coupled receptor bonzo) (G protein-coupled 
receptor STRL33) 
 
103 3023884  | sp | O00270 | GP31_HUMAN Probable G protein-coupled 
receptor GPR31 
 
105 20138087  | sp | Q9Y271 | CLT1_HUMAN Cysteinyl leukotriene receptor 
1 (CysLTR1) (Cysteinyl leukotriene D4 receptor) (LTD4 receptor) (HG55) 
(HMTMF81) 
106 3041709  | sp | P43657 | P2Y5_HUMAN P2Y purinoceptor 5 (P2Y5) 
(Purinergic receptor 5) (RB intron encoded G-protein-coupled receptor) 
 
 
 
110 14285406  | sp | Q9NPB9 | CKRB_HUMAN C-C chemokine receptor type 11 
(C-C CKR-11) (CC-CKR-11) (CCR-11) (Chemokine receptor-like 1) (CCRL1) 
(CCX CKR) 
 
 
113 1352692  | sp | P47900 | P2YR_HUMAN P2Y purinoceptor 1 (ATP 
receptor) (P2Y1) (Purinergic receptor) 
114 8928474  | sp | Q9UKP6 | UR2R_HUMAN Urotensin II receptor (UR-II-R) 
 
116 23821812  | sp | Q9NPC1 | L4R2_HUMAN Leukotriene B4 receptor 2 
(LTB4-R2) (Seven transmembrane receptor BLTR2) (Leukotriene B4 receptor 
BLT2) (LTB4 receptor JULF2) 
117 2851567  | sp | P51684 | CKR6_HUMAN C-C chemokine receptor type 6 
(C-C CKR-6) (CC-CKR-6) (CCR-6) (LARC receptor) (GPR-CY4) (GPRCY4) 
(Chemokine receptor-like 3) (CKR-L3) (DRY6) 
 
119 118228  | sp | P21728 | DADR_HUMAN D(1A) dopamine receptor 
120 18206259  | sp | Q9Y5Y4 | GP44_HUMAN Putative G protein-coupled 
receptor GPR44 (Chemoattractant receptor-homologous molecule expressed 
on Th2 cells) 
121 398967  | sp | P30939 | 5H1F_HUMAN 5-hydroxytryptamine 1F receptor 
(5-HT-1F) (Serotonin receptor) 
 
123 114765  | sp | P07550 | B2AR_HUMAN Beta-2 adrenergic receptor 
124 543727  | sp | P28223 | 5H2A_HUMAN 5-hydroxytryptamine 2A receptor 
(5-HT-2A) (Serotonin receptor) (5-HT-2) 
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125 120425  | sp | P25089 | FML2_HUMAN FMLP-related receptor II (FMLP-
R-II) 
 
127 6225807  | sp | O43613 | OX1R_HUMAN Orexin receptor type 1 (Ox1r) 
(Hypocretin receptor type 1) 
 
129 20138034  | sp | Q9NS75 | CLT2_HUMAN Cysteinyl leukotriene receptor 
2 (CysLTR2) (PSEC0146) (HG57) (HPN321) (hGPCR21) 
130 128359  | sp | P25103 | NK1R_HUMAN Substance-P receptor (SPR) (NK-1 
receptor) (NK-1R) 
 
132 1346295  | sp | P49019 | HM74_HUMAN Probable G protein-coupled 
receptor HM74 
133 2495042  | sp | Q99677 | P2Y9_HUMAN P2Y purinoceptor 9 (P2Y9) 
(Purinergic receptor 9) (G protein-coupled receptor GPR23) (P2Y5-like 
receptor) 
134 20178318  | sp | P25116 | PAR1_HUMAN Proteinase activated receptor 
1 precursor (PAR-1) (Thrombin receptor) (Coagulation factor II 
receptor) 
 
 
 
138 1709580  | sp | P55085 | PAR2_HUMAN Proteinase activated receptor 2 
precursor (PAR-2) (Thrombin receptor-like 1) (Coagulation factor II 
receptor-like 1) 
139 1708027  | sp | P46093 | GPR4_HUMAN Probable G protein-coupled 
receptor GPR4 (GPR19) 
140 416772  | sp | P32238 | CCKR_HUMAN Cholecystokinin type A receptor 
(CCK-A receptor) (CCK-AR) 
141 128364  | sp | P29371 | NK3R_HUMAN Neuromedin K receptor (NKR) 
(Neurokinin B receptor) (NK-3 receptor) (NK-3R) 
142 112816  | sp | P28335 | 5H2C_HUMAN 5-hydroxytryptamine 2C receptor 
(5-HT-2C) (Serotonin receptor) (5HT-1C) 
 
144 123120  | sp | P25021 | HH2R_HUMAN Histamine H2 receptor (H2R) 
(Gastric receptor I) 
145 128393  | sp | P28336 | NMBR_HUMAN Neuromedin-B receptor (NMB-R) 
(Neuromedin-B-preferring bombesin receptor) 
146 114752  | sp | P08588 | B1AR_HUMAN Beta-1 adrenergic receptor 
147 232185  | sp | P30550 | GRPR_HUMAN Gastrin-releasing peptide 
receptor (GRP-R) (GRP-preferring bombesin receptor) 
148 12644029  | sp | Q13639 | 5H4_HUMAN 5-hydroxytryptamine 4 receptor 
(5-HT-4) (Serotonin receptor) (5-HT4) 
 
 
151 10719861  | sp | O15218 | ADMR_HUMAN Adrenomedullin receptor (AM-R) 
 
 
 
 
156 1168220  | sp | P41595 | 5H2B_HUMAN 5-hydroxytryptamine 2B receptor 
(5-HT-2B) (Serotonin receptor) 
 
158 6831552  | sp | O75388 | GP32_HUMAN Probable G protein-coupled 
receptor GPR32 
159 1703010  | sp | P50406 | 5H6_HUMAN 5-hydroxytryptamine 6 receptor 
(5-HT-6) (Serotonin receptor) 
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160 400628  | sp | P30989 | NTR1_HUMAN Neurotensin receptor type 1 (NT-
R-1) (High-affinity levocabastine-insensitive neurotensin receptor) 
(NTRH) 
 
162 118214  | sp | P21918 | DBDR_HUMAN D(1B) dopamine receptor (D(5) 
dopamine receptor) (D1beta dopamine receptor) 
163 2495039  | sp | Q99678 | GP20_HUMAN Probable G protein-coupled 
receptor GPR20 
164 21263703  | sp | Q9Y5Y3 | GP45_HUMAN Probable G protein-coupled 
receptor GPR45 (PSP24-alpha) (PSP24-1) 
165 21263618  | sp | Q9BXC1 | FK79_HUMAN Putative P2Y purinoceptor 
FKSG79 
166 3913747  | sp | O43193 | MTLR_HUMAN Motilin receptor (G protein-
coupled receptor GPR38) 
 
 
169 2494998  | sp | Q92847 | GHSR_HUMAN Growth hormone secretagogue 
receptor type 1 (GHS-R) (GH-releasing peptide receptor) (GHRP) (Ghrelin 
receptor) 
 
 
 
 
 
175 1345607  | sp | P47898 | 5H5A_HUMAN 5-hydroxytryptamine 5A receptor 
(5-HT-5A) (Serotonin receptor) (5-HT-5) 
176 3122159  | sp | O15529 | GP42_HUMAN Probable G protein-coupled 
receptor GPR42 
177 21263819  | sp | O00398 | P2YA_HUMAN Putative P2Y purinoceptor 10 
(P2Y10) (P2Y-like receptor) 
 
179 1169206  | sp | P35462 | D3DR_HUMAN D(3) dopamine receptor 
 
181 13632136  | sp | Q9UHM6 | OPN4_HUMAN Opsin 4 (Melanopsin) 
182 1352610  | sp | P49146 | NY2R_HUMAN Neuropeptide Y receptor type 2 
(NPY2-R) (NPY-Y2 receptor) 
183 27151763  | sp | P18089 | A2AB_HUMAN Alpha-2B adrenergic receptor 
(Alpha-2B adrenoceptor) (Subtype C2) 
184 14194819  | sp | Q9H3N8 | HH4R_HUMAN Histamine H4 receptor (HH4R) 
(GPRv53) (G protein-coupled receptor 105) (GPCR105) (SP9144) (AXOR35) 
 
186 13878604  | sp | Q9Y5X5 | NFF2_HUMAN Neuropeptide FF receptor 2 
(Neuropeptide G protein-coupled receptor) (G-protein-coupled receptor 
HLWAR77) 
187 3023539  | sp | Q99527 | CML2_HUMAN Chemokine receptor-like 2 (IL8-
related receptor DRY12) (Flow-induced endothelial G protein-coupled 
receptor) (FEG-1) (G protein-coupled receptor GPR30) (GPCR-BR) 
 
 
190 112822  | sp | P28566 | 5H1E_HUMAN 5-hydroxytryptamine 1E receptor 
(5-HT-1E) (Serotonin receptor) (5-HT1E) (S31) 
191 28380053  | sp | Q96P88 | GRR2_HUMAN Gonadotropin-releasing hormone 
II receptor (Type II GnRH receptor) (GnRH-II-R) 
 
 
194 3122158  | sp | O14843 | GP41_HUMAN Putative G protein-coupled 
receptor GPR41 
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195 119622  | sp | P24530 | ETBR_HUMAN Endothelin B receptor precursor 
(ET-B) (Endothelin receptor Non-selective type) 
 
197 416926  | sp | P32249 | EBI2_HUMAN EBV-induced G protein-coupled 
receptor 2 (EBI2) 
 
 
200 416726  | sp | P32247 | BRS3_HUMAN Bombesin receptor subtype-3 
(BRS-3) 
201 128997  | sp | P25929 | NY1R_HUMAN Neuropeptide Y receptor type 1 
(NPY1-R) 
202 1351392  | sp | P47901 | V1BR_HUMAN Vasopressin V1b receptor (V1bR) 
(AVPR V1b) (Vasopressin V3 receptor) (AVPR V3) (Antidiuretic hormone 
receptor 1b) 
203 21263685  | sp | Q9BZJ6 | GP63_HUMAN Probable G protein-coupled 
receptor GPR63 (PSP24-beta) (PSP24-2) 
 
205 119606  | sp | P25101 | ET1R_HUMAN Endothelin-1 receptor precursor 
(ET-A) 
206 1709423  | sp | P50391 | NY4R_HUMAN Neuropeptide Y receptor type 4 
(NPY4-R) (Pancreatic polypeptide receptor 1) (PP1) 
207 129557  | sp | P25105 | PAFR_HUMAN Platelet activating factor 
receptor (PAF-R) 
 
 
 
211 20455469  | sp | O00590 | CKD6_HUMAN Chemokine binding protein 2 
(Chemokine-binding protein D6) (C-C chemokine receptor D6) (Chemokine 
receptor CCR-9) (CC-Chemokine receptor CCR10) 
 
213 1170002  | sp | P46091 | GPR1_HUMAN Probable G protein-coupled 
receptor GPR1 
214 118206  | sp | P14416 | D2DR_HUMAN D(2) dopamine receptor 
215 6225810  | sp | O43614 | OX2R_HUMAN Orexin receptor type 2 (Ox2r) 
(Hypocretin receptor type 2) 
 
217 15214047  | sp | Q9NS67 | GP27_HUMAN Probable G protein-coupled 
receptor GPR27 (Super conserved receptor expressed in brain 1) 
218 21263687  | sp | Q9BZJ8 | GP61_HUMAN Probable G protein-coupled 
receptor GPR61 (Biogenic amine receptor-like G-protein-coupled 
receptor) 
219 231454  | sp | P08908 | 5H1A_HUMAN 5-hydroxytryptamine 1A receptor 
(5-HT-1A) (Serotonin receptor) (5-HT1A) (G-21) 
 
 
222 586197  | sp | P37288 | V1AR_HUMAN Vasopressin V1a receptor (V1aR) 
(Vascular/hepatic-type arginine vasopressin receptor) (Antidiuretic 
hormone receptor 1a) (AVPR V1a) 
223 464921  | sp | P34981 | TRFR_HUMAN Thyrotropin-releasing hormone 
receptor (TRH-R) (Thyroliberin receptor) 
 
225 1345939  | sp | P21917 | D4DR_HUMAN D(4) dopamine receptor (D(2C) 
dopamine receptor) 
226 112938  | sp | P29275 | AA2B_HUMAN Adenosine A2b receptor 
227 3122160  | sp | O15552 | GP43_HUMAN Probable G protein-coupled 
receptor GPR43 
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230 20141211  | sp | P18825 | A2AC_HUMAN Alpha-2C-adrenergic receptor 
(Alpha-2C adrenoceptor) (Subtype C4) 
 
 
 
 
235 20137533  | sp | Q9P296 | C5L2_HUMAN C5a anaphylatoxin chemotactic 
receptor C5L2 
236 266719  | sp | P30559 | OXYR_HUMAN Oxytocin receptor (OT-R) 
 
 
239 113118  | sp | P11229 | ACM1_HUMAN Muscarinic acetylcholine 
receptor M1 
 
241 15214046  | sp | Q9NPD1 | GP85_HUMAN Probable G protein-coupled 
receptor GPR85 (Super conserved receptor expressed in brain 2) (PKrCx1) 
 
243 1351831  | sp | P33765 | AA3R_HUMAN Adenosine A3 receptor 
244 20141559  | sp | P41968 | MC3R_HUMAN Melanocortin-3 receptor (MC3-
R) 
 
246 15214315  | sp | Q9NS66 | SRB3_HUMAN Super conserved receptor 
expressed in brain 3 
247 231473  | sp | P30542 | AA1R_HUMAN Adenosine A1 receptor 
248 26393399  | sp | Q9HBW0 | EDG4_HUMAN Lysophosphatidic acid receptor 
Edg-4 (LPA receptor 2) (LPA-2) 
249 3024312  | sp | O14718 | OPSX_HUMAN Visual pigment-like receptor 
peropsin 
250 119130  | sp | P21453 | EDG1_HUMAN Probable G protein-coupled 
receptor EDG-1 
 
252 17380172  | sp | Q9H1Y3 | OPN3_HUMAN Opsin 3 (Encephalopsin) 
(Panopsin) 
253 399002  | sp | Q01718 | ACTR_HUMAN Adrenocorticotropic hormone 
receptor (ACTH receptor) (ACTH-R) (Melanocortin-2 receptor) (MC2-R) 
(Adrenocorticotropin receptor) 
254 267256  | sp | P30518 | V2R_HUMAN Vasopressin V2 receptor (Renal-
type arginine vasopressin receptor) (Antidiuretic hormone receptor) 
(AVPR V2) 
255 12643337  | sp | Q9UPC5 | GP34_HUMAN Probable G protein-coupled 
receptor GPR34 
 
 
 
259 1346548  | sp | P49286 | ML1B_HUMAN Melatonin receptor type 1B 
(Mel-1B-R) 
260 1170006  | sp | P46089 | GPR3_HUMAN Probable G protein-coupled 
receptor GPR3 (ACCA orphan receptor) 
261 3913748  | sp | O43194 | GP39_HUMAN Putative G protein-coupled 
receptor GPR39 
 
263 129207  | sp | P08100 | OPSD_HUMAN Rhodopsin (Opsin 2) 
264 3122157  | sp | O14842 | GP40_HUMAN Putative G protein-coupled 
receptor GPR40 
265 1346544  | sp | P48039 | ML1A_HUMAN Melatonin receptor type 1A 
(Mel-1A-R) 
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266 417280  | sp | P32245 | MC4R_HUMAN Melanocortin-4 receptor (MC4-R) 
 
 
 
 
271 23503039  | sp | P08173 | ACM4_HUMAN Muscarinic acetylcholine 
receptor M4 
272 26393418  | sp | Q9UBY5 | EDG7_HUMAN Lysophosphatidic acid receptor 
Edg-7 (LPA receptor 3) (LPA-3) 
273 115562  | sp | P21554 | CB1R_HUMAN Cannabinoid receptor 1 (CB1) 
(CB-R) (CANN6) 
 
 
 
 
 
279 12644376  | sp | Q01726 | MSHR_HUMAN Melanocyte stimulating hormone 
receptor (MSH-R) (Melanotropin receptor) (Melanocortin-1 receptor) 
(MC1-R) 
280 2495036  | sp | Q15760 | GP19_HUMAN Probable G protein-coupled 
receptor GPR19 (GPR-NGA) 
281 729996  | sp | P33032 | MC5R_HUMAN Melanocortin-5 receptor (MC5-R) 
(MC-2) 
282 113125  | sp | P20309 | ACM3_HUMAN Muscarinic acetylcholine 
receptor M3 
283 543740  | sp | P29274 | AA2A_HUMAN Adenosine A2a receptor 
 
 
 
 
 
289 1346168  | sp | P47775 | GP12_HUMAN Probable G protein-coupled 
receptor GPR12 
 
 
292 543761  | sp | P08912 | ACM5_HUMAN Muscarinic acetylcholine 
receptor M5 
 
 
295 17367264  | sp | Q9Y5N1 | HH3R_HUMAN Histamine H3 receptor (HH3R) 
(G protein-coupled receptor 97) 
 
297 129203  | sp | P03999 | OPSB_HUMAN Blue-sensitive opsin (Blue cone 
photoreceptor pigment) 
298 2495032  | sp | Q99500 | EDG3_HUMAN Lysosphingolipid receptor (EDG-
3) 
 
 
 
302 129215  | sp | P04001 | OPSG_HUMAN Green-sensitive opsin (Green 
cone photoreceptor pigment) 
 
304 548476  | sp | P35408 | PE24_HUMAN Prostaglandin E2 receptor, EP4 
subtype (Prostanoid EP4 receptor) (PGE receptor, EP4 subtype) 
305 2495041  | sp | Q99680 | GP22_HUMAN Probable G protein-coupled 
receptor GPR22 
306 547645  | sp | P35367 | HH1R_HUMAN Histamine H1 receptor 
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307 1351829  | sp | P08913 | A2AA_HUMAN Alpha-2A adrenergic receptor 
(Alpha-2A adrenoceptor) (Alpha-2AAR subtype C10) 
 
309 129219  | sp | P04000 | OPSR_HUMAN Red-sensitive opsin (Red cone 
photoreceptor pigment) 
 
311 3023411  | sp | Q16581 | C3AR_HUMAN C3a anaphylatoxin chemotactic 
receptor (C3a-R) (C3AR) 
 
313 26454626  | sp | Q92633 | EDG2_HUMAN Lysophosphatidic acid receptor 
Edg-2 (LPA receptor 1) (LPA-1) 
314 21263830  | sp | Q96G91 | P2YB_HUMAN P2Y purinoceptor 11 (P2Y11) 
 
316 461697  | sp | P34972 | CB2R_HUMAN Cannabinoid receptor 2 (CB2) 
(CB-2) (CX5) 
 
 
319 1350592  | sp | P47804 | RGR_HUMAN RPE-retinal G protein-coupled 
receptor 
 
321 15214044  | sp | Q9HC97 | GP35_HUMAN Probable G protein-coupled 
receptor GPR35 
 
 
324 1172071  | sp | P43115 | PE23_HUMAN Prostaglandin E2 receptor, EP3 
subtype (Prostanoid EP3 receptor) (PGE receptor, EP3 subtype) 
 
 
 
328 1170009  | sp | P46095 | GPR6_HUMAN Probable G protein-coupled 
receptor GPR6 
 
 
331 21263686  | sp | Q9BZJ7 | GP62_HUMAN Probable G protein-coupled 
receptor GPR62 (hGPCR8) 
332 2494993  | sp | Q15761 | NY5R_HUMAN Neuropeptide Y receptor type 5 
(NPY5-R) (NPY-Y5 receptor) (Y5 receptor) (NPYY5) 
333 544350  | sp | P23945 | FSHR_HUMAN Follicle stimulating hormone 
receptor precursor (FSH-R) (Follitropin receptor) 
334 135920  | sp | P04201 | MAS_HUMAN MAS proto-oncogene 
 
336 1174572  | sp | P21731 | TA2R_HUMAN Thromboxane A2 receptor (TXA2-
R) (Prostanoid TP receptor) 
 
338 113122  | sp | P08172 | ACM2_HUMAN Muscarinic acetylcholine 
receptor M2 
 
340 464360  | sp | P34995 | PE21_HUMAN Prostaglandin E2 receptor, EP1 
subtype (Prostanoid EP1 receptor) (PGE receptor, EP1 subtype) 
341 136448  | sp | P16473 | TSHR_HUMAN Thyrotropin receptor precursor 
(TSH-R) (Thyroid stimulating hormone receptor) 
 
 
344 12230026  | sp | O60883 | ETB2_HUMAN Endothelin B receptor-like 
protein-2 precursor (ETBR-LP-2) 
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346 10720152  | sp | O95665 | NTR2_HUMAN Neurotensin receptor type 2 
(NT-R-2) (Levocabastine-sensitive neurotensin receptor) (NTR2 receptor) 
 
 
349 1172070  | sp | P43116 | PE22_HUMAN Prostaglandin E2 receptor, EP2 
subtype (Prostanoid EP2 receptor) (PGE receptor, EP2 subtype) 
350 2494977  | sp | Q13585 | ML1X_HUMAN MELATONIN-RELATED RECEPTOR (H9) 
 
 
353 1172500  | sp | P43119 | PI2R_HUMAN Prostacyclin receptor 
(Prostanoid IP receptor) (PGI receptor) 
354 24638055  | sp | Q96AM1 | MRGF_HUMAN Mas-related G protein-coupled 
receptor MRGF (Mas-related gene F protein) 
 
 
 
 
 
 
 
 
 
364 7674059  | sp | O14626 | H963_HUMAN Probable G protein-coupled 
receptor H963 
365 28381373  | sp | P22888 | LSHR_HUMAN Lutropin-choriogonadotropic 
hormone receptor precursor (LH/CG-R) (LSH-R) (Luteinizing hormone 
receptor) (LHR) 
 
 
 
 
 
371 12643545  | sp | O15354 | GP37_HUMAN Probable G protein-coupled 
receptor GPR37 precursor (Endothelin B receptor-like protein-1) (ETBR-
LP-1) 
 
 
374 1172442  | sp | P43088 | PF2R_HUMAN Prostaglandin F2-alpha receptor 
(Prostanoid FP receptor) (PGF receptor) (PGF2 alpha receptor) 
375 547920  | sp | P35410 | MRG_HUMAN Mas-related G protein-coupled 
receptor MRG 
 
377 21362643  | sp | Q9HBX9 | LGR7_HUMAN Relaxin receptor 1 (Leucine-
rich repeat-containing G protein-coupled receptor 7) 
378 2495009  | sp | Q13258 | PD2R_HUMAN Prostaglandin D2 receptor 
(Prostanoid DP receptor) (PGD receptor) 
 
 
381 21362625  | sp | Q8WXD0 | LGR8_HUMAN Relaxin receptor 2 (Leucine-
rich repeat-containing G protein-coupled receptor 8) (G protein-coupled 
receptor affecting testicular descent) 
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386 21263835  | sp | Q9H244 | P2YC_HUMAN P2Y purinoceptor 12 (P2Y12) 
(P2Y12 platelet ADP receptor) (P2Y(ADP)) (ADP-glucose receptor) (ADPG-
R) (P2Y(AC)) (P2Y(cyc)) (P2T(AC)) (SP1999) 
 
 
 
390 21542118  | sp | O75473 | LGR5_HUMAN Leucine-rich repeat-containing 
G protein-coupled receptor 5 precursor (Orphan G protein-coupled 
receptor HG38) (G protein-coupled receptor 49) 
 
 
393 1346133  | sp | P48546 | GIPR_HUMAN Gastric inhibitory polypeptide 
receptor precursor (GIP-R) (Glucose-dependent insulinotropic 
polypeptide receptor) 
394 399777  | sp | P30968 | GRHR_HUMAN Gonadotropin-releasing hormone 
receptor (GnRH receptor) (GnRH-R) 
 
 
 
398 2495040  | sp | Q99679 | GP21_HUMAN Probable G protein-coupled 
receptor GPR21 
 
 
 
402 3122322  | sp | Q15391 | P2YX_HUMAN UDP-glucose receptor (G 
protein-coupled receptor GPR105) 
 
 
 
 
 
 
409 17432988  | sp | O75084 | FZD7_HUMAN Frizzled 7 precursor 
(Frizzled-7) (Fz-7) (hFz7) (FzE3) 
410 17433018  | sp | Q13467 | FZD5_HUMAN Frizzled 5 precursor 
(Frizzled-5) (Fz-5) (hFz5) (FzE5) 
411 17433091  | sp | Q9ULW2 | FZ10_HUMAN Frizzled 10 precursor 
(Frizzled-10) (Fz-10) (hFz10) (FzE7) 
412 418253  | sp | P32241 | VIPR_HUMAN Vasoactive intestinal 
polypeptide receptor 1 precursor (VIP-R-1) (Pituitary adenylate cyclase 
activating polypeptide type II receptor) (PACAP type II receptor) 
(PACAP-R-2) 
 
 
 
416 21542119  | sp | Q9BXB1 | LGR4_HUMAN Leucine-rich repeat-containing 
G protein-coupled receptor 4 precursor (G protein-coupled receptor 48) 
417 12643950  | sp | Q9Y2T5 | GP52_HUMAN Probable G protein-coupled 
receptor GPR52 
 
419 2506489  | sp | P47872 | SCRC_HUMAN Secretin receptor precursor 
(SCT-R) 
420 2495077  | sp | Q14833 | MGR4_HUMAN Metabotropic glutamate receptor 
4 precursor (mGluR4) 
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426 27734323  | sp | Q96P67 | GP82_HUMAN Probable G protein-coupled 
receptor GPR82 
 
 
 
430 3041685  | sp | Q02643 | GRFR_HUMAN Growth hormone-releasing 
hormone receptor precursor (GHRH receptor) (GRF receptor) (GRFR) 
431 17433092  | sp | Q9UP38 | FZD1_HUMAN Frizzled 1 precursor 
(Frizzled-1) (Fz-1) (hFz1) (FzE1) 
 
 
434 417555  | sp | Q03431 | PTRR_HUMAN Parathyroid hormone/parathyroid 
hormone-related peptide receptor precursor (PTH/PTHR receptor) 
435 17432964  | sp | O00144 | FZD9_HUMAN Frizzled 9 precursor 
(Frizzled-9) (Fz-9) (hFz9) (FzE6) 
 
437 1171986  | sp | P41586 | PACR_HUMAN Pituitary adenylate cyclase 
activating polypeptide type I receptor precursor (PACAP type I 
receptor) (PACAP-R-1) 
438 6226847  | sp | Q13324 | CRF2_HUMAN Corticotropin releasing factor 
receptor 2 precursor (CRF-R 2) (CRF2) (Corticotropin-releasing hormone 
receptor 2) (CRH-R 2) 
439 12644040  | sp | O00222 | MGR8_HUMAN Metabotropic glutamate 
receptor 8 precursor (mGluR8) 
440 1169956  | sp | P43220 | GLP1_HUMAN Glucagon-like peptide 1 
receptor precursor (GLP-1 receptor) (GLP-1-R) (GLP-1R) 
 
442 17433090  | sp | Q9ULV1 | FZD4_HUMAN Frizzled 4 precursor 
(Frizzled-4) (Fz-4) (hFz4) (FzE4) 
443 12230071  | sp | O95838 | GLP2_HUMAN Glucagon-like peptide 2 
receptor precursor (GLP-2 receptor) (GLP-2-R) (GLP-2R) 
 
 
 
 
448 2495058  | sp | Q16602 | CGRR_HUMAN Calcitonin gene-related peptide 
type 1 receptor precursor (CGRP type 1 receptor) 
 
450 399180  | sp | P30988 | CALR_HUMAN Calcitonin receptor precursor 
(CT-R) 
451 17433019  | sp | Q14332 | FZD2_HUMAN Frizzled 2 precursor 
(Frizzled-2) (Fz-2) (hFz2) (FzE2) 
 
 
 
455 2495078  | sp | Q14831 | MGR7_HUMAN Metabotropic glutamate receptor 
7 precursor (mGluR7) 
 
457 3219999  | sp | P51810 | OA1_HUMAN Ocular albinism type 1 protein 
 
459 1346906  | sp | P49190 | PTR2_HUMAN Parathyroid hormone receptor 
precursor (PTH2 receptor) 
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461 461836  | sp | P34998 | CRF1_HUMAN Corticotropin releasing factor 
receptor 1 precursor (CRF-R) (CRF1) (Corticotropin-releasing hormone 
receptor 1) (CRH-R 1) 
 
 
464 21362642  | sp | Q9HBX8 | LGR6_HUMAN Leucine-rich repeat-containing 
G protein-coupled receptor 6 
 
 
467 1168781  | sp | P41180 | CASR_HUMAN Extracellular calcium-sensing 
receptor precursor (CaSR) (Parathyroid Cell calcium-sensing receptor) 
 
 
 
 
 
 
 
 
476 3024134  | sp | O15303 | MGR6_HUMAN Metabotropic glutamate receptor 
6 precursor (mGluR6) 
 
 
 
 
 
 
483 1346144  | sp | P47871 | GLR_HUMAN Glucagon receptor precursor (GL-
R) 
 
 
 
 
 
489 6226566  | sp | P48960 | CD97_HUMAN Leucocyte antigen CD97 
precursor 
 
 
 
 
 
 
 
 
 
 
 
501 2506490  | sp | P41587 | VIPS_HUMAN Vasoactive intestinal 
polypeptide receptor 2 precursor (VIP-R-2) (Pituitary adenylate cyclase 
activating polypeptide type III receptor) (PACAP type III receptor) 
(PACAP-R-3) (Helodermin-preferring VIP receptor) 
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507 2495033  | sp | Q14330 | GP18_HUMAN Probable G protein-coupled 
receptor GPR18 
 
 
 
 
512 22095550  | sp | Q9HCU4 | CLR2_HUMAN Cadherin EGF LAG seven-pass G-
type receptor 2 precursor (Epidermal growth factor-like 2) (Multiple 
epidermal growth factor-like domains 3) (Flamingo 1) 
 
514 2495075  | sp | Q14416 | MGR2_HUMAN Metabotropic glutamate receptor 
2 precursor (mGluR2) 
 
 
517 22095551  | sp | Q9NYQ6 | CLR1_HUMAN Cadherin EGF LAG seven-pass G-
type receptor 1 precursor (Flamingo homolog 2) (hFmi2) 
518 17433071  | sp | Q9NPG1 | FZD3_HUMAN Frizzled 3 precursor 
(Frizzled-3) (Fz-3) (hFz3) 
 
520 10719900  | sp | O14514 | BAI1_HUMAN Brain-specific angiogenesis 
inhibitor 1 precursor 
 
522 2495072  | sp | Q14246 | EMR1_HUMAN Cell surface glycoprotein EMR1 
precursor (EMR1 hormone receptor) 
 
524 27151770  | sp | Q16570 | DUFF_HUMAN Duffy antigen/chemokine 
receptor (Fy glycoprotein) (GpFy) (Glycoprotein D) (Plasmodium vivax 
receptor) (CD234 antigen) 
 
 
527 22095552  | sp | Q9NYQ7 | CLR3_HUMAN Cadherin EGF LAG seven-pass G-
type receptor 3 precursor (Flamingo homolog 1) (hFmi1) (Multiple 
epidermal growth factor-like domains 2) (Epidermal growth factor-like 
1) 
528 12643618  | sp | O60242 | BAI3_HUMAN Brain-specific angiogenesis 
inhibitor 3 precursor 
 
 
531 12643641  | sp | O75899 | GBR2_HUMAN Gamma-aminobutyric acid type B 
receptor, subunit 2 precursor (GABA-B receptor 2) (GABA-B-R2) (Gb2) 
(GABABR2) (G protein-coupled receptor 51) (GPR 51) (HG20) 
 
533 10719903  | sp | O60241 | BAI2_HUMAN Brain-specific angiogenesis 
inhibitor 2 precursor 
534 6226142  | sp | Q99835 | SMO_HUMAN Smoothened homolog precursor 
(SMO) (Gx protein) 
535 2495074  | sp | Q13255 | MGR1_HUMAN Metabotropic glutamate receptor 
1 precursor (mGluR1) 
 
537 1709020  | sp | P41594 | MGR5_HUMAN Metabotropic glutamate receptor 
5 precursor (mGluR5) 
538 17433053  | sp | Q9H461 | FZD8_HUMAN Frizzled 8 precursor 
(Frizzled-8) (Fz-8) (hFz8) 
 
540 2495076  | sp | Q14832 | MGR3_HUMAN Metabotropic glutamate receptor 
3 precursor (mGluR3) 
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545 17432985  | sp | O60353 | FZD6_HUMAN Frizzled 6 precursor 
(Frizzled-6) (Fz-6) (hFz6) 
 
 
 
549 12643873  | sp | Q9UBS5 | GBR1_HUMAN Gamma-aminobutyric acid type B 
receptor, subunit 1 precursor (GABA-B receptor 1) (GABA-B-R1) (Gb1) 
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Chapter 6: Simulation of EC-II loop closure 
 209
Abstract 
 
 
In G-protein-coupled receptors (GPCRs), the second extracellular loop (EC-II) 
between helices 4 and 5 has been known to be important in binding ligands and in the 
activation process. In the bovine rhodopsin crystal structure, it assumes a closed form, 
which interacts closely with the cis-retinal in the ground state of the protein. Thus, the 
closing of this loop is of critical importance in creating structures for GPCRs. The 
EC_LOOP_SIM protocol of MembStruk was created to simulate the folding process of 
this loop from an “open” to a “closed” form. This method has been validated for the case 
of bovine rhodopsin, with the loop’s final CRMS from the crystal structure of 6.88 Å in 
main chain atoms. When the loops were aligned to each other, the error was 4.71 Å in the 
internal structure. The residues important in binding in the B strand of the EC-II loop beta 
sheet were positioned correctly in this simulated “closed” loop structure. This novel 
approach of folding the EC-II from first principles is important in building structures of 
GPCRs with distant homology to bovine rhodopsin (precluding the usage of homology 
modeling here). In addition, the role of the “opening” and “closing” of this loop on retinal 
binding in rhodopsin is elucidated in this paper. 
 210
Introduction 
 
In the crystal structure of bovine rhodopsin (Palczewski et al., 2000), the EC-II 
loop forms an anti-parallel beta-sheet with one strands (the B or second strand) 
interacting more closely with the bound cis-retinal ligand, as shown in Figure 1. Since 
this crystal structure had retinal in the cis form, it corresponds to the ground state inactive 
form of rhodopsin. It is interesting to note that this loop is uncharacteristic among loops 
in that the crystallographic B-factors in this region are comparable to those in helical 
region. This temperature stability is probably due in a great part to the presence of a 
disulfide linkage between two conserved (across GPCRs) cysteines in the N-terminal side 
of helix 3 and the EC-II loop. This constraint provides the stability needed for such an 
important loop in ligand binding. 
 
 
Figure 1: Structure of the EC-II loop over the bound retinal in the bovine 
rhodopsin crystal structure. Figure: (Onuffer et al., 2002) 
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Various experiments have corroborated the importance of this loop in ligand 
binding and activation in other GPCRs. In chemokine receptors (another class of 
GPCRs), the binding of antibodies directed to the B strand of the EC-II loop was 
inhibiting by the presence of antagonist (Onuffer et al., 2002). This was demonstrated for 
CCR5 binding to TAK779 and E913 (Dragic et al., 2000; Maeda, 2001) and for CXCR4 
binding to AMD3100 (Gerlach, 2001). 
In fact, many of the mutations causing blindness in retinitis pigmentosa (RP) are 
in the ECII loop (Okada et al., 2001) and mutations of the cysteines which form the 
disulfide also cause RP and change ligand binding and receptor activation (Schoneberg et 
al., 2002). 
The coupling between this loop and helix 3 allows for a transfer of movement 
from helix 3 to the loop. A helix 3 movement upon activation is expected from the 
following observation: trans retinal contacts in the rhodopsin crystal structure (Borhan et 
al., 2000) can only match cross-linking experiments if the ligand clashes with the helix 3 
in the ground state conformation (Bourne et al., 2000). A proposed mechanism for loop 
movement upon activation was described previously (Trabanino et al., 2004). In this 
mechanism, the isomerization of retinal leads to a translation of helix 3, which because of 
its coupling to the EC-II loop, would “open” this loop and allow exit of the retinal ligand 
(Figure 2). 
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Figure 2: Schematic of proposed mechanism for loop closure. 
 
TM1
TM2 TM6
TM3TM4
TM7
NT
EC1
20 aa
EC2
32 aa EC3
14 aa
CT
TM5
IC2
16 aa
D
R
Y
IC3
16 aa
TM1
TM2
TM6
TM3
TM4
TM7
NTEC1
EC2
EC3
CT
IC2
TM5
IC3  
 
Thus, the “open” form of ECII may correspond to the activated form of the helix 
bundle by this coupling, as supported by the fact that GPCRs in which this disulfide is 
not present (melanocortin, cannabinoid, and sphingolipid receptors), the agonist-
independent activity (constitutive activity) tends to be high (Milligan, 2003). 
This paper describes the method used by MembStruk for EC-II loop closing and 
validates its use in the only available GPCR crystal structure, bovine rhodopsin. In 
addition, the changes in retinal binding observed in the “open“ loop form of the receptor 
are shown and discussed in the context of a potential retinal binding mechanism which 
involved partitioning from the membrane environment into the receptor interior. 
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Methods 
 
Loop addition and pre-closing optimization 
In the MembStruk protocol, the loops for GPCRs are added using either Whatif 
(Vriend, 1990) or Modeller 6v2. These loops are derived from a database of crystal 
structure fragments and are thus not well representative of the loops which may be 
present in GPCRs. The EC_LOOP_SIM program was created to fold this loop in the 
environment of the particular protein of interest. Thus annealing dynamics using Biograf 
software is performed on the EC-II loop for 100 ps with cycles from 300 to 600 degrees. 
After every two cycles, the loop’s potential energy is minimized. This step ensures that 
internal structures in the added loop are randomized, to avoid bias in later folding due to 
a particular internal structure. This step is optional if one wants to begin the next step 
with an internal structure in the loop (beta-sheet, etc). 
Disulfide bond formation 
The disulfide bond is formed between the cysteines in extracellular 2 (EC-II) loop 
(which are conserved across many GPCRs) and the N-terminal edge of TM3 or EC3. In 
the case of bovine rhodopsin, the alignment of 44 sequences indicates only one pair of 
fully conserved cysteines which are on the same side of the membrane (extracellular 
side). The disulfide bond was formed and optimized (with one cycle of annealing 
dynamics from 300 to 600 degrees after each decrement) with equilibrium distances 
lowered in decrements of 2 Å until the bond distance was 2 Å. Then the loop was 
optimized (one cycle of annealing dynamics) with the default equilibrium disulfide bond 
distance of 2.07 Å. 
 214
Room temperature molecular dynamics 
At this point, it was found that the backbone of the helices needed to be allowed 
movable to accommodate the closing EC-II loop. Thus, TVN molecular dynamics with 
half the bundle movable was performed. The half of the bundle was defined as all atoms 
towards the extracellular side from the hydrophobic center of each helix. After 100 ps, 
the EC-II assumed a “closed” conformation in the simulation of the loop in the crystal 
structure of bovine rhodopsin. The snapshots of this closing are seen in Figure 3. In other 
cases (like human CCR1), however, this MD step was not sufficient to fold the EC-II 
loop into a closed conformation. 
Annealing dynamics with movable side chains 
In such cases, 300 cycles of simulated annealing dynamics was performed on the 
EC-II loop with surrounding side chains in the protein movable. The temperature 
variation was 300 to 600 degrees with a temperature increment of 200 degrees, and a 
potential energy minimization was performed after every two cycles. After every two 
cycles, the residues around the loop which are designated as movable are updated, in 
order to provide a movable time-dependent path for the loop’s closing. 
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Results and discussion 
 
Validation for bovine rhodopsin 
 
In the case of bovine rhodopsin, the closing of the EC-II loop is depicted in Figure 
3ab with snapshots every 20 ps (sequential colors of white, cyan, orange, green, red, blue 
corresponding to those snapshots). These snapshots are taken throughout the course of 
the room temperature molecular dynamics described in the Methods section. The bundle 
opens slightly and allows the entry of the EC-II loop structure into a “closed” 
conformation. This simulation could also be conducted with ligand bound once the 
binding site is determined. 
 
 
 
Figure 3: The snapshots of loop closure every 20 ps in bovine rhodopsin. 
(Progression is white, cyan, orange, green, red, blue) 
 a 
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 b 
 
The comparison between the simulated (cyan) bovine rhodopsin EC-II loop and 
the crystal structure (white) of this loop is shown in Figure 4ab. The CRMS error in the 
main chain atoms of this loop is 6.77 Å. This error is partly due to some translation error 
which may arise from the fact that the simulated protein is not packed in a crystal as for 
the experimental structure. In addition, it may be partly due to the absence of the N-
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terminus (since this is not currently modeled in the MembStruk procedure, it was not 
included here) which packs under the EC-II loop in the crystal structure as shown in 
white in Figure 4. If the loops are aligned by a best-fit algorithm, the error in the internal 
structure is 3.67 Å. This arises from the absence of the hydrogen bonding needed for 
beta-sheet formation. The hydrogen bonding energy wells in the force field parameters 
could be deepened to increase the likelihood of the simulated structure forming a beta-
sheet. 
If the N-terminus is included (orange in Figure 4) in the simulation, the error in 
CRMS improves. The error is 5.73 Å, and after alignment of the loops, the internal 
structure has an error of 3.56 Å. Thus, as expected, the translation of the loop improved 
but the beta-sheet structure still was not formed. The translation may be improved even 
further by packing the N-terminus exactly as in the crystal structure (currently the N-
terminus was displaced slightly from its position in the crystal structure in order to reduce 
clashes with the simulated loop). 
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 Figure 4: Comparison of simulated loop without (cyan) and with (orange) the N-
terminus with the crystal structure of the loop (white). 
 
 
a  
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Role of EC-II loop in ligand binding 
A structure of bovine rhodopsin was previously built using the MembStruk 
version 2.0 with loop open. The binding of the retinal ligand ligand was predicted using 
HierDock (Trabanino et al., 2004). There were three binding modes of retinal found 
amongst the top scoring in this open loop structure, as shown in Figure 5. One binding 
mode (red) corresponded with the mode observed in the crystal structure. The other 
modes were vertical in terms of their orientation and may correspond to intermediate 
binding modes. This is supported by the studies in retinal binding (Isralewitz et al., 1997; 
Schadel et al., 2003) which conclude that retinal binds by partitioning from membrane to 
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the protein interior. Because of its amphipathicity, retinal would be expected to partition 
in a vertical orientation, aligning with the lipids of the bilayer.  
In addition, if the EC-II loop (cyan) from the crystal structure is incorporated, the 
two vertical binding modes are eliminated from the top scoring conformations of 
HierDock. Thus, the closing of the EC-II loop favors the horizontal retinal orientation 
which is able to form the Schiff base linkage and subsequently absorb incident radiation 
in the visible range required for activation and finally vision. 
 
Figure 5: Retinal conformation in an “open” loop predicted rhodopsin structure. 
The position of the EC-II loop in the crystal structure is shown (cyan). 
a 
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b 
 
In fact, if the EC-II is “opened” in the bovine rhodopsin crystal structure, the 
vertical conformations are observed amongst the top HierDock conformations (Figure 6). 
The closest in CMRS of these conformations to the crystal is 2.14 Å (as opposed to the 
1.2 Å CRMS of the best scoring HierDock retinal conformation in the closed EC-II form 
of the crystal structure). In addition, the vertical conformations found from the HierDock 
procedure are oriented with the polar aldehyde tail towards the direction of the 
extracellular region, and thus aligned with the amphipathic orientation of the lipids in the 
membrane bilayer.  
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Figure 6: Retinal conformation in the rhodopsin crystal structure 
with an “open” loop. The position of the EC-II loop in the 
“closed” crystal structure is shown (cyan). 
 
 
 223
Conclusion 
 
The role of the EC-II loop in binding and activation in GPCRs has been verified 
by various experiments. In addition, its role in determining retinal binding, as reported 
here, has been studied as well. It is therefore crucial to simulate the opening and closing 
of this loop for function prediction. This method has been validated in the case of bovine 
rhodopsin and has been used in the simulation of the EC-II loop in human CCR1, where 
is has proven to yield insights into binding of various antagonists (as discussed later in 
Chapter 9). 
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Chapter 7: “Let there be sight”: Molecular mechanism for color 
distinction in humans 
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Abstract 
 
The role of proteins in the modulation of the absorption and fluorescence 
properties of small molecules is a fundamental scientific problem with useful applications 
in other fields such as medicine. This study uses QM and hydrid QMMM techniques to 
ascertain how the molecular design of the three human opsin proteins has made possible 
the modulation of the absorbed frequency of a bound chromophore, in the crucial step of 
vision. It is found that the green to red shift can be attributed to the presence of dipolar 
residues. In addition, molecular dynamics of a QM-fitted retinal protonated Schiff base 
(PSB) within the opsins has allowed the calculation of absorption spectra for the three 
color opsins. It is found that the twisting of the retinal PSB plays the predominant role in 
the green to blue opsin shift, whereas the polarizable aromatic side chains play a 
surprising role of red-shifting the blue opsin with respect to the green opsin, as a fine 
adjustment to the opsin shift.  
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Introduction 
 
The role of proteins in the modulation of the absorption and fluorescence 
properties of small molecules is a fundamental scientific problem with useful applications 
in medicine (immunochemistry and histology). An example of this role is the modulation 
by antibodies of trans-stilbene fluorescence (23). But probably the most interesting 
example is the modulation of retinal absorption by opsin proteins in the crucial step of 
vision, in which electromagnetic radiation is converted into mechanical motion of the 
retinal and subsequently of the protein. 
Retinal is the chromophore responsible for vision in humans. This molecule can 
absorb radiation corresponding to the energy gap of the electronic transition from the 
closed shell singlet to the open shell singlet state. In response, the molecule may undergo 
an isomerization about the 11-12 bond (Figure 1).  
In addition, the terminal aldehyde of 11cis-retinal can form a Schiff base bond 
with amines. The unprotonated form of 11cis-retinal absorbs radiation at a wavelength 
maximum of ~380 nm in organic solvents such as ethanol (1). But this Schiff base can be 
protonated at physiologic pH’s to form a protonated Schiff base (PSB). This resulting 
PSB absorbs radiation at a wavelength maximum of 440 nm.  
Such a covalent linkage occurs via a specific lysine (Lys296) (Figure 2) in opsin 
proteins localized in the retina of humans. These proteins modulate the absorption 
maximum of 11cis-retinal even further. The rod cells of the retina, for example, contain 
rhodopsin, an opsin/retinal complex which absorbs light at ~500 nm. The cone cells 
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contain 3 types of opsins in humans which (in complexes with retinal) absorb light 
maximally in the blue (~425 nm), green (~530 nm), and red (~560 nm) regions of the 
spectrum (2). 
 
Figure taken from (22)
 Figure 1:  Photoisomerization of the free retinal molecule. 
 
 
Figure 2: Schiff base bond of retinal ligand with protein via 
lysine side chain in opsins. 
Figure taken from (22)
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What are the factors which contribute to this spectral tuning of the retinal chromophore? 
This has been a fundamental question which has motivated decades of research. It is has 
generally been determined that 4 factors may contribute to this spectral shift in opsins: 
 
1) The degree of coplanarization of the retinal polyene chain and the ionone ring (3) 
2) Interaction of the retinal Schiff base with its counterion (acidic side chain) (4) 
3) Influence of charged and dipolar residues around the retinal conjugated system (5) 
4) Effect of polarizable side chains (such as aromatic side chains) (6) 
 
The first factor was studied in bacteriorhodopsin (bR) by using retinal analogs which 
have the ionone ring “locked,” preventing it from twisting (3). So this analog locks the 
C6-C7 bond (the bond adjacent to ionone ring), which has been known to modulate 
spectroscopic properties of the protein/retinal complex (14). It was found that the spectral 
shift due to this ionone ring’s twisting was ~1200 cm –1 (in comparison to the total 5100 
cm –1 shift for bR). 
To understand how factors 2, 3, and 4 may result in spectral shifts, one must look at 
the possible resonance structures of the protonated and deprotonated 11cis-retinal schiff 
bases (Figure 3). There are two important facts confirmed by experiment in relation to 
these structures: 1) the excited state wavefunction in theoretical calculations has a larger 
weight put on the resonance structures on the right than the ground state wavefunction 
(7), 2) the electrons are more delocalized (and thus there is less bond alternation) in the 
excited state than in the ground state (7). Thus, the excited state of the PSB retinal has a 
larger dipole moment than the ground state. The positive charge is distributed to the 
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ionone ring upon excitation. The relative stability of these structures, and thus the 
excitation energy, may be influenced by the electric field (or a polarizable medium) in the 
environment of the chromophore. 
 
Figure 
From (8) 
Figure 3: The resonance structures of the protonated and unprotonated 
forms of retinal Schiff base. 
The role of the second factor in spectral tuning was studied in rhodopsin by Sakmar et 
al (4). The residue Glu-113 in rhodopsin is known to be the counterion for the schiff base 
of the conjugated retinal (13). This residue was thus mutated to Gln, Asp, Asn, and Ala. 
As expected, the Schiff base pKa’s were reduced. In addition, the absorption maxima 
were blue-shifted as a result of replacing the anionic Glu residue. This blue-shift, 
corresponding to an increase in the excitation energy, is due to the role of the negatively 
charged counterion in stabilizing the charge distribution of the ground state (which, as 
explained above, has a larger positive distribution around the schiff base region) and 
destabilizing the excited state distribution (which has a larger negative distribution 
around the schiff base region). 
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Experiments have been conducted to determine the contribution to the spectral shift in 
the absence of the first two factors. This was carried out on bacteriorhodopdin by Yan et 
al using retinal analogs which did not have an ionone ring and in which the conjugated 
polyene system was interrupted by hydrogenating the double bond adjacent to the schiff 
base bond. Thus, a spectral shift of 2080 cm -1 was determined in the absence of the 
coplanarization/counterion effects.  
The role of the third factor was further elucidated in a study by Kochendoerfer et al 
(2). They used Raman resonance spectroscopy on the opsin/retinal complexes to 
determine that the peak for the ethylenic stretch gradually was shifted (blue,1559 cm-1 to 
green,1531 cm-1 to red,1526 cm-1) for the opsins. This is a result of the increasing 
electronic delocalization in the red opsin environment (and thus the reduction of bond 
alteration). Furthermore, models of the human opsins were built. From the amino acids 
around the chomophore, it was shown that the distribution of dipolar residues around the 
ionone ring was increased from the blue to red opsin model. Qualitatively, the role of 
these residues  in differentially stabilizing the ground and excited state electron 
distributions in retinal (much the same mechanism as the counterion above) could be 
inferred.  
The role of the last factor was studied by Houjou et al (6) using the ab initio (quantum 
mechanical) method of self-consistent reaction field (SCRF), in which the charge 
distribution of the retinal polarizes the medium, which in turn produces a reaction field 
which acts back on the retinal. The calculated opsin shift arising from the effect of the 
polarizable medium was ~1000 cm –1. 
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The recent crystal structure determination of bovine rhodopsin has helped reveal the 
specific residues which may be involved in spectral tuning in opsins. The sequence 
identities and similarities between bovine rhodopsin and the human opsins are as follows: 
88,91 human rhodopsin,  40,60 human blue opsin,  40,57 human green opsin,  39,56 
human red opsin. The values are probably higher for the transmembrane region alone. 
This high similarity justifies the use of homology modeling and threading techniques to 
determine the opsin structures (12). 
Using such structures, one can perform quantum mechanical calculations to 
determine the spectral tuning of retinal by the protein residues. Since the computational 
costs of such calculations increase rapidly with the number of atoms, it is necessary to 
reduce the system in question or apply approximate calculations in combination with 
accurate quantum mechanical (QM) techniques. 
In this study, the human opsins are constructed using bovine rhodopsin as a template. 
The spectral shift associated with each opsin are ascertained by 1) performing quantum 
mechanical calculations using the Jaguar suite (10) on selected residues in the retinal 
binding site, and 2) running a combined QMMM (Quantum mechanics/ molecular 
mechanics) calculation treating the retinal molecule’s ground and excited states by 
quantum mechanics and the protein environment by molecular mechanics. In this way, 
residues and environmental factors (membrane, dielectric) responsible for spectral tuning 
are determined. 
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Methods 
Opsin structure building 
 
A pairwise multiple sequence alignment of the sequences for bovine rhodopsin 
together with those of the four human opsins (rhodopsin and the three color opsins) was 
carried out using Clustalw (15). Based on this alignment, the sequence of each human 
opsin was threaded through the bovine rhodopsin structural template as follows. Side 
chain replacement using SCWRL (16) of the bovine rhodopsin structure was carried out 
in order to replace those in the bovine rhodopsin structure with the correct sequence of 
the respective opsin. SCWRL obtains optimized rotamers for the side chain using a 
backbone-dependent library of rotamers. As seen in Figure 4, the only gaps in the 
alignment occurred in the N and C terminus. These regions with gaps were excluded 
from the created structures, with the reasoning that they are too far from the bound retinal 
in order to have a significant role in spectral tuning. The protein charges were assigned 
from CHARM22. The structures were optimized using conjugate gradient minimization 
of the protein in vacuum as implemented in MPSim (20). Then the retinal protonated 
Schiff base was placed into the opsins in the same orientation as in the bovine rhodopsin 
crystal structure. SCWRL was used again and the complex minimized. SCWRL was used 
once more and the complex re-minimized. A side chain replacement program called 
SCREAM, which uses an explicit potential energy calculation to score side chain 
rotamers, was subsequently used to finely optimize side chains in the 5 A binding site of 
the retinal PSB.  
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Quantum mechanical calculations on retinal and derivatives 
As a validation for determining the excitation energy for retinal within the opsins, 
some calculations are performed on free 11cis-retinal and protonated Schiff Base (PSB) 
11cis-retinal. The 6-31g** basis set was used at the Hartree-Fock level using the self-
consistent field (SCF) method within the Jaguar suite (10). The molecules were 
gemometry optimized at the ground state electronic configuration (closed shell singlet). 
Then the excited state with the triplet configuration was obtained with the geometry 
optimized structure above to simulate vertical excitation. Finally, using the initial 
wavefunction guesses from the triplet state, the open shell singlet configuration was 
obtained. 
 Fig 4: The alignment of the bovine rhodopsin sequence to the other 3 color opsins 
and human rhodopsin. 
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QM/MM calculation on the opsin/retinal complex (theory) 
 
Since the computational cost of quantum mechanical calculations increases by the 
power of the number of atoms, it is necessary to use a combines QM/MM method for 
large systems. In order to be able to reproduce the complete spectral shift across the 
opsins, the combined QM/MM technique described by Murphy, Philipp et al. (9) was 
used. The system is divided into a quantum mechanical (QM) portion (retinal PSB) and a 
molecular mechanics (MM) portion (opsin); the respective energies are calculated with 
the following expressions: 
 
 
From (9) 
In equation [1], the first term included the Hamiltonian corresponding to the field 
of MM point charges (CHARMM charges) which will influence the wavefunction and 
electronic energy of the QM region. The second term includes the set of Hartree-Fock 
equations for the QM region as if it were not interacting with the protein environment. 
The third term is the nuclear interactions between atoms in the QM region and the last 
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term is the interaction of the QM nuclei with the MM charges. The QM energy will be 
evaluated by Jaguar suite of programs (10). 
In equation [2], the energy of the MM region is given by the typical MM 
expression, with stretches, bends, torsions, electrostatics, and van der Waals terms. This 
MM energy will be evaluated using MPSim (20). 
In certain cases, the QM system is minimized in the field of the protein. To do so, 
an adiabatic minimization procedure was developed (9) in which the QM region is 
minimized (for one geometry step) across its potential energy gradient (the gradient of 
the above energy expressions). This is done with a frozen MM region. Then the MM 
region is minimized (down to a certain rms force tolerance) across its potential energy 
gradient (with QM region fixed). This MM region minimization is done treating the QM 
atoms as partial charges with a certain van der Waals radius (between the radius from 
QM calculation and that from the MM force field). The QM charges are obtained by 
fitting to the electrostatic potential described in the wavefunction. This cycle is repeated 
until the QM region converges (rms reaches a certain tolerance). 
 
1.1 QM/MM calculation on the opsin/retinal complex (application) 
 
The above QMMM method has been implemented to perform the quantum 
mechanical calculations for the ground state (as given in equation [2]) as well as the 
triplet excited state. In this case, the energy gap for exciting the electron would be just the 
subtraction of the ground and excited state energies for the QM regions after QMMM 
minimization. 
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This energy could be related to the frequency of light needed for the excitation, 
and thus the spectral shifts due to the opsin environments could be reproduced.  The 
precise roles of the first 3 factors described section 1.0 was determined.  
 
The last factor probably arises from the close aromatic side chains which may 
polarize in response to the retinal excitation (and its subsequent increase in dipole 
moment). Since the side chains in molecular mechanics are non-polarizable, this factor 
will only be tested with the pure QM calculations as described above. The procedure is as 
follows. The QM region is chosen to be the PSB retinal together with the aromatic 
polarizable residue (tyrosine or tryptophan) at position 265 in the protein. The unpaired 
electrons remain on the retinal chain in the excited state calculation in the field of a 
polarizable ground state aromatic side chain. This calculation is performed both in 
vacuum and in the field of an MM-treated protein environment in order to ascertain any 
additional influence the rest of the protein may have in the polarizability of the aromatic 
side chain. 
1.2 Molecular dynamics using a QM-fitted force field 
Proteins are of course dynamical systems at room temperature. The distributions 
evident in absorption spectra are due to structural fluctuations which occur in the excited 
molecule and affected by fluctuations of surrounding molecules. Since it is currently not 
feasible to perform QM dynamics on large systems, our force field parameters were fit 
more closely to the quantum mechanics for the PSB retinal. After applying these general 
parameters for torsions and bond distance, the PSB retinal structure minimized to a 
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structure which was ~2 kcal/mol from the QM geometry optimized structure. This 
validated the use of the force field for our opsin shift studies. 
Subsequently, the PSB 11cis-retinal/ ospin complex was simulated with molecular 
dynamics in a constant temperature heat bath (TVN ) at 300 K for 100 ps. Then, single 
point QMMM energies as described above were obtained for snapshots obtained every 2 
ps in the dynamics in order to obtain a calculated absorption spectrum reflective of 
dynamical changes in the protein and ligand. 
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Results and discussion 
QM on retinal and derivatives 
The QM geometry optimized structure of retinal is shown in Figure 5. Calculating 
the closed shell singlet (CSS) and open shell singlet energy (OSS) from this geometry 
leads to a 69.3 kcal/mol energy gap. This corresponds to 413 nm photon wavelength 
which corresponds well with the 380 nm determined experimentally. The calculated 
closed shell singlet to triplet energy was 66.8 kcal/mol or 428 nm. This validates the use 
of QM at the hartree-fock level for use in these calculations. Since our method of 
QMMM does currently account for the OSS case, the CSS to triplet transition is studied 
for the purpose of obtaining relative opsin shifts in the case of retinal in the protein. 
The QM geometry optimized structure of a retinal protonated Schiff base (PSB) 
structure is shown in Figure 6. It consists of the bound retinal and three carbons of the 
lysine side chain. The CSS to triplet energy was 42.9 kcal/mol (and CSS to OSS was 47.7 
kcal/mol). When a QMMM calculation is performed with the PSB structure (the same  
conformation as above) treated with QM and the Glu113 counterion treated with MM, the 
CSS to triplet energy is 44.6 kcal/mol. And when the same retinal PSB is placed into the 
bovine rhodopsin crystal structure (matching the ligand orientation with that in the crystal 
structure), the CSS to triplet energy is 43.5 kcal/mol. The relative differences indicate the 
role of the counterions in blue-shifting the energy gap and the role of the rest of the 
bovine rhodopsin protein in red-shifting from there. Later, the dynamics of the ligand in 
protein will show how changes in the ligand conformation in response to the protein also 
modulate this energy gap. 
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QMMM on opsin complexes 
 
QMMM one point calculations were carried out with the retinal PSB in the same 
conformation as above. The calculated energy gaps were 43.48, 44.90, 42.86 kcal/mol for 
red, green, and blue opsins, respectively. The energy gaps shift are 1.42 for red to green 
and –2.04 kcal/mol for green to blue. The experimental values for these opsin shifts are 
2.9 for red to green and 13.3 kcal/mol for green to blue. 
The residues close to the retinal PSB which are present in the red opsin and not in 
the green opsin are shown in Figure 7. These residues are non-polar in the green opsin. In 
particular, the conformation of the Tyr261 (which is F in the green opsin) was thought to 
be important in the opsin shift. When the OH dipole of the tyrosine was rotated 180, the 
calculated energy gap was 43.50, virtually equivalent to the other conformer.  
As can be noted, there are no differences in the region close to the retinal PSB 
which may cause twisting. Thus, the assumption that the ligand is in the same 
conformation in both opsins may be valid. Nevertheless, the role of dynamics on this 
small energy shift was also observed and will be reported later. 
The presence of dipolar residues near the Schiff base side of the retinal PSB was 
thought to play the predominant role in the green to blue shift (2). But that is not the case 
in these calculations. In fact, an opposite shift of ~2 kcal/mol is predicted. Thus the 
polarizable side chains or the twisting of the retinal must play a much more predominant 
role in this particular shift. 
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Role of polarizable side chains on the opsin shift 
 
As mentioned before, polarizable side chains have been implicated in modulating 
the absorption frequency of retinal. Within the binding site of the retinal PSB within the 
opsins, there is a TRP265 in the green and red opsin, whereas in the blue opsin, this 
residue is a TYR265 (Figure 8). So possibly the different effects of these polarizable 
residues may be responsible for the 13 kcal/mol shift in excitation energy between the 
green and blue opsins. 
First, SCREAM was used to obtain rotamers of these residues which were at least 
25 kcal/mol different in energy score. This Monte Carlo side chain sampling would be 
equivalent to a long-time dynamics run, since there are barriers which would need to be 
overcome between these conformations. Then, a QM calculation was performed on the 
retinal PSB and the residue at 265 only. This gives the polarizability contribution 
independent of the rest of the protein. The energy gaps are shown in Table 1. The energy 
gaps are virtually equivalent. But how does this effect change in the protein? 
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Table 1: The energy gaps of bound retinal with a QM treatment of residue 265. 
Green opsin 
Conformation 
number 
Energy gap 
(kcal/mol) 
Blue opsin 
Conformation 
number 
Energy gap 
(kcal/mol) 
1 42.68 1 43.14 
2 42.47 2 43.24 
3 43.51 3 43.12 
4 44.08 4 42.73 
5 42.95 5 43.01 
6 42.76 6 42.87 
  7 42.63 
  8 42.45 
  9 42.77 
  10 43.04 
average 43.08  42.90 
 
The aromatic side chain and retinal PSB were treated as QM in a QMMM 
calculation. The results are shown in Table2. An opposite shift of ~3 kcal/mol is 
predicted. It is thus obvious that twisting of the retinal PSB must cause this shift and this 
was tested. 
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Table 2: The energy gaps of bound retinal with a QM treatment of residue 265 
and MM treatment of the rest of the protein. 
 
 
Green opsin 
Conformation 
number 
Energy gap 
(kcal/mol) 
Blue opsin 
Conformation 
number 
Energy gap 
(kcal/mol) 
1 44.67 1 42.15 
2 44.41 2 42.24 
3 45.21 3 42.01 
4 45.52 4 41.71 
5 44.89 5 42.08 
6 44.62 6 41.95 
  7 41.76 
  8 41.62 
  9 41.78 
  10 42.00 
average 44.89  41.93 
 
   
QM-fitted molecular dynamics on opsin complexes 
 
It is currently not feasible to perform ab initio QM dynamics within protein. But 
the dreiding force field parameters of torsion and bond stretching could be changed to fit 
the QM values, as discussed in Sec. 2.5. Subsequently, molecular dynamics was run for 
100 ps. A one point QMMM calculation was performed on snapshots every 2 ps.The 
calculated CSS to triplet energy gaps from these 50 structures were used to create the 
histograms for all 3 opsins as shown in Figure 9. 
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The peaks of these histograms correspond to energy gaps of 41.00, 42.72, and 
58.73 kcal/mol for the red, green, and blue opsins respectively. The calculated red to 
green shift is 1.72 which corresponds with the 2.9 kcal/mol known from experiment. The 
calculated green to blue shift is 16.01, which correspond with the 13.3 kcal/mol known 
from experiment. This shift is in fact overpredicted by 3.3 kcal/mol. This is where the 
polarizable side chains may play a role - the TRP265 in the green opsin was found to blue 
shift the energy gap by an average of 2.96 kcal/mol (Table 2) as compared with the 
TYR265 in the blue opsin. Thus 16.01 – 2.96 = 13.05 corresponds very well with the 
green to blue opsin shift of 13.3 kcal/mol known from experiment.
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Figure 5: QM geometry optimized structure of retinal. 
Figure 6: QM geometry optimized structure of a retinal protonated Schiff base (PSB). 
 248
Figure 7: Residues close to the retinal PSB which are present in the red opsin and not in 
the green opsin. 
 249
Figure 8: The residue 265 is Trp in the green opsin but Tyr in the blue opsin.  
a)  
b) 
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Figure 9: Calculated absorption spectra for the 3 opsins. 
a) 
 
b) 
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c) 
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Conclusion 
The fundamental question of how opsins modulate the frequency of light 
absorbed by a bound chromophore has been studied for decades. This study used the 
most updated techniques of structure building and optimization  to build the human opsin 
structures. In addition, the roles of these opsin structures in modulating the frequency of 
maximal absorption of light by bound retinal PSB were determined using QM and hybrid 
QMMM techniques.  
This fundamental understanding of this mechanism may lead to design application 
in which proteins (or a synthetic analog of a peptide) may be designed to modulate the 
frequency of light absorbed by any bound chromophore. This would serve well in the 
field medical imaging diagnostic tests. In addition, the chromophore may be modified to 
interact specifically with a native protein and thus absorb at a certain frequency of light.  
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Chapter 8: Ab initio simulation of photoisomerization for full 
retinal chromophore in free and rhodopsin-bound states 
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Abstract 
 The photoisomerization event of retinal is the crucial step in the process of vision 
in which the energy of  a photon of light is converted to a signal transduction cascade. It 
is the interaction of retinal with protein within rhodopsin, a G-protein-coupled receptors, 
which increases the efficiency of this process greatly. This study reports the ab initio 
potential surfaces of the ground and excited states for the full retinal chromophore in the 
free state as well as in the opsin-bound state and demonstrates the conical intersection 
(CI) in these molecules. In addition, the observed difference in the extent and form of this 
CI in the protein-bound state may be crucial in increasing the quantum yield of 
isomerization.  
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Introduction 
The primary event in vision is the conversion of electromagnetic energy into 
mechanical energy of protein movement. This occurs when the chromophore 11cis-
retinal absorbs a photon of light and subsequently isomerizes to yield all-trans-retinal 
(Figure 1). This isomerization process occurs with an experimental quantum yield of 0.2 
(Kropf et al., 1970; Bensasson et al., 1978). The protein rhodopsin (of the G-protein-
coupled receptor superfamily), however, increases the efficiency of this process to .65 
(Schoenlein et al., 1991) which completes in 200 fs (Boucher et al., 1985). 
Quantum mechanically, the isomerization may occur as a two-state or three-state 
process. Schematics of the two processes are shown in Figure 2. In the two-state process, 
the molecule is excited to the FC (Frank-Codon) point on the S1 (first excited state) 
surface after which there is a descent to the CI (conical intersection) where there is 
intersystem crossing to the S0 (ground state) surface. In the three-state process, the 
difference is that there is a small barrier on the S1 surface corresponding to an avoided 
crossing with the S2 surface. The support (experimental and theoretical) for a three-state 
process has focused on the retinal/bacteriorhodopsin system (Hasson et al., 1996; 
Humphrey et al., 1998; Kobayashi et al., 2001), in which the protein catalyzes the 
formation of 13-cis retinal from all-trans-retinal. This bacterial process is a reverse 
isomerization (trans->cis) in which bond selectivity for the rotation is also a significant 
issue. The two-state model remains possible for the retinal/rhodopsin system and in fact 
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there is support for such a path for the 11cis->all-trans isomerization of free retinal  
(Gonzalez-Luque et al., 2000). 
Conical intersections have been found in many photochemical singlet reactions 
(Bernardi et al., 1996) and have been used to explain the observed phenomenon of weak 
fluorescence for various photochemical processes in ethylene, butadiene, and stilbene 
(Zerbetto et al., 1990; Olivucci et al., 1993; Quenneville et al., 2003). In the case of free 
retinal, rapid isomerization with weak fluorescence has been observed experimentally 
(Hochstrasser et al., 1976; Doukas et al., 1983; Alex et al., 1992). 
The relaxation process from FC has been studied using quantum dynamics 
techniques on retinal models (smaller molecules which incorporate crucial elements of 
the retinal structure) in the free state (Vreven et al., 1997; Bub et al., 2000) as well as 
more recently in bacteriorhodopsin  (Warshel et al., 2001; Hayashi et al., 2003) using 
hybrid quantum mechanics/molecular mechanics (QMMM) methodology. In addition, the 
isomerization process and associated conical intersection have been explained by 
graphing the potential surfaces for smaller free retinal models along the minimum energy 
path (MEP) coordinates (Gonzalez-Luque et al., 2000; Migani et al., 2003). In fact, it was 
found that there is an extended intersection space (IS) and not a single CI which is 
responsible for the intersystem crossing (Migani et al., 2003). 
Mapping the isomerization along actual geometric coordinates has been applied to 
ethylene and stilbene (Quenneville et al., 2003) using as the nuclear coordinates the 
torsion of the isomerizing bond and the pyramidalization of associated atoms of this 
bond. This study demonstrated the presence of CI in both molecules. Because of 
computational costs, such a study has not yet been applied to the complete retinal 
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molecule. There has been published work on mapping the isomerization using only the 
coordinate of torsion (Lee et al., 2002), but this did not demonstrate the CI of retinal. 
This paper reports the ab initio calculation of So and S1 potential surfaces with 
respect to the C11-C12  torsion  angle of 11cis-retinal and demonstrates the conical 
intersections in stilbene, retinal, retinal protonated Schiff base (RPSB), and RPSB within 
rhodopsin using QM or QMMM methods. Insights into the role of the potein in 
catalyzing the isomerization process emerge from this study. 
 
Material and methods 
 
Small molecule molecular mechanics optimizations 
 
The potential energies of all small molecules were initially minimized using 
conjugate gradients. Stilbene and retinal (Figure 3ab) were rotated about their 
isomerizing bond to torsion angles from 0 to 180 degrees in increments of 10 degrees. 
The larger RPSB (Figure 3c) form of retinal was rotated from 0 to 180 degrees in 
increments of 30 degrees. Keeping the atoms of the torsion fixed, the potential energies 
of the different torsional forms of the molecules were minimized with the FF description 
of DREIDING (Mayo et al., 1990) using the MPSim (Lim et al., 1997) program. This 
was carried out to an RMS force of 0.05 kcal/mol/Å using conjugate gradients.  
 
Protein MM optimization 
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The crystal structure of bovine rhodopsin (resolution 2.80 Å) was downloaded 
from the protein database (pdb entry 1F88). The Hg ions, sugars, and waters were deleted 
from this structure. This crystal structure is missing 10 complete residues in loop regions 
and the side chain atoms for 15 additional residues. We added the missing residues and 
side chains using WhatIf (Vriend, 1990). Then we added hydrogens to all the residues 
using the PolyGraf software. We then fixed the TM helices and minimized (using 
conjugate gradients) the structure of the loop region to an RMS force of 0.1 kcal/mol/Å. 
The potential energy of the entire structure of rhodopsin was then minimized (using 
conjugate gradients) to an RMS force of 0.1 kcal/mol/Å . This minimized structure 
deviates from the x-ray crystal structure by 0.29 Å coordinate root mean square (CRMS) 
error over all atoms in the crystal structure. 
 
Quantum mechanical calculation 
 
Subsequently, the different torsional forms of the molecules were geometry 
optimized in vacuum with the closed shell singlet (CSS) electronic configuration using 
Jaguar (Jaguar, v4.0) at the Hartree-Fock level with the basis set 6-31g**. Only the C11-
C12 torsions were kept fixed during this geometry optimization (C11-C12 bond length 
was allowed to change). Using this same geometry for each torsional form of the 
molecules, a single point QM calculation of the triplet configuration was performed and 
the resulting orbital guess was used to perform another single point calculation of the 
open shell singlet (OSS). In addition, the molecules were geometry optimized in the 
triplet or the OSS electronic configurations. 
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QMMM calculation 
 
The QM region for this calculation was the entire RPSB which consisted of the 
retinal and lysine side chain capped by a hydrogen before the protein backbone (Figure 
4). The MM region  was the rest of the protein with counterions (Na and Cl) for the 
charged side chains (except for Glu113 which remained salt-bridged to the Schiff base 
proton of the RPSB). At each torsional form of the RPSB, the RPSB/protein complex was 
minimized adiabatically (Appendix) with a QM CSS description of the RPSB. Using this 
geometry, a single point calculation of the triplet configuration was performed. 
Subsequently, a geometry optimization was performed in the triplet configuration using 
the same type of QMMM adiabatic minimization.  The OSS configuration was not 
obtained since it has not been implemented in the QMMM program. The assumption (as 
supported by the energy profiles of the small molecules) is that the triplet and OSS are 
sufficiently close in energy to study the general excited state trends.  
 
 
Results and discussion 
 
 The potential energy plots for the geometry optimized closed shell singlet (GO 
CSS), triplet, open shell singlet (OSS), geometry optimized open shell singlet (GO OSS), 
and geometry optimized triplet (GO triplet) from  the torsional forms of the different 
molecules are shown in Figure 5a-6c. 
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Stilbene QM calculations and symmetry issue 
 
 Stilbene is known to have two characteristic  lower excited states S1 and S2 
characterized by Bu and Ag symmetry respectively (Allen et al., 1989). As such, there are 
two nearby peaks in the experimental absorption spectrum at 290 and 230 nm 
(corresponding to energies of 98.59 and 124.31 kcal/mol respectively). The calculated 
potential energy graph for stilbene is shown in Figure 5a. For structurally symmetric 
molecules like stilbene, the symmetric Ag is solved  for most of the graph’s excited state 
surface. At 90, 0, and 10 degree torsions, however, the lower Bu is solved. Nevertheless, 
the energy gap (from GO CSS to OSS) at 180 degree torsion is 126.98 kcal/mol, 
corresponding very well with the peak at 230 nm (the S2 Ag state). It is expected that the 
Bu state would be clearly solved for an asymmetric molecule. To test this, a methyl was 
added to stilbene. The energy profile for this molecule is shown in Figure 5b. The S1 Bu 
state is now solved. It is thus expected that calculations with asymmetric molecules like 
retinal would yields the asymmetric Bu state.  
The intersections at 90 degrees torsion may correspond to the CI of the S1 state 
with the S0 state. It is conceivable that the molecule in the FC region may relax in terms 
of its nuclear geometry to reach the CI region, where it may undergo intersystem crossing 
without radiation. This proposed path is indicated in dashed lines on the energy profiles 
of this study. This is consistent with the experimental observation of low fluorescence 
quantum yield (0.05) for stilbene (Allen et al., 1989). 
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Retinal QM calculation 
 
 Retinal is known to have S1 and S2 states corresponding to the Bu and Ag 
symmetries (Gonzalez-Luque et al., 2000). The experimental absorption peak (Wolken, 
1966; Dowling, 1987) of 11cis-retinal in ethanol is at 380 nm (corresponding to an 
energy gap of 75.24 kcal/mol).  The potential energy graph for retinal is shown in Figure 
6a. As expected, for this structurally asymmetric molecule, the asymmetric Bu is solved  
for all of the graph’s excited state surface of S1. The energy gap (from GO CSS to OSS) 
at 0 degree torsion is 69.29 kcal/mol, corresponding with the absorption peak at 380 nm 
(S1 Bu state). In addition, a near intersection (~1 kcal/mol gap) of the S0 and S1 surfaces 
occurs at 90 degrees, indicating a possible conical intersection. This is consistent with the 
experimental observation of weak fluorescence. 
 
Retinal PSB calculation 
 
 The potential energy graph for RPSB is shown in Figure 6b. The calculated 
energy gap (from GO CSS to OSS) at 0 degree torsion is 47.43 kcal/mol (S1 Bu state). 
The graph reveals qualitative trends in the energy profiles of the relaxation process of the 
molecule. Interestingly, the profile indicates the lack of the CI point at 90 which was 
observed for the retinal and stilbene cases. How is this different in the protein, where this 
Schiff base linkage actually occurs? 
 
RPSB/opsin QMMM calculation 
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 The potential energy graph for RPSB in bovine rhodopsin is shown in Figure 6c. 
The energy gaps are generally large, which is due to the fact that the geometries were 
minimized using QM and MM forces alternatively  as described in the Appendix. This 
type of adiabatic minimization with both kinds of forces may lead to steeper gradients 
than with separate forces. Nevertheless, in the case of RPSB, insight emerges from a 
qualitative analysis of the graph. The most striking feature is the extensive region of 
overlap between the GO triplet and CSS, which indicates a larger region of intersection 
space within the protein as compared with free retinal. This would explain the large 
increase in isomerization quantum yield from retinal in the free state to retinal in the 
protein-bound state.  
 The overlap between the S1 and S0 surfaces begins at around 60 degrees and ends 
at around 120 degrees. In addition, the CSS energy profiles has a “plateau” shape instead 
of a “hill” shape as in free-retinal, which may lead to less excited retinal reverting to 0 
degrees upon intersecting the CSS surface at ~60 degrees. These features of the potential 
surfaces may explain the more than 3-fold increase in isomerization quantum yield of the 
retinal within the protein. 
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Conclusion 
The interesting phenomenon of conical intersections is thought to be the best 
explanation for the low fluorescence yields of many small molecules. This study observes 
these conical intersections using ab initio potential energy mapping with the torsion of 
the isomerizing bond as the nuclear coordinate. Thus torsion scans were obtained for 
stilbene as well as the full retinal molecule, as well as the protonated Schiff base of 
retinal in free and opsin-bound state. The demonstration of an extensive intersection 
space of the RPSB/opsin complex points to the protein’s role in increasing the surface 
crossing probability through the CI.  
This phenomenon may be used in applications of increasing isomer yields in 
photochemical reactions. Mutant proteins with capabilities of increasing the 
photoisomerization quantum yield or speeding the process by steepening the gradient for 
isomerization may prove to be applicable for various such processes. In addition, the 
fluorescence properties of chemicals can be modified by either modifying the 
chromophore or by exposing it to certain proteins. This may be very useful in 
immunohistochemistry and medical diagnostics. The theoretical understanding of this 
isomerization process may thus have various application beyond the fact that it is of 
fundamental scientific interest. 
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Appendix 
 
The QMMM adiabatic minimization procedure was developed (Murphy et al., 
2000) in which the QM region is minimized (for one geometry step) along its potential 
energy gradient (the gradient of the QM energy expressions). This is done with a frozen 
MM region. Then the MM region is minimized (down to a certain rms force tolerance) 
across its potential energy gradient (with QM region fixed). This MM region 
minimization is done treating the QM atoms as partial charges with a certain van der 
Waals radius (between the radius from QM calculation and that from the MM force 
field). The QM charges are obtained by fitting to the electrostatic potential described in 
the wavefunction. This cycle is repeated until the QM region converges (rms reaches a 
certain tolerance). 
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Figure 1: Photoisomerization of the free retinal molecule and retinal ligand Schiff 
base bound to the protein via lysine side chain in opsins. 
 
a) 
 
Figure taken from 
http://wunmr.wustl.edu/EduDev/L
abTutorials/Vision/Vision.html
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b)  
Figure taken from 
http://wunmr.wustl.edu/EduDev/La
bTutorials/Vision/Vision.html
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Figure 2: Schemes of two and three state isomerization models. 
 
 Figure from (Gonzalez-Luque et al., 2000) 
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Figure 3: Stilbene, retinal, and RPSB (retinal protonated Schiff base). 
 
a) 
 
b) 
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c) 
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Figure 4: RPSB in protein. 
 277
Figure 5: Plots of potential energy for stilbene and met-stilbene. Energy profiles are 
shown for the geometry optimized closed shell singlet (GO CSS), triplet, open shell 
singlet (OSS), geometry optimized open shell singlet (GO OSS), and geometry optimized 
triplet (GO triplet). 
 
a) 
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b) 
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Figure 6: Energy profiles for retinal, RPSB, and RPSB within protein. 
 
a) 
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b) 
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Chapter 9: CCR1 and CCR5 structure and function prediction 
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Abstract 
 
 The G-protein-coupled receptor (GPCR) superfamily has been the target for many 
pharmaceutical drugs and thus the 3D structure of these proteins is essential to future 
rational drug design. Specifically the chemokine receptor family is emerging as a class of 
particular important for the possible treatment of immunological pathologies. The CCR1 
receptor has been implicated in multiple sclerosis and organ transplant rejection whereas 
the homologous receptor CCR5 has been implicated in HIV infection. This study uses the 
MembStruk protocol to predict the structure and the HierDock protocol to predict the 
function of the CCR1 receptor using BX471, as well as 5 other compounds. The CCR5 
receptor was constructed as a homology model from the predicted CCR1 structure and 
the binding of Tak-779 was determined, as well as 4 other compounds. In both receptors, 
the binding and mutation studies correlate well with the predicted values based on the 
structures. The MembStruk protocol was thus validated for these cases and has yielded 
new insights into the binding and important general structural features of these receptors. 
 284
Introduction 
 
Chemokines have been generally accepted as the primary factors for leukocyte 
migration (Mackay, 2001; Thelen, 2001). They are small peptides with a characteristic 
number of conserved cysteine pairs; they act as antagonists or agonists on specific 
receptors in the GPCR superfamily (Onuffer et al., 2002). As such, they are involved in 
specific chemotactic axes (specific  receptor-chemokine pairs) for leukocyte recruitment 
to specific sites (Houshmand et al., 2003). In addition to their leukocyte attractant role, 
chemokines are also involved in cell growth and HIV infection (Mackay, 2001). 
Resultingly, they are involved in a variety of diseases related to inflammatory cell 
localization: asthma, multiple sclerosis, atherosclerosis, arthritis, organ transplant 
rejection, and cancer (Gerard, 2001). The specific role of chemokines in cancer may be 
negative or positive, acting directly as tumor growth factors or indirectly in attracting 
leukocytes which may release tumor growth and angiogenetic factors. Positively, the 
presence of leukocytes may increase tumor rejection. Finally, the specific expression of 
certain chemokine may attract specific chemokine receptor expressing cells to 
metastasize. This case of cancer demonstrates the intrinsic roles of chemokines in 
complex immunological processes. 
 Thus, the development of small antagonists to chemokine receptors is an 
important challenge. The main challenges include antagonist cross-reactivity with other 
GPCRs and reduced affinity in animal models compared to humans (Horuk, 2003). In 
particular, the CCR1 inhibitors of Berlex have demonstrated reactivity to dopaminergic 
and muscarinic receptors (Hesselgesser et al., 1998). In addition, the antagonist BX471 
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has much reduced affinity to the rodent receptors (Liang et al., 2000), thus requiring 
much higher doses to induce the required effect. The reduced affinity in the mouse 
receptor was also found for other similar 4-hydroxypiperidine antagonists (Onuffer et al., 
2003). Such similar problems have been found in the case of CCR5 inhibitors of Shering-
Plough, where reactivity to muscarinic receptors was found (Tagat et al., 2001). Also, the 
antagonist SHC C of Shering Plough was found to have poor rodent receptor affinity 
(Horuk, 2003).     
 To aid in the design of antagonists with reduced cross-reactivity and with better 
affinity to animal receptors, the availability of 3D structures for the receptors is critical. 
Currently, the only 3D experimental structure available is for bovine rhodopsin 
(Palczewski et al., 2000). Since the sequence homology of rhodopsin to most GPCRs is 
less than 20%, homology modeling is not a feasible avenue for building accurate 
structures (Archer et al., 2003). The develop of the MembStruk procedure (Floriano et al., 
2000; Vaidehi et al., 2002; Trabanino et al., 2004) has provided an alternative for 
constructing the 3D structures of GPCRs from mostly first principles. This current study 
utilizes the MembStruk procedure to construct the 3D structure of human CCR1 and 
provides validation for the structure based on binding data, specific protein structural 
features, and based on correlation to mutation data for a homology model of CCR5 from 
CCR1. 
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Methods 
Prediction of TM helical regions 
 The prediction of TM (transmembrane) segments from sequence is achieved using 
the TM2ndS protocol (as discussed in Chapters 2 and 3). This protocol relies on 
hydrophobicity profiles generated for different window sizes and general helix capping 
rules to obtain accurate TM helical predictions. These hydrophobic profiles are by default 
obtained from a Clustalw multiple sequence alignment (Thompson et al., 1994) of 
sequences with over 200 bit score to the query sequence obtained using Blast (Altschul et 
al., 1990; Altschul et al., 1997). The sequences used are shown in Figure 1. The 
hydrophobic profile for window size 12 and the chosen baseline are shown in Figure 2. 
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Figure 1: Sequences obtained from Blast for alignment.  
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Prediction of the hydrophobic center of the helices 
 
As described previously (Trabanino et al., 2004), the hydrophobic center (HC) of each 
helix is determined by analyzing the hydrophobic profiles at various window sizes. A 
range of window sizes for which the maxima are stable is used to calculate a final residue 
number which is taken to be at the center of the membrane bilayer, as discussed in 
Chapter 4. The positions of these HC’s are shown on the hydrophobic profile of Figure 2. 
In addition, the TM helical sequences (before and after capping) and HC positions 
(underlined) are shown in Figure 3. Thus, the individual helices are translated along their 
helical axes so that these residues are aligned to a common plane of the bundle, as shown 
in Figure 4. 
 Figure 2: The hydrophobic profile for CCR1 at window size 12 with HC’s indicated. 
6
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 Figure 3: The CCR1 TM helix predictions with HC’s
indicated. he TM prediction 1  
LLPPLYSLVFVIGLVGNILVVLVL 
LLPPLYSLVFVIGLVGNILVVLVLVQYK 
he TM prediction 2  
  LLNLAISDLLFLFTLPFWIDYKLK 
IYLLNLAISDLLFLFTLPFWIDYKLK 
he TM prediction 3  
MCKILSGFYYTGLYSEIFFIILLTIDRYLAIVH 
MCKILSGFYYTGLYSEIFFIILLTIDRYLAIVH 
he TM prediction 4  
 GVITSIIIWALAILASMPGL 
FGVITSIIIWALAILASMPGLYF 
he TM prediction 5  
LKLNLFGLVLPLLVMIICYTGI 
LKLNLFGLVLPLLVMIICYTGII 
he TM prediction 6  
 IFVIMIIFFLFWTPYNLTILISVFQDF 
LIFVIMIIFFLFWTPYNLTILISVFQDF 
he TM prediction 7  
    YTHCCVNPVIYA 
EVIAYTHCCVNPVIYAFVGER 
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Figure 4: The residue c-alphas predicted to correpond to 
the HC’s aligned to a common plane in CCR1. 
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Initial Rotation  
 
 Once the hydrophobic center is predicted, the sector angle of the face between 
pairs of helices (about a rotatable helix) is determined (Trabanino et al., 2004).Then the 
helical face of the rotatable helix with a maximum hydrophobic moment within that 
sector angle is pointed between these two helices. The orientations of these calculated 
hydrophobic moments are shown in Figure 5. 
Figure 5: Rotational orientations of the hydrophobic 
moments of the helices in CCR1 after the initial rotation. 
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Optimization of helix backbones 
 
After the helices are initially orientated, molecular dynamics at 300 degrees on 
the individual helices is carried out as an initial backbone optimization. MPSim (Lim et 
al., 1997), which is used for all energy calculations and molecular dynamics in 
subsequent steps, was used. Helix 6 exhibited the most bending of the 7 helices and helix 
1 to a lesser extent.  
Optimization of helical rotations 
 Hel 3 
 The rotation of Helix 3 requires more analysis, as it is a helix without one well-
define hydrophobic face.  In addition to this hydrophobic moment analysis, a 360 degree 
energy scan of the helix 3 using Rotmin (Trabanino et al., 2004) was performed. The 
results of this scan are shown in Figure 6.  
Figure 6: 360 degree energy scan of helix 3 without Hel7 HSP.  
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As previously mentioned, helix 3 in GPCRs is a special case in that it, because of its 
position in the bundle, actually has two faces which face the membrane and these faces 
are approximately 90 degrees from each other. As a second check to the rotation by 
energy, two hydrophobic moments could be calculated for the two halves of helix 3 about 
the hydrophobic center. This was done for CCR1 using 7 residues displaced at least one 
residue from the hydrophobic center. The resulting moment orientations for each half are 
shown in Figure 7. This moment orientation corresponds to the rotation indicated by the 
arrow in Figure 6. Thus, this helix 3 rotation was used for later optimization. 
Figure 7: Helix 3 hydrophobic moment orientations for 
the extracellular and intracellular halves of the helix. 
f fExtracellular hal Intracellular hal
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Although it was expected that the moments for the two halves would be 90 degrees to 
each other, this case demonstrates that often the extracellular moment is more reliable 
than the intracellular moment. This is because the extracellular moment is defined for a 
more exposed (to membrane) helical face as shown in Figure 8. 
 
Figure 8: CCR1 structure with the two helix 3 membrane-exposed 
faces shown.  
TM 1 
Hel3 
extracellular  
half is more 
 
  
 
 
 295
Hel 7 rotation – Hel3/7 salt bridge formation 
 
 Even before the rotation of helix 3, the Glu120 of helix 3 was within 7 Å of the 
His293 of helix 7. It should be noted that the previous energy scan of helix 3 was 
performed with a neutral form of His293. At this point, the His was protonated (to Hsp) 
and a 360 degree energy scan was performed on helix 7. The results are shown in Figure 
9. The rotation of helix 7 at +95 degrees was thus chosen for further optimization. 
 
 
Figure 9: 360 degree energy scan for helix 7 with HSP. 
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Hel 6 rotation 
 Helix 6 is also typically a difficult helix to rotate owing to the ill-defined 
hydrophobic moment. This may have a role, since helix 6 has been implicated in rotating 
upon GPCR activation in rhodopsin (Farrens et al., 1996). When validating the 
MembStruk protocol for rhodopsin (Trabanino et al., 2004), helix 6 had the largest error 
in rotation as compared with the ground state of rhodopsin. A recent advance indicates an 
improvement in helix 6 can be obtained by scanning various numbers of middle residues 
(about the HC) for the calculation of the hydrophobic moment. In bovine rhodopsin, this 
lead to two predominant rotations, which correlated with the experimental rotation for the 
ground and activated state of the receptor. The number of middle residues used to obtain 
the helix 6 rotation as in the ground state crystal structure of rhodopsin was 19 or 21. 
Thus, for CCR1, the number of middle residues used was 21 to reproduce this ground 
state rotation. The rotations using 15 and 21 as the number of middle residues are shown 
in Figure 10. 
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Figure 10: a) Helix 6 alternate hydrophobic moment orientations using 
different number of middle residues for calculation. b) 360 degree energy 
scan for helix 6 
a) 
 
  b)
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As a double check for the rotation, a 360 degree energy scan of helix 6 in the structure 
before adding loop revealed this to be the best rotation, as seen in Figure 10b. 
 
Rigid body molecular dynamics (RBMD) 
As discussed previously (Trabanino et al., 2004), molecular dynamics was performed on 
the bundle at this point in order to optimize rotations, tilts, and translations, treating each 
helix as a rigid body. This is done for 50 ps in explicit lipid. 
 
Loop addition 
Loops were added using Modeller 6v2, and the structure’s loop regions were minimized 
in potential energy using the conjugate gradient method. Then the complete structure was 
minimized in potential energy. 
 
EC-II loop simulation 
 
The EC-II loop was folded into a closed form using the procedure outline in Chapter 6. 
The disulfide bond between the conserved cysteines on helix 3 and ECII was formed and 
the loop was annealed from 1000 to 2000 degrees. Then TVN 300 degree molecular 
dynamics was conducted on half of the bundle to allow optimization of loop with 
movable TM backbone. Finally, the loop was again annealed with movable side chains in 
the vicinity of the loop for ~120 ps. The progression of the loop closing at each step is 
shown in Figure 11. 
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Figure 11: Snapshots of the EC-II loop closing in CCR1. 
 
 
 
 
 
 
 
 
 
 
 Start 100 ps TVN Dyn 140 ps annealing 
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Homology model of CCR5 
From the final human CCR1 structure, the homology model of CCR5 was constructed. 
Since the whole sequence homology is 54% and gaps were not present consecutively 
more than once, the model building was straightforward. The Clustalw sequence 
alignment between these two proteins is shown in Figure 12. 
 
Figure 12: Alignment of human CCR1 and CCR5 sequences. 
 
 
 
Another issue was the helix 7 rotation, which was rotated with His in the protonated form 
in CCR1 to form a salt bridge with the helix 3 Glu120. In CCR5, this Glu is not present, 
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so for the case of CCR5, the helix 7 rotation was determined by the hydrophobic moment 
orientation of helix 7 alone. The orientation before rotation is shown in Figure 13.   
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Figure 13: Orientation of helix 7, which was rotated -45 degrees for 
rotation by hydrophobicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The helix 7 was rotated –45 degrees. The final structure was minimized in potential 
energy. 
 
HierDock function prediction 
As described previously (Trabanino et al., 2004), the molecular surface of the 
protein was determined and spheres were mapped onto this surface. All the spheres 
within the protein were divided into 14 boxes of volume 7 Å3. The molecule BX471 
(shown in Figure 14) was docked to these spheres using DOCK 4.0. The box with the 
best conformation energetically was used for later fine HierDock. 
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Figure 14: Structure of BX471 CCR1 antagonist. Figure: (Onuffer et 
al., 2002) 
The spheres of the best box were then used to perform the fine-grain HierDock. This 
method was modified to look for conformations which anchored to the Glu190 of ECII 
with a distance within 4 Å. Also, HierDock without anchoring was also performed on all 
the five ligands (proprietary) and BX471. The rank scoring of these bound ligands was 
obtained by either perturbing from the BX471 structure or from the HierDock structure in 
the same binding mode (whichever was less in energy). 
For finer optimization of the BX471 ligand, the EC-II loop was then annealed 
(temperatures in cycles 300 to 600 for 96 ps) with ligand present and His189 (adjacent to 
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Glu) in a neutral state. The ligand was then annealed (temperatures in cycles 300 to 600 
for 120 ps). The loop was annealed again for 120 ps and then the ligand for 120 ps. The 
distance between the protonated amine of the ligand and the oxygen of the Glu190 was 
3.8 Å at this point. The side chain of Glu190 was minimized with a constraint of 2.5 Å 
between the proton of the ligand amine and the Glu oxygen. Then the entire complex was 
minimized in potential energy with no constraints. The final distance between the 
protonated amine of ligand and the oxygen of the Glu190 was 3.3 Å. 
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Results and discussion 
 
Structural features of human CCR1 
There are a variety of interhelical interactions which were obtained using the 
MembStruk protocol between helices 1,2,3,4,7 as shown in Figure 15. In addition hel 7/3 
salt bridge is shown in Figure 16. 
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Figure 15: General and detailed views of the CCR1 interhelical 
interactions. 
 
 
TM1
 
 
 
 307
 
 
 
 
 
 
 
 
 
 
3.56 
2 88
2.88 TM7
TM2 
TM7
TM3 
TM1
TM7 
 308
 
 
 
 
 
 
 
 
 
Figure 16: The helix 3/7 salt bridge formed between the Hel3 Glu120 and 
Hel7 Hsp293. 
3.4
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Binding site of BX471 in human CCR1 
The optimized binding site of BX471 within the human CCR1 structure is shown 
in Figure 17.  The details of the binding site are shown in Figure 18. The Glu 120 
interacts with the tertiary amine of the ligand although this interaction may be weaker and 
is probably a water-mediated interaction. Of the other polar interactions, the Hsp293 
interacts with the carbonyl and ether oxygens of the ligand very well while the amide 
nitrogen interacts with the Asp80 of helix 2 through a longer distance interaction. Various 
hydrophobic residues interact via hydrophobic interactions with the rings of the ligand. 
As can be seen, the ligand does not disrupt the polar interactions with keep the helices 
fixed relative to one another, a good feature for a high affinity antagonist. 
Figure 17: General front and top views of the BX471 binding 
site in human CCR1. 
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Figure 18: Detailed view of the BX471 binding site in human CCR1. 
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Rank ordering of the 6 compounds 
The rank ordering of the 6 compounds (five are proprietary) is shown in Figure 
19. The worst binder actually had internal strain and it is as of yet unclear whether it may 
prefer another different binding mode (a common problem with the bad binders). 
 
Figure 19: Rank ordering for the 6 compounds in CCR1. 
 
 
 
Mouse/Human structural differences 
As discussed previously, the binding affinity of BX471 is greatly reduced in the 
mouse receptor. The MembStruk structure provides insight into the structural cause of the 
difference. The alignment of Human/Mouse sequences is shown in Figure 20. In Figure 
21, the differences in the 5 Å binding site are shown in detail. The greatest difference is 
in the ECII loop, with the Glu120 as a Lys in the Mouse, which may have electrostatic 
repulsion with the bound ligand and thus may explain the low affinity for the mouse 
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receptor. Another notable difference is the Valine to Ala at the end of helix 6, although 
this residue does not interact greatly with the ligand energetically. 
Figure 20: Alignment of human and mouse CCR1 sequences. The residues in 
bold are within 5 Å of the bound ligand, while those residues in red are different 
between mouse and human. The TM helices are underlined.   
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Figure 21: The residues within 5 Å of the bound ligand 
which are different between mouse and human CCR1. The 
mouse residue is shown second. 
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CCR5 function prediction 
The putative binding sites of Tak-779 (shown in Figure 22) in the homology 
model of CCR5 were determined as above, with the exception that the spheres were 
divided into sphere clusters using Pass instead of dividing into separate boxes. The two 
best binding sites are shown in Figure 23. The second binding site conformation was used 
to extract the spheres (in the vicinity of the ligand) for fine HierDock. The final HierDock 
conformation for Tak-779 and four other published ligands (sch350634, sch351125, 
trans-pyrrolidine1, cis-pyrrolidine1) are shown in Figure 24. A comparison of the binding 
sites of BX471 in CCR1 and Tak-779 in CCR5 is shown in Figure 25. It can be seen that 
BX471 interacts with TMs 2, 3, 5, 6 and 7 while Tak-779 interacts with TMs 1, 2, 3, and 7 
only. A detailed picture of the Tak-779 binding site is shown in Figure 26. The 
correlation with mutation studies (Dragic et al., 2000; Kazmierski et al., 2003) is good. 
The residues which have been shown to interact strongly by mutation are colored red. Tyr 
108 forms a hydrogen bond with the carbonyl oxygen of the ligand and also has van der 
Waals interactions with the ring. The Trp86 and Tyr37 interact via pi-cation interactions 
with the ligand’s quaternary amine and also provide hydrophobic interactions with the 
carbon units of the ligand. Of the medium experimental interactors, shown in green in 
green, Glu 283 interacts via a long distance interaction with the quaternary amine, as is 
expected for a quaternary amine. 
The important differences between CCR1 and CCR5 are the presence of more 
polar residues on TM’s 4 and 5 [Y170->I164 (TM4); N204->V199 (TM5)] and the 
presence of more nonpolar residues on TM’s 6 and 7 [V263->T259 (TM6); V288->T284 
(TM7)] for CCR1. To reduce cross-reactivity to CCR5 receptor, polar group may be 
 315
added onto the ligand where it interacts with helices 4 and 5. This demonstrates the use of 
the 3D structures to reduce cross-reactivity. 
 
 
Figure 22: CCR5 antagonist Tak-779. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Two possible binding sites of Tak-779 within human CCR5.  
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Figure 24: Binding sites of Tak-779 and 4 other compounds after 
HierDock. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 25: A comparison between the binding sites of BX471 and Tak-779.  
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Figure 26: Detailed view of the Tak-779 binding site within human CCR5.  
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Conclusions 
 
The structure of CCR1 exhibits various interactions interhelically and with the 
bound ligand. The rank ordering of a series of compounds is determined correctly based 
on this structure. These provide validation not only of the structure but also of the 
MembStruk protocol in general. In addition, the homology model of CCR5 from this 
CCR1 structure also has binding to the Tak-779 ligand which correlates well with 
experimental mutation studies. This provides indirect validation of the CCR1 structure as 
well as providing insights into CCR5 features important for binding such quaternary 
amine ligands. The CCR1 structure also provides information as to the possible 
differences in the structure which may lead to differences in binding affinity in the mouse 
and human. Such 3D structures provide a wealth of information needed to explaining 
binding of known ligands as well as provide an avenue for designing new drugs with 
desired selectivities across species (mouse and human) and receptors (CCR1 vs CCR5). 
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Appendix: High resolution tree diagrams displaying the relationships between 
TM cores of human GPCRs.  
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